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Introduction and outline of thesis 11
Breast cancer 
Breast cancer is one of the most commonly diagnosed cancers and the leading cause 
of death from cancer in women in the western world1. Women in these countries 
have a 12-13% risk of developing breast cancer in their life and incidence rates are 
increasing, due to changes in reproductive factors (use of postmenopausal hormone 
therapy), increase in breast cancer screening and population graying1, 2. On the other 
hand, mortality rates are decreasing due to early detection through mammography and 
advances in breast cancer treatment3, 4.
Treatment of breast cancer
Treatment of early stage breast cancer consists of loco-regional control and prevention of 
development of distant metastases. Loco-regional control is managed through removal 
of the tumor in the breast and spread to the lymph nodes with surgery with or without 
radiotherapy. The cause of breast cancer-related deaths are distant metastases, which are 
thought to develop from tumor cells that have detached from the primary tumor and 
circulate in the blood or already have formed undetectable micro metastases at time of 
surgery5, 6. Adjuvant systemic therapy, i.e. chemotherapy, endocrine therapy and targeted 
trastuzumab therapy, are aimed at eradicating these circulating tumor cells and micro 
metastases in order to prevent development of distant metastases. Data from the Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown that administration 
of adjuvant systemic therapy results in a statistically significant beneficial disease-free 
and overall survival of breast cancer patients7-10. On the other hand, adjuvant systemic 
therapy can cause a wide range of acute and long-term side effects11. It is therefore of 
crucial importance to identify patient that will develop distant metastases and who may 
benefit from adjuvant systemic treatment and at the same time identify patients who will 
not develop distant metastases in order to spare those from unnecessary side effects of 
these therapies. Prognostic and predictive factors are needed that aid in the estimation 
of patients’ prognosis and response to adjuvant systemic therapy. 
Prognostication in breast cancer
Prognostic and predictive factors are aimed at estimating which patients necessitate 
adjuvant systemic treatment by estimating the patients’ risk of developing distant 
metastases and response to treatment12. Nowadays, clinical and pathological factors, 
such as age, menopausal status, tumor size, lymph node status, tumor differentiation 
grade, hormone receptor status and human epidermal growth factor receptor 2 (HER2) 
overexpression, are used in daily practice to select patients that might benefit from 
adjuvant systemic treatment13. However, these prognostic and predictive factors, 
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separately or in combination with one another (e.g. St. Gallen recommendations, 
Nottingham Prognostic Index, Adjuvant! Tool) still do not provide an optimal patient 
stratification and consequently recommendations for adjuvant systemic treatment are 
not accurate14-16. As a result, a proportion of patients that does need systemic treatment, 
but are classified as “good prognosis”, inadequately does not receive systemic treatment 
and is therefore undertreated. On the other hand, a substantial proportion of patients 
that will be cured by surgery and radiotherapy alone do receive systemic treatment and 
are therefore over treated and unnecessarily exposed to these treatment’s toxicities. 
There is therefore a great need for new and more accurate prognostic and predictive 
factors. 
There are several new pathological and molecular variables in development that are 
consistently associated with outcome or response to loco regional and systemic treatment. 
In 2007, the American Society of Clinical Oncology Committee recommended 
the following new prognostic markers in clinical practice for breast cancer patients: 
urokinases plasminogen activator (uPA); plasminogen activator inhibitor-1 (PAI-1); 
and multiparameter gene expression assays, mammaprint and oncotypeDX17-19. The 
prognostic value and clinical application of these factors are currently being evaluated in 
clinical trials18, 19. However, these new prognostic factors have several limitations. First, 
they are not suitable for all tumors, since fresh frozen material is often needed, which 
is not always available. In addition, the major critique of microarray-based prognostic 
tools is the fact that these gene prints were constructed using top-down analyses 
and were not defined based on a biological rationale20. The better understanding of 
underlying breast cancer biology aids in distinguishing biologically differing breast 
tumors. Biomarkers predictive for patient prognosis and treatment efficacy, which are 
based on these differences in biology, provide more solid tools for prognostication and 
treatment response prediction. 
PART I: PROGNOSTIC BIOMARKERS IN THE 
INTERACTIONS BETWEEN THE HOST’S IMMUNE 
SYSTEM AND BREAST CANCER
The first part of this thesis focuses on the interactions taking place between breast 
tumors and the immune system. There is strong evidence that the host’s adaptive 
immune system is able to control tumor progression21. On the other hand, due to their 
intrinsic genetic unstable nature, tumor cells may acquire properties to escape from 
such immune recognition22. Various interactions underlie this balance between tumor 
immune control and escape. We investigated the expression and prognostic effect of 
various crucial immunological markers and their interactions in a well-described large 
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cohort of breast cancer patients primarily treated with surgery at the Leiden University 
Medical Center, with long-term follow-up data. 
Cytotoxic T-lymphocytes (CTL) are capable of recognizing tumor-associated antigens 
presented by classical human leukocyte antigen (HLA) class I (HLA-A, HLA-B, HLA-C) 
on the tumor cell surface. In order to avoid immune recognition by CTL, cancer cells 
may lose expression of classical HLA class I23. Another tumor escape mechanism from 
immune surveillance is attraction and induction of immunosuppressive regulatory 
T cells (Treg) in the tumor microenvironment24. In Chapter 2 these tumor escape 
mechanisms, classical HLA class I down regulation and attraction of Treg, are related to 
patients’ outcome especially concerning response to chemotherapy treatment.
Loss of expression of classical HLA class I on the tumor cell surface makes malignant 
cells prone to natural killer (NK) cell recognition25. Non-classical HLA class I molecules 
(HLA-E, HLA-G) also play a crucial role in immune surveillance by NK-cells. 
Expression of these molecules on the cell surface causes an inhibitory effect on NK-cell 
attack25-27. The prognostic role of tumor expression of HLA-E and HLA-G in relation 
to classical HLA class I expression is described in Chapter 3.  
The activating receptor NK cell lectin-like receptor gene 2D (NKG2D) is a stimulatory 
immune receptor that is expressed on NK cells, NKT cells and T cells 28. Ligands which 
bind NKG2D receptors comprise major histocompatibility complex class I chain-related 
proteins A and B (MIC-AB) and unique long 16 (UL16) binding proteins 1-6 (ULBP1-
6)29, 30. Expression of these ligands may be induced upon infection and other inducers 
of cellular stress, such as malignant transformation, and is unusual in normal cells31. 
By binding to the NKG2D receptors on NK and T cells, the NKG2D ligands may 
initiate an immune response against cells expressing these ligands. Overexpression and 
shedding of NKG2D ligands have been reported31. It is unclear whether up regulation 
of NKG2D ligands on tumor cells results in activation of an immune response or leads 
to overstimulation and down regulation of NKG2D on immune cells 28 and the effects 
of up regulation of the ligands on patient prognosis has been found to variate between 
tumor types. The prognostic effect of NKG2D ligands expression in breast cancer is 
described in Chapter 4.  
A variety of immune reactions have been found to date in breast cancer. Studies have 
demonstrated that breast cancer is highly immunogenic, but on the other hand also 
capable of evading immune recognition. This suggests that various interactions exist 
between breast tumors and the immune system and that in order to get a good perspective 
on the effects of the immune system on tumor progression and patient outcome in 
these cancer patients, such interactions should be accounted for. This emphasizes the 
importance of research on combinations of markers of immune surveillance together 
with markers of tumor immune escape. In Chapter 5, tumor immune subtypes were 
constructed, considering various interactions that can take place between tumor and 
immune system and reflecting the various stages of tumor immune escape from high 
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immune susceptibility to high immune evasion. In this study, the prognostic effect of 
the tumor immune subtypes in breast cancer was evaluated. 
PART II: PROGNOSTIC BIOMARKERS IN 
ELDERLY BREAST CANCER PATIENTS 
Breast cancer in the elderly 
Because of a graying population, breast cancer is increasingly becoming a disease 
affecting older women32. This older breast cancer population differs clinically in 
many aspects from younger breast cancer patients. Due to patient co-morbidity and 
the potential for therapy to amplify pre-existing medical conditions, the balance 
between treatment toxicity and benefits is uncertain33. In addition, life expectancy is 
significantly shorter in elderly breast cancer patient resulting in elderly breast cancer 
patients dying more often “with the disease” instead of “from the disease”34-36. These 
competing risks of death highly influence treatment significance. Furthermore, patient 
preferences are different in older breast cancer patients compared to their younger 
counterparts. In addition to clinical aspects, there are indications that elderly breast 
cancer differs in underlying biology. Characteristics such as hormone receptor status, 
human epidermal growth factor receptor 2 (HER2) status and amount of tumor cell 
proliferation have been found to differ considerably in tumors from elderly compared 
to young patients37-39. However, though these significant differences between elderly 
and young breast cancer patients exist, evidence-based treatment guidelines specific for 
elderly patients are lacking. Translational cancer research, which lies on the basis of 
evidence-based treatment, is in the elderly still rare but therefore urgently needed.
Breast cancer stem cells
Cancer stem cells, defined as a small subset of tumor cells with stem cell-like features, 
including epithelial-to-mesenchymal transition, have the capacity of self-renewal 
and differentiation; giving rise to a heterogeneous tumor cell population40. Various 
putative markers of breast cancer stem cells have been proposed, including aldehyde 
dehydrogenase-1 (ALDH1) activity, CD44+/CD24-, CD133, and ITGA6.40-43 In 
particular, ALDH1 expression has shown promise as a clinically relevant marker for 
unfavorable clinical prognosis.42, 44, 45
It is unknown whether expression of ALDH1 is associated with age and has influence 
on clinical outcome in elderly breast cancer patients. Chapter 6 describes the age 
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distribution of ALDH1 expression and its prognostic role in young and elderly breast 
cancer patients in our above-described cohort. 
Molecular subtypes 
Gene expression studies have identified several distinct breast cancer subtypes based on 
gene expression patterns, that showed marked differences in patient prognosis46-48. This 
“intrinsic” classification proposes four different classes of breast tumors: Luminal A 
and B, which are mostly hormone receptor-positive and show high expression of genes 
characteristic of the luminal epithelial cell layer, including expression of ER, GATA3 
and genes regulated by these47, 48, Basal-like tumors, which typically are triple-negative 
tumors (ER, PR, and HER2 negative) and exhibit high expression of genes characteristic 
of the basal epithelial cell layer such as cytokeratin (CK) 5, 6 and 17 46 and the ERBB2 
tumor subtype, which clusters near the basal-like tumor, are mostly hormone receptor-
negative and show high overexpression of HER2 and high HER2 gene amplification47, 
48. Concerning outcome, hormone receptor-positive tumors are associated with the best 
patient outcome where, compared to Luminal B tumors, Luminal A tumors seem to be 
the most indolent tumors47. Hormone receptor-negative intrinsic subtypes, ERBB2 and 
Basal-like tumors have an aggressive natural history, resulting in an unfavorable patient 
outcome47. The distribution and prognostic effect of intrinsic breast cancer subtypes 
specific in the elderly breast cancer population compared to younger breast cancer 
patients is still unknown. Using immunohistochemical (IHC) surrogates, which we 
validated against gene expression determined intrinsic subtypes, Chapter 7 describes 
the identification of breast tumor intrinsic subtypes in our breast cancer cohort and 
the distribution and prognostic effect of these intrinsic subtypes in elderly compared to 
their younger counterparts. 
Tumor immune subtypes
Among others, age-specific immune surveillance may contribute to the strong 
association between breast cancer and increasing age. The mechanisms involved in 
immune surveillance have been shown to alter with ageing50; a decline in immune 
system functioning, which is commonly defined as immunosenescence51. It has been 
suggested that thymic involution, intrinsic changes due to cell damage leading to altered 
signaling, and chronic antigen stimulation during life are the main underlying causes 
for immuosenescence50. Among others, immunosenescence comprises the decrease in 
production of new T cells and oligoclonal expansion of CD8+ memory T cells, which 
may limit the ability to respond to newly encountered viruses 52, 53 and may result in a 
decreased exportation of naïve T cells to peripheral tissue54, 55. Consequently further 
restriction of the ability to renew the immune repertoire occurs. In addition, a decreased 
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toxicity and a decreased IL-2 production have been observed for NK cells 50 and in 
animal studies it has been shown that a high number of immune suppressive Tregs 
were found in old mice56, 57. Preclinical data therefore suggest that immunosenescence 
may impair immune surveillance and consequently tumor immune surveillance may be 
affected in elderly50.  Chapter 8 describes a study where the distribution of key markers 
for cellular immune response, classical HLA class I, HLA-E, HLA-G, CD8, NK cells, 
and Treg were compared between elderly and young breast cancer patients and the age-
specific prognostic effect of previously described tumor immune subtype was assessed.
Finally, Chapter 9 includes a summary of this thesis as well as conclusions and discussion 
on future perspectives. Chapter 10 provides a summary in Dutch. 
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ABSTRACT
Purpose We hypothesized that T cell immune interaction affects tumor development 
and thus clinical outcome. Therefore, we examined the clinical impact of human 
leukocyte antigen (HLA) class I tumor cell expression and regulatory T cell (Treg) 
infiltration in breast cancer.
Experimental Design Our study population (n=677) consisted of all early breast 
cancer patients primarily treated with surgery in our center between 1985 and 1994. 
Formalin-fixed paraffin-embedded tumor tissue was immunohistochemically stained 
using HCA2, HC10 and Foxp3 monoclonal antibodies. 
Results HLA class I expression was evaluated by combining results from HCA2 and 
HC10 antibodies and classified into three groups: loss, downregulation and expression. 
Remarkably, only in patients who received chemotherapy, both presence of Treg 
(p=0.013) and higher HLA class I expression levels (p=0.002) resulted in less relapses, 
independently of other parameters. Treg and HLA class I were not of influence on 
clinical outcome in patients who did not receive chemotherapy. 
Conclusions We showed that HLA class I and Treg both affect prognosis, exclusively 
in chemotherapy-treated patients and are therefore one of the few predictive factors for 
chemotherapy response in early breast cancer patients. Chemotherapy may selectively 
eliminate Treg, thus enabling Cytotoxic T-lymphocytes to kill tumor cells that have 
retained HLA class I expression. As a consequence, HLA class I and Treg can predict 
response to chemotherapy with high discriminative power. These markers could be 
applied in response prediction to chemotherapy in breast cancer patients. 
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INTRODUCTION
Breast cancer is the most common cancer in women: it affects one in nine women. 
Systemic treatment improves disease free survival (DFS) and overall survival (OS) 
in patients with early breast cancer.1 Decisions regarding this systemic therapy are 
depending on prognostic and predictive factors, which divide patients into different 
risk-groups.2 With the current classifications, however, prediction of outcome is still not 
optimal and additional prognostic and predictive factors are needed to improve tailored 
treatment.
It is widely accepted that the adaptive immune system plays an important role in 
controlling tumor growth and spread.3 Cytotoxic T-lymphocytes (CTL) are capable 
to affect tumor development. However, due to their intrinsic genetic unstable nature, 
tumor cells may acquire properties to escape from CTL recognition. Among these 
properties are downregulation or complete loss of Human Leukocyte Antigen (HLA) 
class I expression. In addition, immunosuppressive regulatory T cells (Treg) may be 
induced.4
HLA class I molecules play a pivotal role in CTL-mediated immune responses and have 
been found to be a prognostic factor in various types of cancer.5-7 Previous studies 
have demonstrated that HLA class I expression is frequently down-regulated in breast 
cancer.8, 9 However, the reports on prognostic influence of HLA class I expression 
in breast cancer have contradictory results.10-12 Some found no significant correlation 
between percentage of tumor cells expressing HLA class I and survival of breast cancer 
patients.10, 12 In contrast, another study found that total loss of HLA class I was an 
independent indicator of good prognosis.11 
Treg act as immunosuppressors and maintain immunological self-tolerance. Numbers 
of tumor-infiltrating Treg are known to be increased in several malignancies and a 
correlation was found with worse disease stage and prognosis in cancer. 13, 14In breast 
cancer, the presence of Treg in the tumor environment has been found in several 
studies.15-17 Moreover, these studies found a higher prevalence of Treg in tumor 
microenvironment and in peripheral blood of patients suffering breast cancer compared 
to healthy donors.15-17 One study found higher numbers of Treg to be correlated with 
worse disease stage and shorter survival.15 Interestingly, chemotherapy has been found 
to be involved in presence and prognostic influence of Treg.16 The numbers of Treg in 
tumor tissue decreased after chemotherapy administration and there was an association 
between disappearance of Treg and pathologic complete response to preoperative 
chemotherapy. 
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The purpose of our study was to analyze the prognostic relevance of HLA class I 
expression and Treg infiltration in a large cohort of early breast cancer patients. In 
addition, we explored the predictive value of these markers for chemotherapy response. 
MATERIALS AND METHODS
Patients and tumors
The patient population comprised all non-metastasized breast cancer patients primarily 
treated with surgery in the Leiden University Medical Center between 1985 and 1994 
(n=677). Patients with bilateral tumors or a prior history of cancer, other than basal cell 
carcinoma or cervical carcinoma in situ, were excluded. The following data were known: 
age, tumor differentiation grade and morphology, TNM stage, local and systemic 
therapy, locoregional/distant tumor recurrence, secondary tumor, alive/death, estrogen 
receptor (ER), progesterone receptor (PgR),Ki67, and human epidermal growth factor 
receptor 2 (HER2). All tumors were graded according to current pathological standards, 
by one pathologist (VS).
Antibodies
The mouse monoclonal antibodies HCA2 and HC10 which recognize HLA class I heavy 
chains (kindly provided by Prof. Dr. J. Neefjes) were used. The reactivity spectrum of 
HCA2 comprises all HLA-A chains (except HLA-A24) as well as some HLA-B, HLA-C, 
HLA-E, HLA-F, HLA-G chains.18, 19 HC10 reacts mostly with HLA-B and HLA-C 
heavy chains and some HLA-A (HLA-A10, -A28, -A29, -A30, -A31, -A32, -A33.20, 21 
Mouse antibodies against human Foxp3 (ab20034 clone 236A/E7: AbCam, UK) were 
used for Treg identification. The reactivity spectrum of Foxp3 comprises Treg and may 
include small numbers of CD8+ cells 22, but so far it is the best single marker of Treg.23 
Immunohistochemistry
For HLA class I staining, slides of 4 μm were cut from a priory constructed tissue micro 
array (TMA). For staining of Treg sections of 4 μm were cut from the original formalin-
fixed paraffin-embedded (FFPE) tumor blocks. Tissue sections were deparaffinised and 
rehydrated. Endogenous peroxidase was blocked for 20 minutes in hydrogen-peroxide 
methanol. For antigen retrieval, 0.01 M citrate buffer (pH6.0) was used for 10 minutes at 
maximum power in a microwave oven. Sections were incubated overnight with HCA2 
or HC10 at room temperature using predetermined optimal concentrations. After 
incubation with secondary antibody envision anti-mouse (Dako Cytomation K4001), 
sections were visualised using DAB-solution (25ml DAB in 225 ml 0.05M Tris-HCl). 
Tissue section were counterstained with haematoxylin, dehydrated and mounted in 
malinol. All slides were stained simultaneously to avoid inter-assay variation. For each 
patient normal epithelium, stromal cells or lymphoid cells served as internal positive 
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Total HLA Class I Treg
Loss Downregulation Expression Absence Presence
N % N % N % N % N % N %
Age P: 0.449 P: 0.902
<40 48 8.4 8 6.6 15 7.5 19 9.4 24 7.5 21 8.8
40-50 145 25.3 37 30.3 58 29.0 44 21.8 84 26.2 61 25.5
50-60 132 23.0 31 25.4 42 21.0 45 22.3 77 24.1 53 22.2
>60 249 43.4 46 37.7 85 42.5 94 46.5 135 42.2 104 43.5
Grade P: <0.001 P: 0.047
I 80 14.2 28 23.7 26 13.1 16 8.0 52 16.5 27 11.4
II 282 49.9 55 46.6 114 57.6 87 43.3 163 51.7 113 47.7
III 203 35.9 35 29.7 58 29.3 98 48.8 100 31.7 97 40.9
Histological type P: 0.135 P: 0.290
Ductal 513 89.4 102 86.4 178 89.9 190 94.5 286 90.8 215 90.3
Lobular 46 8.0 14 11.9 16 8.1 10 5.0 27 8.6 18 7.6
Other 7 1.2 2 1.7 4 2.0 1 0.5 2 0.6 5 2.1
Tumor stage P: 0.760 P: 0.850
pT1 211 38.0 46 39.3 73 37.4 71 36.0 120 38.7 87 37.5
pT2 272 49.0 55 47.0 92 47.2 103 52.3 151 48.7 112 48.3
pT3/4 72 13.0 16 13.7 30 15.4 23 11.7 39 12.6 33 14.2
Nodal stage P: 0.871 P: 0.831
pN0 307 55.1 64 53.3 107 55.4 111 56.3 170 54.5 128 55.4
pN+ 250 43.6 56 46.7 86 44.6 86 43.7 142 45.5 103 44.6
Estrogen receptor P: 0.004 P: 0.465
Negative 203 37.6 37 30.8 64 33.0 93 46.5 109 36.3 88 39.5
Positive 337 62.4 83 69.2 130 67.0 107 53.5 191 63.7 135 60.5
Progesterone receptor P: <0.001 P: 0.140
Negative 223 41.6 44 37.6 64 32.8 105 52.5 116 38.8 100 45.2
Positive 313 58.4 73 62.4 131 67.2 95 47.5 183 61.2 121 54.8
Ki67 expression P: 0.161 P: 0.001
Negative 458 85.4 103 88.0 169 87.1 161 81.3 270 90.0 176 80.0
Positive 78 14.6 14 12.0 25 12.9 37 18.7 30 10.0 44 20.0
HER2 overexpression P: 0.147 P: 0.403
No overexpression 378 89.6 92 94.8 128 87.7 148 88.1 213 88.8 157 91.3
Overexpression 44 10.4 5 5.2 18 12.3 20 11.9 27 11.2 15 8.7
Local therapy P: 0.051 P: 0.985
MST-radiotherapy 223 38.9 46 37.7 75 37.5 85 42.1 125 39.2 90 38.0
MST+radiotherapy 108 18.8 25 20.5 27 13.5 46 22.8 60 18.8 44 18.6
BCS-radiotherapy 5 0.9 2 1.6 2 1.0 0 0 3 0.9 2 0.8
BCS+radiotherapy 238 41.5 49 40.2 96 48.0 71 35.1 131 41.1 101 42.6
Systemic therapy P: 0.426 P: 0.294
Chemotherapy 112 19.5 20 16.4 39 19.5 48 23.8 64 20.0 48 20.1
Endocrine therapy 75 13.1 12 9.8 25 12.5 28 13.9 49 15.3 24 10.0
Both 18 3.1 3 2.5 9 4.5 6 3.0 11 3.4 7 2.9
No systemic therapy 369 64.3 87 71.3 127 63.5 120 59.4 196 61.2 160 66.9
Table 1 Correlations between HLA class I expression and presence of  Treg and well-established prognostic factors 
using chi-square test.
Abbreviations N number of  patients; % percentage; HLA class I human leukocyte antigen class I; Treg regulatory T cell; 
HER2 human epidermal growth factor receptor 2; MST Mastectomy; BCS breast conservative surgery.
proefschrift.indb   25 18-12-2014   16:35:02
26 Chapter 2
control for HLA class I antibody reactivity. Slides from human tonsil tissue served as 
positive control for Treg staining. For each staining, slides that did undergo the whole 
immunohistochemical staining procedure, but without primary antibodies served as 
negative controls. 
Evaluation of immunostaining
Microscopic analysis of HCA2 and HC10 was assessed by two independent observers 
(EdK and QT) in a blinded manner. Percentage of tumor cells that showed membranous 
staining was assessed. HCA2 and HC10 staining were scored in 5 categories according to 
the defined standard method of the International HLA and Immunogenetics Workshop 
(IHIWS, score 1: 0-5 percent of tumor cells positively stained; score 2: 5-25; score 
3: 25-50; score 4: 50-75; score 5: 75-100).24 Quantification of Treg within the tumor 
was microscopically assessed in 10 high power fields (hpf) by two observers (EdK: 
100%; AS: 30%) in a blinded manner. Treg was scored into two categories: absence and 
presence of Treg infiltration.
Statistical analysis
Statistical analyses were performed using the statistical package SPSS (version 15.0 
for Windows, Spps Inc, Chicago, IL, USA). Cohen’s kappa coefficient revealed a 
satisfactory agreement in classification (kappa=0.73). The χ² test was used to evaluate 
associations between various clinicopathological parameters and HLA class I expression 
and infiltration of Treg. Relapse-free period (RFP) was the time from date of surgery 
until a locoregional recurrence and/or distance recurrence, whichever came first. 
Clinical follow-up policy was equal for all patients in the study. Overall survival (OS) 
was defined from date of surgery until death. The Kaplan–Meier method was used for 
calculation of survival probabilities and the log-rank test for comparison of survival 
curves. RFP is reported as cumulative incidence function, after accounting for death as 
competing risk.25 Cox regression was used for univariate and multivariate analysis for 
RFP and OS. Significant or close to significant variables (p<0.1) in univariate analysis 
were included in multivariate analysis. To analyze the predictive effect of HLA class I 
and Treg, analyses were performed in which was stratified for adjuvant chemotherapy 
administration.
RESULTS
Patient and tumor characteristics
Tumor material was available and incorporated in the TMA of 86% (574/677) of the 
patients. Clinicopathological and treatment characteristics are shown in table 1. Median 
age of patients was 57 years (range= 23-96 years). Median follow-up of patients alive 
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was 19 years (range=0-23 years). Chemotherapy treatment consisted of a combination of 
cytostatic drugs, always containing cyclophosphamide.
Expression of HLA class I and infiltration of Treg
Microscopical quantification was successful in 94% (538/574) of tumors for HC10 and 
in 96% (548/574) for HCA2 (figures 1 A, B). A total of 523/574 tumors (91%) could 
be quantified for both and were therefore available for total HLA class I expression 
evaluation. Three groups were defined for HLA class I expression: (1) HLA class I loss 
(both HCA2 and HC10 scored 0-5%), 23% of tumors, (2) HLA class I downregulation 
(either HCA2 or HC10 scored 0-5%), 38% of tumors and (3) HLA class I expression 
(both HCA2 and HC10 scored 5-100%), 39% of tumors (table1).
A total of 556/574 (97%) tumors could be evaluated for Treg infiltration (figures 1 C,). 
Tumors with absence of Treg (0Treg/10hpf) and presence of Treg (≥1 Treg/10hpf) were 
seen in 57% and 43% of patients respectively (table 1).
Prognostic value of HLA class I and Treg
In order to analyze the prognostic effect of HLA class I and Treg, all patients who did 
not receive any systemic therapy were analyzed. There were no statistically significant 
differences in outcome for RFP (logrank: p=0.27) or OS (logrank: p=0.55) between 
different HLA class I expression levels (figures 2a, b). Treg showed no differences, neither 
in outcome for RFP (logrank: p=0.93) nor OS (logrank: p=0.14) between intra-tumoral 
Figure 1 Representative examples of  
immunohistochemical stainings A) HCA2 score: 
0-5%. B) HCA2 score 75-100%. C) Presence of  
Treg. Representative Foxp3-positive cell is indicated 
by an arrow. 
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absence and presence (figures 3a, b). In contrast with the data in patients who did not 
receive systemic treatment, analysis of HLA class I expression in chemotherapy-treated 
patients showed statistically significant differences for RFP between groups (logrank: 
p=0.003) (figure 2c). Of patients with expression of HLA class I, 68% were relapse free 
after 15 years, compared to 51% and 30% for downregulation and loss of HLA class I 
expression respectively. Infiltration of Treg showed, similarly to HLA class I, moderate 
differences in outcome between groups among chemotherapy-treated patients (logrank: 
p=0.06) (figure 3c). Patients with intra-tumoral infiltration of Treg had less relapses 
compared to patients with no infiltration of Treg. Cox proportional multivariate analysis 
was performed with data from chemotherapy-treated patients including the parameters 
that showed a trend of influence on outcome (p<0.1) in Cox proportional univariate 
analysis; lymph node status, HLA class I and Treg (table 2). This analysis revealed that 

































































































Figure 2 HLA class I tumor expression and clinical outcome. Relapses over time (A) and overall survival (B) of  non-
systemically treated patients. Relapses over time (C) and overall survival (D) of  chemotherapy-treated patients.
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loss, HR 3.34, 95%CI 1.67-6.67) and Treg (p=0.01, HR 2.04, 95%CI 1.16-3.57) were all 
independent prognostic factors for RFP among chemotherapy treated patients. 
Predictive value of HLA class I and Treg
In order to prove that HLA class I and Treg were statistically significant cooperating 
with chemotherapy, an interaction term was introduced in Cox regression analysis. This 
analysis showed that both HLA class I (p< 0.001; Downregulation HR: 2.15, 95%CI: 
1.17-3.96; Loss HR: 3.15, 95%CI: 1.92-5.15) and Treg (p<0.001; HR 2.47, 95%CI 1.54-
3.95) significantly interacted with chemotherapy administration. These data indicated 
that both HLA class I expression and Treg tumor infiltration possess prognostic value 




























































































Figure 3 Treg tumor infiltration and clinical outcome. Relapses over time (A) and overall survival (B) of  non-systemically 
treated patients. Relapses over time (C) and overall survival (D) of  chemotherapy-treated patients.
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UNIVARIATE MULTIVARIATE
N HR 95% CI p-value HR 95% CI p-value
Age
<40 25 1.00 0.370
40-50 57 1.01 0.537-1.888
50-60 30 0.67 0.303-1.472
>60 18 0.51 0.183-1.413
Grade
I 15 1.00 0.887
II 57 1.12 0.490-2.558
III 57 0.99 0.428-2.271
Histological type
Ductal 117 1.00 0.453
Other 12 0.453 0.594-3.209
Tumor stage
pT1 35 1.00 0.416
pT2 70 0.88 0.491-1.560
pT3/4 20 1.39 0.657-2.950
Nodal stage
pN- 38 1.00 0.002 1.00 0.001
pN+ 92 2.92 1.480-5.741 3.08 1.539-6.179
Estrogen receptor
Negative 58 1.00 0.207
Positive 65 1.41 0.828-2.390
Progesterone receptor
Negative 57 1.00 0.377
Positive 69 1.27 0.750-2.138
Ki67 expression
Negative 101 1.00 0.866
Positive 23 0.68 0.438-1.712
HER2 overexpression
Negative 82 1.00 0.497
Positive 17 1.29 0.622-2.663
Local treatment
MST-Radiotherapy 33 1.00 0.109
MST +radiotherapy 35 1.78 0.889-3.548
BCS +radiotherapy 62 1.01 0.524-1.955
Endocrine therapy
Negative 112 1.00 0.501
Positive 18 0.76 0.347-1.678
HLA
Expression 54 1.00 0.005 1.00 0.002
Downregulation 47 1.71 0.929-3.159 2.11 1.127-3.947
Loss 23 3.11 1.577-6.116 3.34 1.671-6.670
Treg
>0 54 1.00 0.060 1.00 0.013
0 75 1.67 0.979-2.857 2.04 1.164-3.568
Table 2 Cox univariate and multivariate analysis for recurrence free period (RFP) of  patients who did receive 
chemotherapy. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; HLA class I human leukocyte 
antigen class I; Treg regulatory T cell; HER2 human epidermal growth factor receptor 2; MST mastectomy; BCS breast 
conserving surgery.
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DISCUSSION
Our study showed that HLA class I and Treg are independent prognostic markers 
for chemotherapy-treated patients with substantial discriminative power. Parameters 
that are able to determine which breast cancer patients may benefit from adjuvant 
chemotherapy are few.26 Known factors which tend to indicate better chemotherapy 
response are negative ER, high tumor grade and high proliferative activity, but their 
predictive value is marginal.27 In our study, independently of those factors, both high 
levels of HLA class I expression and presence of Treg resulted in statistically significant 
less relapses over time. Most importantly, these results can be explained by underlying 
biology and correspond with results of previous studies.
In concordance with previous studies, downregulation and loss of HLA class I was 
frequently seen in our study.9-11 Prior studies indicate that breast cancer is immunogenic 
and induces tumor associated antigen (TAA)-specific CTL.28 These findings may imply 
that breast cancer cells with downregulation or loss of HLA class I expression escaped 
from immune destruction and therefore selectively grew out.29 This seems quite a 
common phenomenon in breast cancer considering the fact that we and others, found 
HLA class I downregulation or loss in more than half of the tumors. In addition, Treg 
were found in a significant number of tumors. Tumors may either attract these immune-
suppressing cells in order to evade attack from effector T cells, or Treg may consider 
tumor cells as normal cells and thus prevent immune attack. Our data indicate that the 
immune system is closely involved in the development of breast cancer. At the time 
of a clinically manifest tumor, the balance between immune attack and tumor growth 
obviously is at the site of the tumor. 29
We showed that expression levels of HLA class I had a specific prognostic effect, but 
only in chemotherapy-treated patients. Previous studies on HLA class I expression in 
breast cancer did not stratify for systemic therapy. A total of 3 studies have evaluated 
HLA class I expression and its effect on prognosis in breast cancer.10-12 Two studies 
found that HLA class I expression levels had no influence on the prognosis of patients, 
which is in concordance with our findings in patients that were not systemically 
treated. 10, 12Our study also showed that infiltration of Treg was a predictive marker 
for chemotherapy response in breast cancer patients. These finding are supported by 
Ladoire et al. who found that the number of Treg declined due to chemotherapy, showing 
that chemotherapy affects Treg and thus may counteract by restrained CTL. More 
importantly, complete absence of Treg after chemotherapy administration, resulted in 
a better response with higher rates of pathological complete response (pCR), further 
supporting our findings of a predictive role of Treg. 16 Other studies have shown that 
infiltration of Treg in breast tumors resulted in a worse prognosis in terms of relapses 
and survival.15, 30 Our study could not statistically prove such a relation in patients who 
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did not receive systemic treatment. In order to unravel the complex tumor-immune 
system interactions during tumor development, further studies are needed.
The specific prognostic effects found for HLA class I and Treg among chemotherapy-
treated patients can be explained by the following biological explanation. In our 
population, choice of chemotherapy comprised cyclophosphamide which positively 
influences host immune responses against cancer.31-33 It is hypothesized that several 
mechanism are the basis for this phenomenon: enhanced homeostatic expansion of 
antigen-specific T cells by creation of a niche in the immune system, stimulation of 
dendritic cells (DC), induction of T cell growth factors such as type I interferons (IFN) 
and selective elimination of Treg. 31-33Ceasing of Treg through cyclophosphamide 
effects, results amongst other things in enhanced expansion and function of responding 
of CTL.32, 33 Ladoire et al. found that after preoperative chemotherapy absolute numbers 
of tumor-infiltrating Treg significantly declined, and numbers of effector T cells and 
CTL remained stable. In addition, a pathologic complete response was associated 
with a combination of absence of infiltration of Treg and presence of CTL after 
chemotherapy.16 In our study this phenomenon was associated only in tumors that 
retained HLA expression, suggesting that upon counteraction of Treg, CTL are able to 
affect tumor metastases development.
In summary, HLA class I and Treg have an independent prognostic effect for 
chemotherapy-treated patients, which can be explained by underlying biology. Both 
factors resulted in a very high differentiation in sensitivity to chemotherapy. Predictive 
factors for chemotherapy response in breast cancer are highly necessitated. Therefore, 
we conclude that HLA class I and Treg are candidate markers for further investigation 
in randomized studies and may be applied for chemotherapy response prediction.  
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ABSTRACT
Non-classical human leukocyte antigens (HLA), HLA-E and HLA-G, are known to 
affect clinical outcome in various tumor types. We examined the clinical impact of 
HLA-E and HLA-G expression in early breast cancer patients, and related the results to 
tumor expression of classical HLA class I.
Our study population (n=677) consisted of all early breast cancer patients primarily 
treated with surgery in our center between 1985 and 1995. Tissue micro array (TMA) 
sections of arrayed tumor and normal control material were immunohistochemically 
stained for HLA-E and HLA-G. For evaluation of HLA-E and HLA-G and the 
combined variable, HLA-EG, a binary score was used. Expression of classical HLA 
class I molecules was previously determined. 
HLA-E, HLA-G and HLA-EG on breast tumors were classified as expression in 50%, 
60% and 23% of patients respectively. Remarkably, only in patients with loss of classical 
HLA class I tumor expression, expression of HLA-E (p=0.027), HLA-G (p=0.035) or 
HLA-EG (p=0.001) resulted in a worse relapse free period. An interaction was found 
between classical and non-classical HLA class I expression (p=0.002), suggestive for a 
biological connection. 
We have demonstrated that, next to expression of classical HLA class I, expression of 
HLA-E and HLA-G is an important factor in the prediction of outcome of breast cancer 
patients. These results provide further evidence that breast cancer is immunogenic, but 
also capable of evading tumor eradication by the host’s immune system, by up- or down 
regulation of HLA class Ia and class Ib loci. 
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INTRODUCTION
There has been strong evidence that tumor progression is controlled by the host’s 
immune system 1. However, due to their intrinsic genetic unstable nature, tumor 
cells may acquire properties to escape from immune recognition 2. These poorly 
immunogenic clones frequently have lost expression of classical human leukocyte antigen 
(HLA) class I (HLA-A, HLA-B, HLA-C) which enables them to escape cytotoxic T 
lymphocyte (CTL) attack. However, in that case they may be vulnerable to natural killer 
(NK) cell elimination. Expression of non-classical HLA class I molecules (HLA-E, 
HLA-G), which play a pivotal role in immune surveillance by NK-cells, may therefore 
also determine outcome of tumor immune interaction 3. Under normal circumstances, 
expression of the HLA-E molecule is found in most tissues that express HLA-A, -B, 
-C or -G molecules and is thought to provide an important “self-signal” to the immune 
system by accommodating and presenting peptide fragments from leader sequences of 
these molecules 3, 4. HLA-G expression, on the other hand, has very restricted tissue 
expression and has been mostly found in extravillous trophoblastic cells, where it 
mediates semi-allograft immunotolerance during pregnancy 5. Expression of HLA-E 
and HLA-G on the cell surface can respectively bind with the inhibitory receptors 
CD94/NKG2A and KIR2DL4/p49 of NK cells, and thereby cause inhibition of their 
proliferation and cytotoxic effector functions 6, 7. HLA-E also binds activating CD94/
NKG2C receptors, present on T and NK cells, however with a 6-fold lower affinity 8. 
Tumors may acquire or upregulate expression of HLA-E and HLA-G as protective 
property against immune recognition and elimination of tumors 3. HLA-E is regularly 
expressed in various healthy tissues and correlates with expression of classical HLA 
class I molecules. This physiological correlation with classical HLA class I molecules 
has been found to be disturbed in tumors, suggesting that malignant cells which escape 
T cell immune recognition by downregulation of classical HLA class I expression, 
may further escape immune recognition by upregulation of HLA-E 9. In addition, 
expression of HLA-G protects against “missing self” recognition of NK. Expression 
of this molecule, which is rarely found in healthy tissues, is frequently observed in 
pathological conditions such as in tumors 10, 11. Previous studies showed that both 
HLA-E and HLA-G had increased expression in different types of tumor 12-15. Studies 
on the prognostic value of HLA-E expression in colorectal and cervix cancer showed 
that expression of this molecule correlated to tumor progression and had a trend 
towards a worse clinical outcome. The prognostic value of HLA-G expression has been 
investigated in colorectal, gastric, esophageal squamous cell carcinoma and non-small 
cell lung cancer and revealed it to be an independent prognostic factor for poor clinical 
outcome 16-19. In addition, expression of HLA-G has also been found in breast cancer, 
however no statistically significant associations were found with outcome of patients 
20-22. 
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The prognostic effect of HLA-E and HLA-G expression in breast cancer is unknown. 
The purpose of this study was to analyze the prognostic relevance of expression of 
HLA-E and HLA-G in a large cohort of early breast cancer patients. Previously, we 
determined classical HLA class I expression in the same patient cohort. Therefore, we 
were able to stratify patients based on classical HLA class I expression of tumors and 




The patient population comprised all non-metastasized breast cancer patients primarily 
treated with surgery in the Leiden University Medical Center between 1985 and 1994 
(n=677). Patients with bilateral tumors or a prior history of cancer (other than basal 
cell carcinoma or cervical carcinoma in situ) were excluded. The following data were 
known: age, tumor grade, histological type, TNM stage, local and systemic therapy, 
locoregional/distant tumor recurrence, secondary tumor, survival, and expression of 
estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth 
factor receptor 2 (HER2) 23. All tumors were graded according to current pathological 
standards, by a pathologist (VS). In addition, for about half the cohort of patients 
(n=266) a TMA of paired histologically normal breast tissue was available. Normal 
breast tissue originated from the cancer-affected breast, but localized more distal from 
the tumor tissue.
Immunohistochemistry
MEM-E/02 (AbCam, UK) and 4H84 (Nuclilab, NL) antibodies were used to recognize 
HLA-E and HLA-G respectively. MEM-E/02 reacts specifically with the denatured 
heavy chain of human HLA-E24. The 4H84 antibody recognizes denatured HLA-G 
molecules and has been described to react with classical HLA class I molecules 25-27. 
Tissue section of 4 μm were cut from a previously constructed tissue micro array (TMA) 
of formalin-fixed paraffin-embedded tumors 23. Tissue sections were deparaffinized 
and rehydrated. For antigen retrieval, 0.01 M Trizma EDTA (TE) buffer (pH6.0) was 
used for 10 minutes at maximum power in a microwave oven. Endogenous peroxidase 
was blocked for 20 minutes in 0.3% hydrogen-peroxide methanol. Sections were 
incubated overnight with primary monoclonal antibodies using predetermined optimal 
concentrations. After 30 minutes incubation with secondary antibody Envision anti-
mouse (Dako Cytomation K4001), sections were visualised using DAB-solution. 
Tissue section were counterstained with haematoxylin, and then dehydrated and finally 
mounted in malinol. For each primary antibody, all slides were stained simultaneously 
to avoid inter-assay variation. For each staining, placenta tissue slides served as positive 
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control. Negative controls were placenta tissue slides that did undergo the whole 
immunohistochemical staining without primary antibodies. Sections of paired normal 
tissue TMA were stained with MEM-E/02 and 4H84 in order to assess frequency of 
staining in normal breast tissue samples. 
Tumor staining for classical HLA class I using the mouse monoclonal antibodies HCA2 
and HC10 (anti-HLA-A and anti-HLAB/C respectively) was previously described 28. 
Evaluation of immunostaining
Microscopic analysis of HLA-E and HLA-G was assessed by two independent 
observers (AS and EdK) in a blinded manner. Both markers were scored in a binary 
manner, considering any specific staining of tumor cells as positive expression and 
no staining as no expression. A combined variable of HLA-E and HLA-G scores was 
created: HLA-EG. HLA-EG expression was considered positive when both HLA-E 
and HLA-G were expressed and negative when either HLA-E or HLA-G was not 
expressed.
Statistical analysis
Statistical analyses were performed using the statistical package SPSS (version 16.0 for 
Windows, Spps Inc, Chicago, IL, USA). Cohen’s kappa coefficient was used to asses 
inter-observer agreement in quantification. This revealed a substantial agreement in 
classification for HLA-E (kappa=0.72) and a very good agreement in classification for 
HLA-G (kappa=0.90). The χ² test was used to evaluate associations between various 
clinicopathological parameters and HLA-E and HLA-G expression. Relapse free period 
(RFP) was the time from date of surgery until an event (locoregional recurrence and/
or a distance recurrence, whichever came first). Overall survival (OS) was defined as 
date of surgery until death. The Kaplan–Meier method was used for survival plotting 
and log-rank test for comparison of survival curves. RFP is reported as cumulative 
incidence function, after accounting for death as competing risk 29. Cox regression 
was used for univariate and multivariate analysis for RFP and OS. Significant variables 
(p<0.1) in univariate analysis were included in multivariate analysis. To analyze the 
independent prognostic effect of HLA-E and HLA-G on clinical outcome, tumors were 
stratified based on a previously determined expression characteristics of classical HLA 
class I molecules. 
We finally analyzed whether the specificity of the anti-HLA-G antibody would interfere 
with the results of our survival analyses by separately analyzing the set of patients 
in which those who stained positive for this antibody on normal breast tissue were 
excluded.
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RESULTS
Patient and tumor characteristics
Tumor material was available and incorporated in the TMA of 86% (574/677) of the 
patients. Paired normal breast tissue was available on TMA in 46% (266/574) of the 
patients. Median age of patients was 57 years (range= 23-96 years). Median follow-up 
of patients alive was 19 years (range=14-23 years). Clinicopathological and treatment 
characteristics are shown in table I.
Expression of HLA-E and HLA-G
Microscopical quantification was successful in 86% (493/574) of tumors for HLA-E and 
in 87% (501/574) for HLA-G. Respectively 14% and 13% of tumors were damaged or 
lost on the TMA slides, a problem associated with preparation, staining and mounting of 
TMA slides. Two groups, expression versus no expression, were defined for HLA-E and 
HLA-G (figure 1 A-D). Expression was found in 50% (247/493) and in 60% (299/501) 
of tumors for HLA-E and HLA-G respectively (table I). Expression of HLA-EG was 
found in 23 % (100/428) of tumors. HLA-G stained positive in 1% (3/266) of normal 
tissue samples (figure 1E, F), while HLA-E showed positive staining in all normal tissue 
samples (figure 1 G). 
HLA-E, HLA-G and HLA-EG and prognostic associations with outcome
In the whole cohort of patients HLA-E, HLA-G and HLA-EG showed no statistically 
significant difference in outcome between expression versus no expression for RFP (log 
rank p-values respectively: 0.52, 0.95, 0.72) or OS (log rank p-values respectively: 0.86, 
0.74, 0.27) (figures 2 A, D, G and 3 A, D, G).
Next, we stratified patients based on classical HLA class I tumor expression, classified 
as expression versus loss. Among the subgroup of classical HLA class I expression 
results were similar as in the whole cohort of patients: neither for HLA-E, HLA-G, nor 
HLA-EG a statistically significant difference was found for different expression levels 
in outcome for RFP (log rank p-values respectively: 0.73, 0.69, 0.51) or OS (log rank 
p-values respectively: 0.64, 0.74, 0.22) (figures 2 B, E, H and 3 B, E, H). Interestingly, 
among the subgroup of patients with loss of tumor expression of classical HLA class 
I, HLA-E and HLA-G expression showed significant differences for RFP (log rank 
p-values respectively: 0.03, 0.04) and OS (log rank p-values respectively: 0.03, 0.12) 
between both expression groups (figures 2 C, F and 3 C, F). Of the patients with no 
tumor expression of HLA-E or HLA-G, respectively 60% and 56% of patients were 
relapse free after 10 years, whereas of the patients with tumor expression of HLA-E 
or HLA-G, respectively 35% and 39% of patients were relapse free after 10 years. The 
combination variable HLA-EG showed, similarly to HLA-E and HLA-G separately, 
differences in outcome between expression and no expression among the subgroup of 
classical HLA class I loss, but at a much higher level of significance than each separately 
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Total HLA-E HLA-G
No expression Expression p-value No expression Expression p-value
N % N % N % N % N %
Age 0.378 0.221
<40 48 8,4 17 6,9 28 11,4 22 7,4 16 7,9
40-50 145 25,3 64 25,9 59 24 74 24,7 59 29,2
50-60 132 23 57 23,1 56 22,8 61 20,4 50 24,8
>=60 249 43,4 109 44,1 103 41,9 142 47,5 77 38,1
Grade <0.001 0.242
I 80 14,2 44 18,1 29 12 40 13,4 23 11,8
II 282 49,9 132 54,3 105 43,6 158 53 92 47,2
III 203 35,9 67 27,6 107 44,4 100 33,6 80 41
Histological type 0.094 0.465
Ductal 513 90,6 214 87,7 225 93,4 266 89 180 92,3
Lobular 53 9,4 30 12,3 16 6,6 33 10,1 15 7,7
Tumor stage 0.094 0.616
pT1 211 38 96 40,2 87 36,6 112 38,8 67 34,4
pT2 272 49 108 45,2 128 53,8 142 49,1 103 52,8
pT3/4 72 13 35 14,6 23 9,7 35 12,1 25 12,8
Nodal stage 0.332 0.151
pN0 307 55,1 138 57,7 129 53,5 159 54,3 112 57,7
pN1-3 250 44,9 101 42,3 112 46,5 134 45,7 82 42,3
Estrogen receptor 0.004 0.095
Negative 203 37,6 72 31,4 106 44,7 100 35,3 82 42,9
Positive 337 62,4 157 68,6 131 55,3 183 64,7 109 57,1
Progesterone receptor 0.021 0.499
Negative 223 41,6 81 35,1 106 45,9 115 41,1 84 44,2
Positive 313 58,4 150 64,9 125 54,1 165 58,9 106 55,8
Her2 overexpression 0.008 0.014
No overexpression 435 80,9 200 87,7 186 78,5 236 84,6 145 75,5
Overexpression 103 19,1 28 12,3 51 21,5 43 15,4 47 24,5
Classical HLA I 0.003 <0.001
Negative 112 21,3 68 30,1 40 17,9 78 28,4 28 14,6
Positive 401 69,9 158 69,9 183 82,1 197 71,6 164 85,4
Local Therapy 0.407 0.661
MAST-RT 223 38,9 109 44,1 92 37,4 116 38,8 78 38,6
MAST+RT 108 18,8 41 16,6 50 20,3 52 17,4 43 21,3
BCS-RT 5 0,9 2 0,8 1 0,4 2 0,7 2 1
BCS+RT 238 41,5 95 38,5 103 41,9 129 43,1 79 39,1
Systemic therapy 0.076 0.004
Chemotherapy 112 19,5 37 15 57 23,2 43 14,4 52 25,7
Endocrine therapy 75 13,1 42 17 32 13 52 17,4 20 9,9
Both 18 3,1 7 2,8 10 4,1 12 4 6 3
None 369 64,3 161 65,2 147 59,8 192 64,2 124 61,4
Total 574 100 247 100 246 100 299 100 202 100
TABLE 1. Correlations between HLA-E and HLA-G expression and well-established prognostic factors using chi-
squared test. Abbreviations N number of  patients; % percentage; HLA-E human leukocyte antigen E; HLA-G human 
leukocyte antigen G; HER2 human epidermal growth factors receptor 2; MAST Mastectomy; BCS breast conservative 
surgery. 
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(log rank p-values: RFP:0.001; OS: 0.007) (figures 2 I and 3 I). Among the patients 
with no expression of HLA-EG, 55% were relapse free after 10 years, compared to 
17% for expression of HLA-EG. Cox proportional multivariate analysis was performed 
for relapses over time including the following factors: tumor stage, lymph node status, 
ER-status, HER2 expression, local therapy, endocrine therapy and HLA-EG. This 
analysis revealed that lymph node status and HLA-EG (p= 0.011, Hazard Ratio (HR): 
2.87, 95% Confidence interval (CI): 1.28-6.43) were independent factors for RFP among 
the subgroup of classical HLA class I loss patients (table II). These data showed that 
HLA-EG possesses a specific prognostic effect, but only among classical HLA class I 
loss patients. In order to prove that classical HLA class I and HLA-EG were significantly 
cooperating variables, an interaction term was introduced in Cox regression analysis. 
This analysis showed a statistically significant interaction (p= 0.002) between the two 
Figure 1 Representative examples 
of  immunohistochemical stainings 
with MEM-E/02 and 4H84 
antibodies on mammary tissues, 
performed according to standard 
protocols (details in Materials and 
Methods) A) HLA-E negative 
tumor B) HLA-E positive tumor 
C) HLA-G negative tumor D) 
HLA-G positive tumor E) HLA-G 
negative normal tissue F) HLA-G 
positive normal tissue G) HLA-E 
positive normal tissue.
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Figure 2 Relapses over time related with HLA-E (A,B,C), HLA-G (D,E,F) and HLA-EG (G,H,I) tumor expression, 
among the total population (A,D,G), patients with classical HLA class I tumor expression (B,E,H), and patients with 
loss of  classical HLA class I tumor expression (C,F,I). Remarkably, only in patients with loss of  classical HLA class I 
expression, HLA-E, HLA-G and HLA-EG affect relapses over time. Log-rank p-values are shown in each graph. 
markers, suggesting that there is a biological connection between classical HLA class I 
and HLA-EG. 
Correction for specificity of antibodies
The 4H84 antibody has been described to occasionally cross-react with classical HLA 
class I molecules 27. Therefore, we performed additional immunohistochemical analyses 
to examine whether this cross-reaction would interfere with our survival results. 
Expression on paired normal breast tissue of half the cohort was found in 1% (3/266) 
for HLA-G. These 3 patients who showed weakly positive staining for HLA-G on 
normal breast tissue, also stained positive for classical HLA class I on normal and tumor 
tissue, indicating that the 4H48 antibody possibly occasionally cross-reacted with these 
classical HLA class I molecules. It should be noted however that the staining on normal 
tissue was only modest when compared to tumor staining with the 4H84 antibody 
(compare fig 1F with 1D). In order to examine whether the occasional cross-reaction 
of the 4H84 antibody would interfere with our results, we performed a sub-analysis 
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by selecting only the tumors of the 266 patients of whom paired normal tissue was 
available. In this analysis, we excluded the 3 cases which showed positive staining for 
HLA-G on normal breast tissue (the presumed cases which showed cross-reaction for 
the 4H84 antibody) and examined whether survival analyses would reveal similar results 
as to when these cases would not be excluded. When excluding these 3 cases, no survival 
analyses reached statistical significance (log rank p-values ≥ 0.426) in neither the total 
population of patients nor the patient population with expression of classical HLA class 
I. This was concordant with the results found without exclusion of these cases (log-rank 
p-values ≥ 0.693). Importantly, no expression was seen of HLA-G in normal breast 
tissue of patients whose tumor showed no classical HLA class I expression, but resulted 
positive for HLA-G expression. Together, these results suggests that the occasional 
cross-reaction of 4H84 with classical HLA class I molecules did not interfere with our 
results. 
Figure 3 Kaplan Meier analysis of  overall survival related with HLA-E (A,B,C), HLA-G (D,E,F) and HLA-EG 
(G,H,I) tumor expression, among the total population (A,D,G), patients with classical HLA class I tumor expression 
(B,E,H), and patients with loss of  classical HLA class I tumor expression (C,F,I). Remarkably, only in patients with 
loss of  classical HLA class I expression, HLA-E, HLA-G and HLA-EG affect overall survival. Log-rank p-values are 
shown in each graph.
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Univariate Multivariate
N HR 95% CI p-value HR 95% CI p-value
Age
<40 8 1.00 0.580
40-50 37 1.23 0.426-3.544
50-60 31 1.54 0.526-4.508
>60 46 1.02 0.349-2.949
Grade
I 28 1.00 0.068
II 55 1.29 0.661-2.507
III 35 2.09 1.048-4.172
Histological type
Ductal 102 1.00 0.884
Other 16 0.95 0.470-1.917
Tumor stage
pT1 46 1.00 0.006 1.00 0.679
pT2 55 1.71 0.994-2.953 1.25 0.590-2.644
pT3/4 16 2.99 1.526-5.870 0.88 0.260-2.964
Nodal stage
pN- 64 1.00 <0.001 1.00 <0.001
pN+ 56 4.10 2.482-6.783 3.60 1.812-7.165
ER-status
Negative 37 1.00 0.057 1.00 0.237
Positive 83 0.62 0.376-1.014 0.70 0.385-1.266
PgR-status
Negative 44 1.00 0.202
Positive 73 0.73 0.445-1.186
HER2
No overexpression 102 1.00 0.075 1.00 0.069
Overexpression 10 1.73 0.947-3.176 2.21 0.939-5.217
Ki67 
Ki67- 91 1.00 0.841
Ki67+ 26 0.94 0.523-1.695
Local therapy
MAST-RT 46 1.00 <0.001 1.00 0.320
MAST+RT 25 2.97 1.631-5.422 2.15 0.796-5.813
BCS 51 0.96 0.542-1.703 1.23 0.572-2.663
Endocrine therapy
ET+ 15 1.00 0.048 1.00 0.471
ET- 107 0.52 0.273-0.994 0.74 0.318-1.698
Chemotherapy
CT+ 23 1.00 0.130
CT- 99 0.65 0.371-1.136
HLA-EG
No expression 81 1.00 0.002 1.00 0.011
Expression 12 3.08 1.512-6.251 2.87 1.278-6.430
TABLE 2.  Cox univariate and multivariate analysis for relapses free period (RFP). 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% confidence interval; HER2 human epidermal growth 
factor receptor 2; MAST Mastectomy; BCS breast conservative surgery.
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DISCUSSION
Tumor-immune interaction may be of great importance for clinical outcome 2. In this 
study we showed that in tumors devoid of classical HLA class I expression, HLA-E and 
HLA-G expression were of statistically significant influence on outcome of breast cancer 
patients independently of known clinicopathological parameters, with an almost 3 times 
higher risk of relapse over time for patients with expression of HLA-EG compared to 
patients with no expression of HLA-EG. This is the first study providing evidence for 
a prognostic value of non-classical HLA class I molecule expression in a large cohort 
of breast cancer patients. In addition, to our knowledge we are the first to report that 
such an effect on outcome of patients interplays with expression of classical HLA class 
I molecules. Importantly, these results can be explained by underlying biology and 
support and add to previous studies on tumor-immune interaction in breast cancer 3, 
12-19.  
Previous studies have found elevated expression levels of the non-classical HLA class 
I molecules, HLA-E and HLA-G, in tumor tissues 3, 12-19. Normally, HLA-G is not 
expressed on non-malignant cells. Corresponding to this fact, we found in our study 
that 4H84 HLA-G antibody did stain in a considerable number of tumor tissues, but 
in a negligible number of normal mammary tissues. Under normal circumstances 
HLA-E surface expression is dependent on the availability of HLA class I signal 
sequence-derived peptides. Therefore, HLA-E surface expression is usually found to be 
co-expressed with classical HLA class I, which comes to expression in almost all healthy 
tissues 3, 4. Corresponding to this fact, we did not find any normal mammary tissue that 
did not express HLA-E molecules. In some tumor tissue however, HLA-E expression 
seems to be independent of the availability of classical HLA class I sequence-derived 
peptides and can be expressed in cells that lack classical HLA class I expression 9, 30. 
Indeed, we found cytoplasmic expression of HLA-E in classical HLA class I negative 
tumors in our study. The disturbed balances of expression of classical HLA class I, 
HLA-E and HLA-G, as found in our study, suggests a cooperation between these 
molecules in evading immune recognition. According to the immunoediting hypothesis, 
tumors may become shaped through interaction with the immune system, leading to the 
selective outgrowth of highly tumorigenic clones that escape from immune recognition 
and elimination 31. Downregulation of classical HLA class I expression in tumors, with 
simultaneous loss of cell surface expression of HLA-E due to lack of peptide fragments 
which it can bind, is believed to reflect CTL immune escape 3. However, these tumor 
cells become highly vulnerable to NK cells, which recognize these “missing self” 
cells 14. Through a variety of factors, such as epigenetic control, hypoxia, stress and 
cytokines, expression of HLA-G and HLA-E may be upregulated and counteract this 
susceptibility to NK cells 3, 10, 32, 33. Supportive for a specific NK cell inhibition of 
the non-classical HLA class I molecules, for both HLA-E and HLA-G an inverse 
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correlation was found with NK cell infiltrate in a colorectal cancer and gastric cancer 
study respectively 34, 35. In addition, in various studies using colon cancer and melanoma 
cell lines it was demonstrated that overexpression of HLA-E and HLA-G respectively 
directly inhibited NK-mediated cell lysis 35-39. The statistical interaction between 
HLA-E and HLA-G with classical HLA class I molecules, as found in our study, adds 
to this evidence, suggesting that specifically in tumors devoid of classical HLA class I 
expression, upregulation of HLA-E and HLA-G expression counteracts the resulting 
NK cell susceptibility, leading to immune escape of tumor cells. Our study supports 
and adds to previous findings, suggesting that HLA-E and HLA-G contribute to tumor 
immune escape, specifically NK cells, a phenomenon that is likely to have impact on 
clinical outcome of patients. 
Prognostic associations of HLA-E and HLA-G have been studied in various types of 
tumors 16-19, 30, 35. In cervical cancer HLA-E expression increased with the progression 
of the lesion. One study analyzed the prognostic effect of HLA-E expression in 
colorectal cancer. A statistically significant association with outcome was noticed where 
high expression of HLA-E resulted in a worse disease free survival of patients 35. 
HLA-G expression showed a positive correlation with higher histological grade and 
clinical stage in colorectal cancer, gastric cancer, epithelial squamous cell carcinomas 
(ESCC) and cutaneaous T cell lymphoma. In addition, expression of HLA-G was an 
independent prognostic factor for a worse outcome of patients in colorectal cancer, 
ESCC and non small cell lung cancers 16, 18, 19. We described that tumor expression 
of HLA-E and HLA-G has an independent prognostic influence in breast cancer 
patients, resulting in a worse patient outcome. Previously, similar results for disease free 
survival were found for breast cancer, albeit that these results did not reach statistical 
significance 20. This study was similar to ours in terms of patients selection criteria 
and immunohistochemical staining methods, but was probably limited by the small 
number of breast cancer patients studied (n=43). The results of our study demonstrate 
for the first time a statistically significant association of HLA-E and HLA-G expression 
with clinical outcome in a large cohort of breast cancer patients, which is particularly 
revealed in patients with tumors lacking expression of classical HLA class I molecules. 
Moreover, patients with tumors with simultaneous expression of HLA-E and HLA-G 
had an increased risk of relapses compared to patients with tumors expressing either 
HLA-E or HLA-G, a phenomenon that has been previously described as well 13. In 
addition we were able to demonstrate a statistical interaction in outcome analyses, 
indicating that the effect on outcome of HLA-E and HLA-G expression and the effect 
on outcome of HLA class I expression do not only operate simultaneously, but that 
the combined effect on outcome of these molecules is more than additive. These data 
correspond to the hypothesis that tumor expression of the non-classical HLA class I 
molecules E and G may indeed serve to protect tumor cells from NK-cell attack, but 
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this is mostly relevant in a situation that NK cells are activated, i.e. in case classical HLA 
class I molecule expression is downregulated 10.
Together, these results provide new insights in breast cancer tumorigenesis and provide 
further evidence that the immune system is able to recognize and eliminate breast cancer 
cells. However, it is also evident that breast cancer cells are capable of escaping immune 
attack. A better understanding of the various phases of tumor immune interactions 
in breast cancer, i.e. elimination, equilibrium and finally escape, may lead to a better 
prediction of clinical outcome of patients. Furthermore, this knowledge may be used for 
the development of tailored immunotherapeutic treatment modalities. 
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ABSTRACT
Background Cell surface NKG2D ligands (NKG2DL) bind to the activating NKG2D 
receptor present on NK cells and subsets of T cells, thus playing a role in initiating an 
immune response. We examined tumor expression and prognostic effect of NKG2DL 
in breast cancer patients. 
Methods Our study population (n=677) consisted of all breast cancer patients primarily 
treated with surgery in our center between 1985 and 1994. Formalin-fixed paraffin-
embedded tumor tissue was immunohistochemically stained with antibodies directed 
against MIC-A/MIC-B (MIC-AB), ULBP-1, ULBP-2, ULBP-3, ULBP-4, and ULBP-5. 
Results NKG2DL were frequently expressed by tumors (MIC-AB, 50% of the 
cases; ULBP-1, 90%; ULBP-2, 99%; ULBP-3, 100%; ULBP-4, 26%; ULBP-5, 90%) 
and often showed co-expression: MIC-AB and ULBP-4 (p=0.043), ULBP-1 and 
ULBP-5 (p=0.006), ULBP-4 and ULBP-5 (p<0.001). MIC-AB (p=0.001) and ULBP-2 
(p=0.006) expression resulted in a statistically significant longer relapse free period 
(RFP). Combined expression of these ligands showed to be an independent prognostic 
parameter for RFP (p<0.001, HR 0.41). Combined expression of all ligands showed no 
associations with clinical outcome. 
Conclusions We demonstrated for the first time that NKG2DL are frequently expressed 
and often co-expressed in breast cancer. Expression of MIC-AB and ULBP-2 resulted 
in a statistically significant beneficial outcome concerning RFP with high discriminative 
power. Combination of all NKG2DL showed no additive or interactive effect of ligands 
on each other, suggesting that similar and co-operative functioning of all NKG2DL can 
not be assumed. Our observations suggest that among driving forces in breast cancer 
outcome are immune activation on one site and tumor immune escape on the other site. 
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BACKGROUND
Breast cancer is the most commonly diagnosed female cancer and is the leading cause of 
death from cancer in women in the western world 1. Decisions regarding use of systemic 
therapy are mainly based on prognostic and predictive factors like lymph node status, 
tumor size, grade, hormone receptor and human epidermal growth factor receptor 2 
(HER2) expression 2, 3. However, current prognostic and predictive factors still do 
not provide optimal risk-stratification. Therefore, additional prognostic and predictive 
information could result in an improved tailored treatment for patients with breast 
cancer. 
There is strong evidence that the immune system plays a role in tumor growth and 
progression 4, 5. An effective immune response may lead to recognition of tumor cells, 
resulting in their eradication. However, due to their genetic unstable nature, tumor cells 
may arise which display properties that enables them to escape from immune recognition 
4, 5. Indeed, downregulation or loss of proteins that are crucial for immune responses, 
like classical human leukocyte antigens (HLA) class I, or upregulation of proteins that 
confer resistance to immune recognition, like non-classical HLA class I, are frequently 
found in various types of tumors 6-10.
The activating receptor natural killer cell lec-tin-like receptor gene 2D (NKG2D) is a 
stimulatory immune receptor that is expressed on natural killer (NK) cells, NKT cells, 
γδ+ T cells and CD8+ T cells 11. Ligands which bind NKG2D receptors comprise major 
histocompatibility complex class I chain-related proteins A and B (MIC-AB) and unique 
long 16 (UL16) binding proteins 1-6 (ULBP1-6) 12, 13. Expression of these ligands may 
be induced upon infection and other inducers of cellular stress and is unusual in normal 
cells 14. By binding to the NKG2D receptors on NK and T cells, the NKG2D ligands 
may initiate an immune response against cells expressing these ligands. Overexpression 
and shedding of NKG2D ligands have been reported 14. It is, however, unclear whether 
these features also results in activation of an immune response or lead to overstimulation 
and downregulation of NKG2D on immune cells 11. 
Malignant transformation of cells may be among stimuli inducing expression of 
NKG2D ligands as such expression has been found in various tumor types 8-10, 15-18. 
This may be a mechanism for preventing tumor growth by advancing an anti-tumor 
immune response. Convincing evidence has been found in in vivo studies, which have 
shown that in mouse models transfection with NKG2D ligands resulted in a NKG2D-
mediated tumor rejection 19, 20. Other studies showed that downregulation or complete 
knockout of NKG2D in mice resulted in an impaired immune response against tumor 
cells, higher expression levels of NKG2D ligands, and an increased incidence of certain 
tumors 21, 22.
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A few studies have investigated tumor expression of NKG2D ligands and associations 
with clinical outcome in human breast, colorectal, and ovarian cancer 8-10, 15, 16. 
Expression of MIC-A was frequently found in all tumors studied and resulted in a 
statistically significant favorable patient’s prognosis in colorectal cancer, while it was not 
statistically significantly associated with outcome in breast cancer and ovarian cancer 
8-10, 16. ULBP1-5 expression was also found to be expressed in many tumor samples of 
colorectal and ovarian cancer 9, 10, 15. In colorectal cancer expression of ULBP5 was an 
independent prognostic factor for a favorable clinical outcome 9. In contrast to these 
results, expression of ULBP2 and ULBP4 were found to be independent prognostic 
factors for a worse outcome of ovarian cancer patients 10, 15. Taken together, several 
studies suggest that evasion of NKG2D-mediated immune regulation plays an important 
role in tumor progression, but some studies contradict this suggestion. Contradictory 
results may be explained by assuming functional differences in immune regulation of 
the different ligands. Moreover, expression of NKG2D ligands may behave different 
among different tumor types 9. It is known that overexpression or shedding of these 
ligands leads to overstimulation and downregulation of NKG2D on immune cells 10, 15, 
thereby evading an immune response. 
In breast cancer, the prognostic effect of NKG2D ligands and their mutual relationship 
is largely unknown. Therefore, the purpose of this study was to analyze the clinical 




The patient population comprised all non-metastasized breast cancer patients primarily 
treated with surgery between 1985 and 1994 at the Leiden University Medical Center 
(n=677). Patients with bilateral tumors or a prior history of cancer, other than basal 
cell carcinoma or cervical carcinoma in situ, were excluded. The following data were 
known: age, tumor morphology and differentiation grade, TNM stage, type of local and 
systemic therapy, recurrence and survival status, estrogen receptor (ER), progesterone 
receptor (PgR), and human epidermal growth factor 2 (HER2) expression (Table1). All 
these parameters were determined according to current pathology standards. A tissue 
micro array (TMA) of available formalin-fixed paraffin-embedded (FFPE) tumors of 
the patient cohort has been previously constructed and described (n=574) 23. Approval 
was obtained from the Leiden University Medical Center Medical Ethics Committee. 
All samples were handled in a coded fashion, according to National ethical guidelines 
(“Code for Proper Secondary Use of Human Tissue”, Dutch Federation of Medical 
Scientific Societies).
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Immunohistochemistry
Antibodies specific against MIC-AB (ab54413; Abcam), ULBP-1 (HPA007547; Atlas 
antibodies), ULBP-2 (af1298; R&D systems), ULBP-3 (CUMO3-100; BAMOMAB), 
ULBP-4 (RAET1E) and ULBP-5 (RAET1G, both kindly provided by Dr. Robert A 
Eagle, Cambridge, UK) 9, 24 were used for immunohistochemical staining of tumor 
tissue. The specificity of anti-ULBP-2 antibody has been previously determined, 
which showed occassional cross-reactity with highly related molecules RAET1L and 
to a lesser extent with RAET1G, but a good recognition of ULBP-2 25. We are not 
aware of antibodies which can specifically discriminate between ULBP2, RAET1L and 
RAET1G extracellular domains. 
TMA sections of 4μm were cut, deparaffinized and rehydrated. Endogenous peroxidase 
was blocked in 0.3% hydrogen-peroxide methanol for 20 minutes. Heat-induced antigen 
retrieval for 10 minutes at maximum power in a microwave oven was performed. 
Sections were incubated overnight with primary antibodies using predetermined 
optimal dilutions and incubations times. Sections for ULBP-2 staining were incubated 
with Rabbit Anti-Goat Immunoglobulins (DAKO) followed by StreptABComplex 
(DAKO) for 30 minutes. Sections for all other stainings were incubated with secondary 
antibody Envision (Dako cytomation K4001 or K4003) for 30 minutes. Stainings 
were visualized using DAB-solution (Dako cytomation K3468), counterstained with 
haematoxylin, dehydrated, and finally mounted in malinol. For each type of antibody, 
all tissue sections were stained simultaneously to avoid inter-assay variation. 
Evaluation of immunostaining
Microscopic analysis of MIC-AB, ULBP-1, ULBP-2, ULBP-3, ULBP-4 and ULBP-5 
expression was performed by two independent observers in a blinded manner. Since 
staining of tumors was relatively homogenous, for each tumor the overall intensity of 
staining (negative (0), weak (1), intermediate (2) or strong (3)) was determined. 
Statistical analysis
Statistical analyses were performed using the statistical package SPSS (version 16.0 for 
Windows, Spps Inc, Chicago, IL, USA). Cohen’s kappa coefficient was used to assess inter-
observer agreement in quantification. This revealed a moderate agreement for ULBP-5 
(kappa=0.410), a substantial agreement in classification for MIC-AB (kappa=0.790) and 
ULBP-4 (kappa=0.650), and an almost perfect agreement for ULBP-1 (kappa=0.913), 
ULBP-2 (kappa=0.940), and ULBP-3 (kappa=0.869). The χ2 test was used to evaluate 
associations between expression of the different NKG2D ligands. Relapse free period 
(RFP) was the time from date of surgery until an event (locoregional recurrence and/or 
a distance recurrence, whichever came first). The Kaplan–Meier method was used for 
survival plotting and log-rank test for comparison of survival curves. RFP is reported 
as cumulative incidence function, after accounting for death as competing risk 26. 
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Total MICAB ULBP1 ULBP2
Low High Low High Low High
N % N % N % N % N % N % N %
Age
<40 48 8.4 4 4.0 31 8.7 22 10.0 10 6.1 34 8.7 9 7.3
40-50 145 25.3 28 28.0 86 24.0 62 28.2 32 19.4 85 21.7 42 34.1
50-60 132 23.0 26 26.0 78 21.8 45 20.5 44 26.7 100 25.6 20 16.3
>=60 249 43.4 42 42.0 163 45.5 91 41.4 79 47.9 172 44.0 52 42.3
Grade
I 80 14.2 22 22.0 38 10.9 39 18.1 9 5.5 41 10.7 27 22.1
II 282 49.9 42 42.0 181 51.7 109 50.5 80 49.1 188 49.0 65 53.3
III 203 35.9 36 36.0 131 37.4 68 31.5 74 45.4 155 40.4 30 24.6
Histological type
Ductal 513 90.6 91 91.0 322 91.7 194 89.8 151 92.6 354 92.2 106 86.9
Lobular 53 9.4 9 9.0 29 8.3 22 10.2 12 7.4 30 7.8 16 13.1
T-status
T1 211 38.0 40 41.7 124 35.7 96 44.9 37 23.3 128 33.7 59 50.4
T2 272 49.0 44 45.8 176 50.7 87 40.7 96 60.4 198 52.1 46 39.3
T3/4 72 13.0 12 12.5 47 13.5 31 14.5 26 16.4 54 14.2 12 10.3
N-status
N0 307 55.1 60 61.2 181 52.8 118 54.9 69 44.5 196 51.7 74 62.2
N1-3 250 44.9 38 38.8 162 47.2 97 45.1 86 55.5 183 48.3 45 37.8
ER-status
Negative 203 37.6 33 33.7 137 39.3 95 43.8 55 34.8 147 38.2 45 37.5
Positive 337 62.4 65 66.3 212 60.7 122 56.2 103 65.2 238 61.8 75 62.5
PgR-status
Negative 223 41.6 33 33.3 147 42.6 88 40.9 68 43.0 169 43.8 40 33.9
Positive 313 58.4 66 66.7 198 57.4 127 59.1 90 57.0 217 56.2 78 66.1
Her2-status
No overexpression- 378 89.6 78 92.9 264 88.0 174 89.7 125 89.3 291 90.9 79 84.9
Overexpression 44 10.4 6 7.1 36 12.0 20 10.3 15 10.7 29 9.1 14 15.1
Local Therapy
MAST-RT 223 38.9 41 41.0 146 40.8 80 36.4 79 47.9 149 38.1 53 43.1
MAST+RT 108 18.8 17 17.0 66 18.4 46 20.9 33 20.0 83 21.2 15 12.2
BCS-RT 5 0.9 0 0.0 5 1.4 2 0.9 2 1.2 5 1.3 0 0.0
BCS+RT 238 41.5 42 42.0 141 39.4 92 41.8 51 30.9 154 39.4 55 44.7
Systemic therapy
CT alone 112 19.5 17 17.0 73 20.4 44 20.0 25 15.2 80 20.5 24 19.5
HT alone 75 13.1 8 8.0 54 15.1 31 14.1 29 17.6 54 13.8 16 13.0
CT&HT 18 3.1 1 1.0 13 3.6 3 1.4 9 5.5 14 3.6 3 2.4
None 369 64.3 74 74.0 218 60.9 142 64.5 102 61.8 243 62.1 80 65.0
Total 574 100 100 100 358 100 220 100 165 100 391 100 123 100
Table 1 Correlations between MIC-A-B, ULBP-1, ULBP-2 expression and well-established prognostic factors. Missing 
values are not shown. 
Abbreviations N number of  patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human 
epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET 
endocrine therapy; CT chemotherapy.
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Cox regression was used for univariate and multivariate analysis for RFP. Significant 
variables (p<0.1) in univariate analysis were included in multivariate analysis. 
RESULTS
Patient and tumor characteristics
Median age of patients was 57 years (range: 23-96 years). Median follow-up of patients 
alive was 19 years (range: 14-23 years). Clinicopathological and treatment characteristics 
are shown in table 1.
Expression of NKG2D ligands
Most of the NKG2D ligands examined in this study were frequently expressed among 
the breast tumor cohort: MIC-AB in 50% of the cases; ULBP-1 in 90%; ULBP-2 in 
99%; ULBP-3 in 100%; ULBP-4 in 26%; and ULBP-5 in 90%. A broad distribution of 
immunohistochemical staining-intensities was seen for ULBP-2, ULBP-3 and ULBP-5, 
while MIC-AB, ULBP-1 and ULBP-4 showed a skewed distribution of staining-
intensities where most tumors stained weakly positive (representative examples of 
staining: Figure 1). Therefore, the median intensity was taken as a cut-off value for 
all ligands to categorize low and high expression resulting in respectively 50%, 43%, 
24%, 27%, 26%, 10% of tumors with high expression of MIC-AB (Figure 1B), ULBP-1 
(Figure 1D), ULBP-2 (Figure 1F), ULBP-3 (Figure 1H), ULBP-4 (Figure 1J) and 
ULBP-5 (Figure 1L) and respectively 50%, 57%, 76%, 73%, 90% of the tumors with 
low expression of MIC-AB (Figure 1A), ULBP-1 (Figure 1C), ULBP-2 (Figure 1E), 
ULBP-3 (Figure 1G), ULBP-4 (Figure 1I) and ULBP-5 (Figure 1K). 
NKG2D ligands were found to be frequently co-expressed: MIC-AB positively 
correlated with ULBP-4 (p=0.043); ULBP-1 showed a positive correlation with ULBP-5 
(p=0.006); ULBP-4 had a positive correlation with ULBP-5 (p<0.001). 
Association of NKG2D ligands with clinicopathological parameters 
High expression of NKG2D ligands was generally associated with favorable 
clinicopathological parameters (table 1 and 2): statistically significant associations were 
found between high expression of MIC-AB and lower tumor grade (p=0.012); high 
expression of ULBP-1 and higher tumor grade (p<0.001), smaller tumor size (p<0.001) 
and more lymph node positive tumors (p=0.049); high expression of ULBP-2 and 
younger age (p=0.022), lower tumor grade (p<0.001), smaller tumor size (p=0.005) and 
more lymph node negative tumors (p=0.046); high expression of ULBP-3 and higher 
tumor grade (p=0.001); high expression of ULBP-4 and smaller tumor size (p=0.001); 
high expression of ULBP-5 and more PgR negative tumor status (p=0.016). 
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Associations with outcome of NKG2D ligands
When analyzed separately, MIC-AB and ULBP-2 showed statistically significant results 
on outcome analyses (log rank p-values respectively: 0.001, 0.006), where high expression 
of MIC-AB and ULBP-2 showed to have fewer relapses over time compared to low 
expression (Figure2 A, C). For MIC-AB low expression, 51% of patients were relapse 
Figure 1 Representative examples of  
immunohistochemical stainings of  primary breast 
cancer tissues for respectively no expression 
and high expression of  MIC-AB (A: intensity 
0 (negative); B: intensity 2 (intermediate)), 
ULBP-1 (C: intensity 0 (negative); D: intensity 2 
(intermediate)), ULBP-2 (E: intensity 0 (negative); 
F: intensity 3 (strong)), ULBP-3 (G: intensity 0 
(negative); H: intensity 3 (strong)), ULBP-4 (I: 
intensity 0 (negative); J: intensity 1 (weak)), and 
ULBP-5 (K: intensity 0 (negative); L: intensity 3 
(strong)) in breast cancer. Immunohistochemistry 
was performed according to standard protocols as 
described in Materials and Methods. 
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Total ULBP3 ULBP4 ULBP5
Low High Low High Low High
N % N % N % N % N % N % N %
Age
<40 48 8.4 25 8.2 11 9.8 29 7.8 15 11.8 38 8.5 3 6.4
40-50 145 25.3 84 27.5 24 21.4 91 24.6 33 26.0 119 26.7 9 19.1
50-60 132 23.0 68 22.3 22 19.6 86 23.2 30 23.6 103 23.1 12 25.5
>=60 249 43.4 128 42.0 55 49.1 164 44.3 49 38.6 185 41.6 23 48.9
Grade
I 80 14.2 45 15.0 10 9.1 51 13.9 13 10.6 62 14.2 2 4.3
II 282 49.9 160 53.2 43 39.1 181 49.5 67 54.5 219 50.0 21 45.7
III 203 35.9 96 31.9 57 51.8 134 36.6 43 35.0 157 35.8 23 50.0
Histological type
Ductal 513 90.6 281 93.4 102 92.7 330 89.9 113 91.9 396 90.2 43 93.5
Lobular 53 9.4 20 6.6 8 7.3 37 10.1 10 8.1 43 9.8 3 6.5
T-status
T1 211 38.0 113 38.4 40 36.0 118 33.0 57 46.0 159 36.8 19 40.4
T2 272 49.0 142 48.3 54 48.6 180 50.3 61 49.2 209 48.4 26 55.3
T3/4 72 13.0 39 13.3 17 15.3 60 16.8 6 4.8 64 14.8 2 4.3
N-status
N0 307 55.1 158 53.9 61 55.5 193 53.2 66 54.5 237 54.7 24 53.3
N1-3 250 44.9 135 46.1 49 44.5 170 46.8 55 45.5 196 45.3 21 46.7
ER-status
Negative 203 37.6 113 38.8 37 33.6 135 37.8 43 35.0 152 35.3 21 45.7
Positive 337 62.4 178 61.2 73 66.4 222 62.2 80 65.0 278 64.7 25 54.3
PgR-status
Negative 223 41.6 130 45.0 42 38.2 141 39.6 51 41.5 158 37.2 26 55.3
Positive 313 58.4 159 55.0 68 61.8 215 60.4 72 58.5 267 62.8 21 44.7
Her2-status
Overexpression - 378 80.9 207 89.6 82 89.1 256 88.6 93 93.9 311 90.7 35 85.4
Overexpression + 44 19.1 24 10.4 10 10.9 33 11.4 6 6.1 32 9.3 6 14.6
Local Therapy
MAST-RT 223 38.9 116 38.0 43 38.4 141 38.1 46 36.2 165 37.1 24 51.1
MAST+RT 108 18.8 56 18.4 24 21.4 86 23.2 14 11.0 94 21.1 3 6.4
BCS-RT 5 0.9 3 1.0 1 0.9 1 0.3 3 2.4 4 0.9 0 0.0
BCS+RT 238 41.5 130 42.6 44 39.3 142 38.4 64 50.4 182 40.9 20 42.6
Systemic therapy
CT alone 112 19.5 65 21.3 23 20.5 81 21.9 20 20.3 93 20.9 8 17.0
HT alone 75 13.1 32 10.5 10 8.9 52 14.1 16 12.6 60 13.5 5 10.6
CT&HT 18 3.1 10 3.3 2 1.8 13 3.5 1 0.8 11 2.5 1 2.1
None 369 64.3 198 64.9 77 68.8 224 60.5 90 70.9 281 63.1 33 70.2
Total 574 100 305 100 112 100 370 100 127 100 445 100 47 100
Table 2 Correlations between ULBP-3, ULBP-4 and ULBP-5 expression and well-established prognostic factors. 
Missing values are not shown. 
Abbreviations N number of  patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human 
epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET 
endocrine therapy; CT chemotherapy.
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free after 20 years, while of patients with high expression of MIC-AB 27% showed a 
relapse within 20 years. For ULBP-2, 20 year RFP rates for low expression versus high 
expression were respectively 56% and 43%. No statistically significant associations with 
outcome were seen for ULBP-1, ULBP-3, ULBP-4 and ULBP-5 (Figure 2 B, D-F). 
Cox univariate regression analysis was performed for expression of each type of ligand. 
MIC-AB (Hazard ratio (HR) 0.60, 95% confidence interval (95%CI) 0.448-0.810, 
p=0.001) and ULBP-2 (HR 0.63, 95%CI 0.454-0.869, p=0.005) showed statistically 
significant results for a favorable RFP, while all other types of ligands did not reach 
statistical significance (data not shown). 
To seek how combined expression of MIC-AB and ULBP2 ligands would predict 
patient outcome a new variable was made representing expression of both ligands: 
(1) Both MIC-AB and ULBP-2 low expression; (2) either MIC-AB or ULBP-2 high 
expression; (3) both MIC-AB and ULBP-2 high expression. Combined expression of 
MIC-AB and ULBP-2 resulted in a prognostic factor (log rank p-value: <0.001; Figure 
3), where low expression of both ligands versus high expression of either ligand versus 
high expression of both ligands resulted in respectively 23%, 48% and 60% of patients 
to be relapse free after 20 years. Cox proportional multivariate analysis showed the 
combined ligand variable to be statistically significant for RFP independently of known 



















Figure 2 Relapses over time related with expression of  MIC-AB (A), ULBP-1 (B), ULBP-2 (C), ULBP-3 (D), ULBP-4 
(E), and ULBP-5 (F). X-axis represents patient follow-up in years; Y-axis represents cumulative relapses in %. Log-
rank p-values are shown in each graph. Only expression of  MIC-AB and ULBP-2 resulted in statistically significantly 
favorable relapse-free period (RFP).
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0.54, 95%CI 0.380-0.757; MIC-AB and ULBP-2 both low versus both high: HR 0.41, 
95%CI 0.246-0.682; p-value<0.001) (Table 3). 
Relapse Free Period UNIVARIATE MULTIVARIATE
N HR 95% CI p-value HR 95% CI p-value
Age
<40 48 1.00 0.422
40-50 145 0.97 0.612-1.539
50-60 132 1.17 0.734-1.853
>60 249 0.90 0.574-1.408
Grade
I 80 1.00 0.001 1.00 0.473
II 282 1.43 0.945-2.172 1.18 0.711-1.948
III 203 2.02 1.326-3.078 1.34 0.802-2.231
Histological type
Ductal 513 1.00 0.291
Other 53 1.24 0.832-1.846
Tumor stage
pT1 211 1.00 <0.001 1.00 0.298
pT2 272 1.59 1.205-2.093 1.17 0.832-1.637
pT3/4 72 2.49 1.706-3.635 1.45 0.908-2.316
Nodalstage
pN- 307 1.00 <0.001 1.00 <0.001
pN+ 250 3.06 2.379-3.945 2.70 1.987-3.669
ER-status
Negative 203 1.00 0.725
Positive 337 1.05 0.808-1.359
PgR-status
Negative 223 1.00 0.744
Positive 313 0.96 0.743-1.236
HER2
No overexpression 378 1.00 0.401
Overexpression 44 1.21 0.776-1.883
Endocrine therapy
ET- 481 1.00 0.197
ET+ 93 1.24 0.896-1.705
Chemotherapy
CT- 444 1.00 0.839
CT+ 130 0.97 0.730-1.291
MIC-AB & ULBP-2
Both Low 68 1.00 <0.001 1.00 <0.001
Either one high 275 0.59 0.426-0.820 0.54 0.380-0.757
Both high 64 0.38 0.230-0.612 0.41 0.246-0.682
Table 3 Cox univariate and multivariable analysis for recurrence free period (RFP) for combined expression of  MIC-AB 
and ULBP-2. Missing values are not shown. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PgR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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In order to analyze the frequencies and prognostic effect of number of co-expressed 
and amount of co-expression of NKG2D ligands, two new variables were constructed. 
First, the total number of the different NKG2D ligands that were expressed. For that 
purpose, the number of NKG2D ligands with high expression was counted. So for 
each tumor, this resulted in a minimal and maximal possible score of respectively 0 
and 6. Second, the total amount of NKG2D ligand expression. For that purpose, the 
intensity of staining (ranging from 0 to 3) of NKG2D ligands was added, obtaining a 
total NKG2D ligand intensity score. So for each tumor, this resulted in a minimal and 
maximal possible score of respectively 0 and 18. 
The median number of NKG2D ligands with high expression was 1 (range 0-6). For 




Figure 3 Relapses over time related with combined 
expression of  MIC-AB and ULBP-2. X-axis represents 
patient follow-up in years; Y-axis represents cumulative 
relapses in %.  Log-rank p-values are shown in the graph. 
Combined low expression of  MIC-AB and ULBP-2 
resulted in the worst outcome of  patients concerning 
relapse-free period (RFP); while combined high 
expression of  both ligands resulted in the most favorable 
outcome of  patients. 
5 and 6 numbers of different NKG2D ligands highly expressed were combined as one 
single group: ≥ 3 ligands of high expression. 
No associations were seen for the number of NKG2D ligands with high expression 
for RFP outcome analyses (log rank p-value: 0.967); patients with tumors with a low 
number of NKG2D ligands with high expression resulted in a similar RFP compared to 
a high number of NKG2D ligands with high expression (Figure 4A). 
The median total amount of NKG2D ligand intensity score was 8 (range 4-16). No 
tumors showed complete lack (score 0) or high intensity expression of all NKG2D 
ligands (score 18). 
For outcome analyses, NKG2D scores 14-16 were combined and classified as ≥ 14, 
since these subgroups separately contained only one patient. No association was seen 
for amount of total NKG2D ligand expression and RFP (log rank p-value: 0.721); high 
total NKG2D ligand expression resulted in some cases in a worse RFP (e.g. score 11) 
while in others it resulted in a favorable RFP (e.g. score 13) and vice versa, low total 
NKG2D ligand expression resulted for some patients in a favorable RFP (e.g. score 6) 
and for other patients in a worse RFP (e.g. score 4) (Figure 4B).
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DISCUSSION
The importance of interaction between tumor development and the immune system 
for cancer outcome is highlighted by an overwhelming number of studies, performed in 
vitro, in vivo and using patient cohorts. Recent studies have shown that NKG2D ligands 
may play an important role in cancer immunosurveillance and cancer immunoediting 
8-10, 15-22. In this study, we examined the impact of tumor expression of NKG2D 
ligands on the prognosis of breast cancer patients. The data of our study indicate that 
NKG2D ligands are frequently high expressed in breast tumors and that this expression 
influences prognosis of patients. We were able to statistically prove that high expression 
levels of MIC-AB and ULBP-2 resulted in a RFP benefit. Combining expression of 
MIC-AB and ULBP-2 resulted in a very accurate stratification of patients for prognosis 
concerning RFP. The prognostic potential of this combined variable was comparable to 
that of lymph node status: patients with low tumor expression of both ligands had an 
almost 2.5 times increased risk of developing relapses compared to patients with high 
tumor expression of both ligands. 
NKG2D ligands are expressed on the cell surface in response to stress or malignant 
transformation 11. Our study confirms that breast cancer tumor cells show frequent and 
high expression of NKG2D ligands, as has been found in other studies for various types 
of tumors such as ovarian cancer, colorectal cancer and breast cancer 8-10, 15, 16. Though 
all studies show consistently frequent expression of NKG2D ligands, very diverse 






























Figure 4 Relapses over time related with combined number of  NKG2D ligands with high expression (A) and amount of  
expression of  NKG2D ligands (B). (A) legends in graph show total number of  NKG2D ligands with high expression; 
(B) legends in graph show total intensity score of  all NKG2D ligand expression. X-axis represents patient follow-up in 
years; Y-axis represents cumulative relapses in %. Log-rank p-values are shown in the graph. No associations were found 
with outcome concerning RFP for either combined number of  expressed (A) or combined amount of  expression (B) 
of  ligands. 
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types 8-10, 15, 16. This may be explained by functional differences in immune regulation 
for varying expression levels of different ligands in different environments. Expression 
of NKG2D ligands may induce an immune response through binding to the NKG2D 
receptor, present on NK cells and a subset of T cells 11. Therefore, selective outgrowth 
of malignant cells that do not express these NKG2D ligands may be a mechanism of 
tumor immune escape. On the other hand, overexpression of NKG2D ligands could 
lead to overstimulation and thereby insensibility or anergy of immune cells, which 
would result in evasion of immune attack by tumors overexpressing NKG2D ligands 
11. Adding to this hypothesis, it has been reported that NKG2D ligands on the cell 
membrane may be cleaved and produce soluble molecules. This shedding of NKG2D 
ligands could systemically downregulate NKG2D receptor expression and thereby 
result in an impaired anti-tumor reactivity of NK and T cells 11, 27. Taken together, the 
mechanisms by which NKG2D ligands mediate immune function or dysfunction may 
be diverse in different tumors and differ according to circumstances. The contradictory 
results on the prognostic effect of NKG2D ligands found between different studies on 
different tumors may be reflected by the functional and mechanistic implications of 
interaction between NKG2D and its ligands. In ovarian cancer expression of NKG2D 
ligands resulted in a worse patient outcome, probably due to chronic overexpression 
and shedding of these ligands, leading to overstimulation and downregulation of the 
NKG2D receptor of NK and T cells and, therefore, an impaired immune response 
10, 15. Supporting the hypothesis that elevated expression of NKG2D ligands results 
in immune escape in ovarian cancer, one study found elevated levels of MIC-AB and 
ULBP-2 to be positively correlated to less intra-tumor epithelial CD57+ cells. The 
results found in breast cancer in the present study are contradictory to the results found 
in ovarian cancer, but similar to those found in colorectal cancer 9, 16. The results in our 
study and colorectal cancer are supported by the theory that expression of NKG2D 
ligands results in activation of immune cells which is reflected in a patient beneficial 
outcome for high ligand expression 9, 16. We found frequent and high expression of 
ligands in our study and statistically significant associations between expression levels 
of these ligands, indicating their cooperation with each other. Adding to the hypothesis 
that low expression of these ligands is a result of selective pressure by the immune 
system that results in cancer immune evasion or immunoediting, low expression of 
MIC-AB and ULBP-2 were prognostic factors for an unfavorable RFP of patients. 
When expression of MIC-AB and ULBP-2 were combined they showed to add to each 
others prognostic effect which is in line with the results found in previous studies 9, 10 
and suggests that NKG2D ligands operate together and in a similar manner. 
 
Since the exact functioning of all NKG2D ligands and their cooperative function 
is largely unknown, we performed outcome analyses with two different variables 
that represented combined number of highly co-expressed ligands and amount of 
co-expression of all ligands. The results of these analyses revealed no patterns of any 
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cooperative functioning between all ligands, as both variables showed no consistent 
and significant relationship with clinical outcome of disease. This suggests that the 
original hypothesis of all NKG2D ligands having a similar functioning and additive 
effect on each other’s functioning in activating or evading an immune response, may be 
too simplistic. Considering our results and those as found in literature, altogether, each 
NKG2D ligand analysed separately does not show equal effects on clinical outcome, 
and different ligands show varying prognostic effects in different tumors. Specific 
combinations of ligands (e.g. MIC-AB and ULBP-2 in our study, ULBP2 and ULBP4 
in ovarian cancer 10) do show additive effects or statistical interactions on prognostic 
value. However, as highlighted by our combined analyses, a simple additive effect of all 
NKG2D ligands, by considering a similar or cooperative functioning of all these ligands, 
can not be assumed. This indicates the complexity of NKG2D ligands functioning and 
emphasizes the importance of further research on the precise mechanisms of actions 
of NKG2D ligands, separately, in combination with each other, and under different 
circumstances.
CONCLUSIONS
We have shown in this study, for the first time, that breast tumors may express all 
of the known NKG2D ligands and that expression of MIC-AB and ULBP-2 
results in a favorable outcome concerning RFP. A variable combining MIC-AB and 
ULBP-2 expression has shown to be a prognostic parameter independently of known 
clinicopathological parameters and with high discriminative power. Our results suggest 
that NKG2D ligands play a crucial role in tumor immunoediting in breast cancer 
and provide further evidence that tumor-immune interactions play an important role 
in breast cancer. In addition, by NKG2D ligand combined analyses we highlight the 
importance of further studies on unraveling the precise separate functioning of these 
ligands. 
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ABSTRACT
Introduction There is strong evidence that the host’s cellular immune response is 
linked to tumor progression, however its impact on patient outcome in breast cancer 
is poorly understood. The purpose of this study is to define tumor immune subtypes, 
focusing on cellular immune responses and investigate their prognostic effect in breast 
cancer patients.
Methods Our training (n=440) and validation cohort (n=382) consisted of all early 
breast cancer patients primarily treated with surgery in our center between 1985 and 
1996. Tumor tissue sections were immunohistochemically stained for CD8 (CTL) and 
PEN5 (NK cells). Tumor expression of classical and non-classical HLA class I, and 
tumor-infiltrating Tregs were previously determined. Tumor immune subtypes were 
constructed based on quantification of these markers and biological rationale. 
Results High, intermediate and low immune susceptible tumor immune subtypes 
were found in respectively 16%, 63% and 20% of patients in the training cohort and 
16%, 71% and 13% in the validation cohort. The subtypes showed to be statistically 
significant prognostic in multivariate analyses for relapse free period (RFP) (p<0.0001, 
intermediate versus high: hazard ratio (HR) 1.95; low versus high HR 2.98) and 
relative survival (RS) (p=0.006, intermediate versus high HR 3.84; low versus high: 
HR 4.26). Validation of these outcome analyses confirmed the independent prognostic 
associations: RFP (p=0.025) and RS (p=0.040). 
Conclusion The tumor immune subtypes that we present represent a prognostic 
profile with solid underlying biological rationale and with high discriminative power 
confirmed in an independent validation cohort. Our results emphasize the importance 
of tumor immune surveillance in the control of tumor development and, therefore, 
in determining patient prognosis. Tumor immune subtype profiling is promising 
for prognosis prediction and the achievement of tailored treatment for breast cancer 
patients.
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INTRODUCTION
Breast cancer is the most commonly diagnosed female cancer and is the leading cause 
of death from cancer in women in the western world1. Decisions regarding use of 
systemic therapy in primarily non-metastasized breast cancer patients are mainly based 
on prognostic and predictive factors like lymph node status, tumor size, grade, hormone 
receptor and human epidermal growth factor receptor 2 (HER2) expression2. However, 
currently these do not provide optimal risk-stratification. Therefore, additional 
prognostic and predictive information is sought in order to improve tailored treatment 
for patients with breast cancer. 
There is strong evidence that a host’s cellular immune response is able to control tumor 
progression3. However, due to their intrinsic genetic unstable nature, tumor cells may 
acquire properties to escape from such immune recognition4. Various interactions 
underlie the balance between immune control and tumor escape (Figure 1). Cytotoxic 
Figure 1 Tumor immune subtypes showing a schematic overview of  different stages of  immune surveillance and 
tumor immune escape classified into 7 tumor immune subtypes, graded from (1) to (7) in ascending order from highly 
immunogenic and therefore high immune susceptibility (green) to high immune escape and low immune susceptibility 
(red), concerning combinations of  CTL infiltration, NK cell infiltration, Treg infiltration, classical HLA class I tumor 
expression and HLA-EG tumor expression. Tumor immune subtypes were clustered by combining from the original 
tumor immune subtypes groups as shown in by encircled groups (high immune susceptible) clustered (1) and (2)(green 
circle), (intermediate immune susceptible) clustered (3) and (4)(orange circle), (low immune susceptible) clustered (5), 
(6) and (7) (red circle). 
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T-lymphocytes (CTL) are capable of recognizing tumor-associated antigens presented 
by classical human leukocyte antigen (HLA) class I (HLA-A, HLA-B, HLA-C) on the 
tumor cell surface. In order to avoid immune recognition from CTL, cancer cells may 
lose expression of classical HLA class I5. However, this makes them prone to natural 
killer (NK) cell recognition6. Non-classical HLA class I molecules (HLA-E, HLA-G) 
play a crucial role in immune surveillance by NK-cells. Expression of these molecules on 
the cell surface causes an inhibitory effect on NK-cell attack6-8. Another tumor escape 
mechanism from immunosurveillance is attraction and induction of immunosuppressive 
regulatory T cells (Treg) in the tumor microenvironment9. 
A variety of immune reactions have been found to date in breast cancer. Studies have 
indicated that breast cancer is highly immunogenic and often shows high numbers of 
tumor-infiltrating lymphocytes10, 11. However, as previously reported by our group and 
others, loss of classical HLA class I expression, upregulation of non-classical HLA-E 
and HLA-G expression 12-14 and induction and infiltration of Treg in the tumor 
microenvironment 13, 15-17 are frequent events in breast cancer, indicating that breast 
tumors are also capable of evading immune recognition. Together, this suggests that 
complex interactions take place between breast tumor cells and cells from the immune 
system18. Therefore, to get a good perspective on the effects of the immune system 
on tumor progression and patient outcome, such interactions should be accounted for. 
Indeed, previous studies of our group and others showed interactions between classical 
HLA class I and Treg, where loss of HLA class I in combination with presence of 
Treg in the tumor microenvironment resulted in a worse patient’s outcome 16, 18. This 
was also the case for classical HLA class I and HLA-E and HLA-G tumor expression, 
where HLA-E and HLA-G expression resulted in a worse patient outcome exclusively 
in patients with loss of tumor expression of classical HLA class I12. Together, this 
emphasizes the importance of research on combinations of markers of immune 
surveillance together with markers of tumor immune escape. We defined tumor 
immune subtypes, with focus on cellular immune responses, based on tumor expression 
of classical HLA class I, HLA-E and HLA-G, and tumor infiltration of CTL, NK cells, 
and Treg.  The aim was to investigate the distribution and prognostic effect of the 
different immune subtypes in a large cohort of breast cancer patients and subsequently 
validate these effects on a second cohort of breast cancer patients. 
PATIENTS AND METHODS
Patients and tumors
The total patient population comprised all retrospectively assessed primarily non-
metastasized breast cancer patients primarily treated with surgery in the Leiden University 
Medical Center between 1985 and 1996 (n=822).  Patients with bilateral tumors or a prior 
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history of cancer (other than basal cell carcinoma or cervical carcinoma in situ) were 
excluded. The following data were known: age, tumor grade, histological type, TNM 
stage, local and systemic therapy, time of locoregional/distant tumor recurrence, survival 
time, and expression of estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2)(19). All tumors were graded according to 
current pathological standards by an experienced breast cancer pathologist. Approval 
for the study was obtained from the Leiden University Medical Center Medical Ethics 
Committee. All samples were handled in a coded fashion, according to national ethical 
guidelines (“Code for Proper Secondary Use of Human Tissue”, Dutch Federation of 
Medical Scientific Societies). The REMARK criteria were respected for analyses of the 
immune subtypes and writing of this article(32). No statistically significant differences 
were found in patient or tumor characteristics between the training cohort (1985-1990 
(n=440)) and a validation set (1990-1996 (n=382)).
Immunohistochemistry
Mouse antibody against CD8 (ab17147 clone 144B: AbCam, UK) and PEN5 (IM2354, 
clone 5H10.21.5: Beckman Coulter, NL) were used for immunohistochemical staining 
of respectively CTL and NK cells in tissue sections cut from  intra-operatively 
derived FFPE tumor material according to previously described standard protocols 16. 
Previously described were immunohistochemical stainings for expression of classical 
HLA class (anti-HLA-A and anti-HLAB/C; Dr. J. Neefjes, Netherlands Cancer 
Institute, Amsterdam, the Netherlands, HLA-E (ab2216 clone MEM-E/02: AbCam, 
UK), HLA-G (kindly provided by Prof. Dr. P.J. Van de Elsen) and Treg infiltration 
(FoxP3, ab20034 clone 236A/E7: AbCam, UK) 12, 16. 
Evaluation of immunostaining
Quantification of CD8-positive stained cells and PEN5-positive stained cells in 
microscopical fields containing tumor was performed by two independent observers 
in a blinded manner in both training and validation cohorts. CD8 tumor infiltration 
was classified in two groups: (1) low CTL infiltration, 0-100 CD8 tumor infiltrating 
cells/mm2; (2) high CTL infiltration, 100-3000 CD8 infiltrating cells/mm2. For 
PEN5, only few positive infiltrating cells were seen. Therefore, any versus none 
PEN5-positive infiltrating cell were considered as presence and absence of NK cell 
infiltration respectively. Expression of classical HLA class I, HLA-E and HLA-G and 
Treg infiltration were previously categorized respectively as loss versus expression, no 
expression versus expression and absent versus present infiltration 12, 16.  
Statistical analysis
Statistical analyses were performed using the statistical packages SPSS (version 16.0 for 
Windows, Spps Inc, Chicago, IL, USA) and Stata (version 10.0 for Windows, StataCorp, 
College Station, TX, USA). Cohen’s kappa coefficient represented the inter-observer 
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agreement. The χ² test evaluated associations between clinicopathological parameters 
and tumor immune subtypes. Relapse-free period was defined as the time from date 
of surgery until any recurrence and was reported as cumulative incidence function, 
after accounting for death as competing risk. The Kaplan–Meier method was used for 
survival plotting and log-rank test for comparison of curves. Cox proportional hazard 
analysis calculated univariate and multivariable analysis for relapse-free period. Relative 
survival was calculated by the Hakulinen method as the ratio of the survival observed 
among the cancer patients and the survival that would have been expected based on 
the corresponding (age, sex, and year) general population. National life tables were 
used to estimate expected survival. Relative excess risks of death were estimated using 
a multivariable generalized linear model with a Poisson distribution, based on collapsed 
relative survival data, using exact survival times. Hazard ratio’s and relative risks were 
served as indications for respectively risk of relapse and relative risk of survival. Variables 
with a P-value of < 0.10 in univariate analysis were entered in multivariable analysis. 
RESULTS
Patient and tumor characteristics
Tumor material was available of 86% (380/440) and 87% (334/382) of the patients in the 
training cohort and validation cohort respectively. For the training cohort the median 
age of patients was 58 years (range= 23-96 years) and the median follow-up was 19 years 
(range= 0.1-22). For the validation cohort the median age and follow-up of patients were 
respectively 58 years (range= 32-90) and 13 years (range= 0.2-17). Clinicopathological 
and treatment characteristics are shown in supplementary tables (training cohort table 
1A, 1B; validation cohort table 2A, 2B). 
Tumor immune subtypes
The Cohen’s kappa coefficient for inter-observer agreement of CTL and PEN5 
quantification all reached a coefficient of 0.82 or higher. Missing immunohistochemical 
data was due to tissue damage.
Tumor immune subtypes, representing tumor adaptive immune escape variants were 
constructed from available data (Figure1). The defined tumor immune subtypes were in 
ascending order from high immune susceptibility to low immune susceptibility: (1) CTL 
are able to recognize tumor-associated antigens (TAA) presented by classical HLA class 
I and anti-tumor immune reaction can take place: Tumors with expression of classical 
HLA class I, high infiltration of CTL and absence of infiltration of Treg; (2) Tumors 
with a lack of classical HLA class I expression can escape CTL recognition, but NK 
cells are able to recognize these cells and anti-tumor immune reaction can take place: 
Tumors with loss of expression of classical HLA class I, no expression of HLA-EG, 
present infiltration of NK cells and absent infiltration of Treg; (3) Classical HLA class 
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I present TAA and could be recognized by CTL, but a low infiltration of CTL results 
in a limited anti-tumor immune reaction: Tumors with expression of classical HLA 
class I but low CTL infiltration; (4) Classical HLA class I present TAA and could be 
recognized by CTL, but immunosuppressive Treg weaken CTL function, resulting in 
a limited anti-tumor immune reaction: Tumors with expression of classical HLA class 
I, high infiltration of CTL, but also present infiltration of Treg; (5) Tumors with lack 
of classical HLA class I escape CTL recognition, but could be recognized by NK cells, 
which however are not present, resulting in failure of anti-tumor immune reaction: 
Tumors with loss of expression of classical HLA class I and absent NK cell infiltration; 
(6) Tumors with lack of classical HLA class I expression escape CTL recognition, but 
could be recognized by NK cells, however immunosuppressive Treg weaken NK cell 
function 19, resulting in failure of anti-tumor immune reaction: Tumors with loss of 



























Figure 2 Outcome analyses by tumor immune subtypes for Relapse free period (RFP) (A, B) and relative survival (RS) 
(C, D) according to the 7 tumor immune subtypes that are described in the Results section for training cohort patients 
(A, C), and for validation cohort patients (B, D). Tumor immune subtypes representative for more tumor immune 
escape resulted in an unfavorable patient outcome concerning RFP and RS compared to more immunogenic tumor 
immune subtypes. Log-rank P-values are shown in each graph. 
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Characteristic Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P RER 95% CI P RER 95% CI P
Age
<40 74 1.00 0.354 1.00 0.048 1.00 0.031
40-50 92 0.87 0.58-1.33 0.79 0.49-1.28 0.60 0.32-1.12
50-60 81 1.24 0.82-1.88 1.51 0.96-2.38 1.49 0.83-2.65
>60 133 0.95 0.64-1.42 1.20 0.71-2.03 1.05 0.54-2.05
Grade
I 53 1.00 0.030 1.00 0.293 1.00 0.005 1.00 0.023
II 186 1.38 0.86-2.22 1.30 0.73-2.31 1.74 0.82-3.68 0.62 0.30-1.30
III 136 1.83 1.13-2.96 1.55 1.55-0.86 2.73 1.29-5.75 1.20 0.60-2.41
Histological type
Ductal 345 1.00 0.405 1.00 0.333
Other 31 1.23 0.76-2.00 1.34 0.74-2.40
Tumor stage
pT1 127 1.00 0.001 1.00 0.045 1.00 <0.001 1.00 0.003
pT2 198 1.34 0.97-1.86 1.03 0.70-1.51 1.84 1.18-2.86 1.90 1.10-3.29
pT3/4 45 2.56 1.51-3.69 1.75 1.06-2.88 3.69 2.18-6.24 3.40 1.68-6.89
Nodal stage
Negative 199 1.00 <0.001 1.00 <0.001 1.00 <0.001 1.00 <0.001
Positive 171 3.09 2.30-4.16 2.78 1.97-3.92 2.97 2.04-4.33 2.30 1.48-3.56
ER status
Negative 133 1.00 0.890 1.00 0.157
Positive 229 1.02 0.76-1.38 0.77 0.54-1.10
PgR status
Negative 155 1.00 0.765 1.00 0.248
Positive 201 1.05 0.78-1.41 0.81 0.56-1.16
HER2 status
Negative 271 1.00 0.166 1.00 0.004 1.00 0.154
Positive 32 1.42 0.87-2.32 2.03 1.25-3.30 1.59 0.84-3.00
Immune phenotyope
High immune susceptibility 48 1.00 0.005 1.00 <0.001 1.00 0.098 1.00 0.006
Intermediate immune susceptibility 186 1.80 1.06-3.05 1.95 1.13-3.39 1.95 0.98-3.98 3.84 1.62-9.09
Low immune susceptibility 59 2.56 1.44-4.57 2.98 1.62-5.48 2.02 0.97-4.53 4.26 1.70-10.70
Table 1 Cox univariate and multivariate analysis in the training cohort of  breast cancer patients for recurrence free 
period and relative survival for tumor immune subtypes classified into 3 groups that are described in the Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
infiltration; (7) Tumor with lack of classical HLA class I expression but expression of 
non-classical HLA-EG escape from both CTL recognition and NK cell recognition: 
Tumor with loss of expression of classical HLA class I and expression of HLA-EG.
A more simplified tumor immune subtype variable was constructed by joining together 
tumor immune subtypes: High (subtypes 1-2), intermediate (subtypes 3-4) and low 
(subtypes 5-7) immune susceptibility (Figure 1, clustered groups shown by circles). 
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Characteristic Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P RER 95% CI P RER 95% CI P
Age
<40 74 1.00 0.354 1.00 0.048 1.00 0.031
40-50 92 0.87 0.58-1.33 0.79 0.49-1.28 0.60 0.32-1.12
50-60 81 1.24 0.82-1.88 1.51 0.96-2.38 1.49 0.83-2.65
>60 133 0.95 0.64-1.42 1.20 0.71-2.03 1.05 0.54-2.05
Grade
I 53 1.00 0.030 1.00 0.293 1.00 0.005 1.00 0.023
II 186 1.38 0.86-2.22 1.30 0.73-2.31 1.74 0.82-3.68 0.62 0.30-1.30
III 136 1.83 1.13-2.96 1.55 1.55-0.86 2.73 1.29-5.75 1.20 0.60-2.41
Histological type
Ductal 345 1.00 0.405 1.00 0.333
Other 31 1.23 0.76-2.00 1.34 0.74-2.40
Tumor stage
pT1 127 1.00 0.001 1.00 0.045 1.00 <0.001 1.00 0.003
pT2 198 1.34 0.97-1.86 1.03 0.70-1.51 1.84 1.18-2.86 1.90 1.10-3.29
pT3/4 45 2.56 1.51-3.69 1.75 1.06-2.88 3.69 2.18-6.24 3.40 1.68-6.89
Nodal stage
Negative 199 1.00 <0.001 1.00 <0.001 1.00 <0.001 1.00 <0.001
Positive 171 3.09 2.30-4.16 2.78 1.97-3.92 2.97 2.04-4.33 2.30 1.48-3.56
ER status
Negative 133 1.00 0.890 1.00 0.157
Positive 229 1.02 0.76-1.38 0.77 0.54-1.10
PgR status
Negative 155 1.00 0.765 1.00 0.248
Positive 201 1.05 0.78-1.41 0.81 0.56-1.16
HER2 status
Negative 271 1.00 0.166 1.00 0.004 1.00 0.154
Positive 32 1.42 0.87-2.32 2.03 1.25-3.30 1.59 0.84-3.00
Immune phenotyope
High immune susceptibility 48 1.00 0.005 1.00 <0.001 1.00 0.098 1.00 0.006
Intermediate immune susceptibility 186 1.80 1.06-3.05 1.95 1.13-3.39 1.95 0.98-3.98 3.84 1.62-9.09
Low immune susceptibility 59 2.56 1.44-4.57 2.98 1.62-5.48 2.02 0.97-4.53 4.26 1.70-10.70
Table 1 Cox univariate and multivariate analysis in the training cohort of  breast cancer patients for recurrence free 
period and relative survival for tumor immune subtypes classified into 3 groups that are described in the Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
Associations between clinicopathological patient and tumor characteristics and tumor 
immune subtypes classified into 7 groups and into 3 groups are shown in supplementary 
tables 1A, B and 2A, B respectively. No statistically significant validated association was 
found between patient and tumor characteristics and tumor immune subtypes classified 
into 7 groups and into 3 groups. 
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Tumor immune subtypes classified into 7 groups
Distribution in patient training and validation cohort
The tumor immune subtypes classified into 7 groups could be determined for patients 
with data available for all immune markers: 77% (293/380) of patients in the training 
cohort; 66% validation cohort. Distributions of immune subtypes and associations with 
Characteristic Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P RER 95% CI P RER 95% CI P
Age
<40 63 1.00 0.147 1.00 0.431
40-50 83 0.62 0.38-1.03 0.58 0.30-1.10
50-60 76 0.57 0.33-0.97 0.80 0.42-1.53
>60 112 0.68 0.42-1.10 0.77 0.35-1.69
Grade
I 63 1.00 0.001 1.00 0.433 1.00 0.026 1.00 0.603
II 156 1.45 0.82-2.59 1.68 0.68-4.16 1.83 0.64-5.28 1.99 0.50-7.99
III 108 2.54 1.43-4.52 1.86 0.72-4.79 3.27 1.16-9.21 1.69 0.40-7.14
Histological type
Ductal 293 1.00 0.298 1.00 0.300
Other 35 1.35 0.77-2.35 1.46 0.71-3.01
Tumor stage
pT1 162 1.00 <0.001 1.00 0.171 1.00 0.002 1.00 0.227
pT2 130 2.18 1.46-3.23 1.78 0.98-3.26 2.57 1.34-4.90 1.96 0.85-4.52
pT3/4 32 2.46 1.34-4.51 1.54 0.63-3.77 4.30 1.86-9.96 2.30 0.78-6.79
Nodal stage
Negative 182 1.00 <0.001 1.00 0.01 1.00 <0.001 1.00 0.208
Positive 142 2.81 1.93-4.08 2.06 1.19-3.57 3.09 1.73-5.13 1.59 0.77-3.25
ER status
Negative 155 1.00 0.034 1.00 0.889 1.00 0.008 1.00 0.488
Positive 164 0.67 0.46-0.97 1.04 0.60-1.82 0.44 0.24-0.81 0.78 0.39-1.57
PgR status
Negative 161 1.00 0.006 1.00 0.184 1.00 0.028 1.00 0.232
Positive 150 0.59 0.40-0.86 0.68 0.38-1.20 0.54 0.31-0.93 0.65 0.31-1.38
HER2 status
Negative 249 1.00 0.002 1.00 0.934 1.00 <0.001 1.00 0.232
Positive 27 2.36 1.36-4.09 0.97 0.42-2.22 3.52 1.91-6.49 1.71 0.71-4.10
Immune phenotyope
High immune susceptibility 34 1.00 0.005 1.00 0.025 1.00 0.089 1.00 0.040
Intermediate immune susceptibility 156 2.66 1.15-6.16 2.45 0.87-6.89 5.31 0.64-31.33 5.47 0.72-41.70
Low immune susceptibility 29 4.72 1.83-12.18 4.73 1.48-15.06 11.12 1.12-55.41 10.95 1.31-91.63
Table 2 Cox univariate and multivariate analysis in the validation cohort of  breast cancer patients for recurrence free 
period and relative survival for tumor immune subtypes classified into 3 groups that are described in the Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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known clinicopathological parameters are shown in supplementary tables (training 
cohort Table 1A; validation cohort Table 2A). 
Prognostic associations with patient outcome 
The association of tumor immune subtypes classified into 7 groups in the training cohort 
with relapse-free period and relative survival are shown in Figure 2. Analysis of relapse-
Characteristic Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P RER 95% CI P RER 95% CI P
Age
<40 63 1.00 0.147 1.00 0.431
40-50 83 0.62 0.38-1.03 0.58 0.30-1.10
50-60 76 0.57 0.33-0.97 0.80 0.42-1.53
>60 112 0.68 0.42-1.10 0.77 0.35-1.69
Grade
I 63 1.00 0.001 1.00 0.433 1.00 0.026 1.00 0.603
II 156 1.45 0.82-2.59 1.68 0.68-4.16 1.83 0.64-5.28 1.99 0.50-7.99
III 108 2.54 1.43-4.52 1.86 0.72-4.79 3.27 1.16-9.21 1.69 0.40-7.14
Histological type
Ductal 293 1.00 0.298 1.00 0.300
Other 35 1.35 0.77-2.35 1.46 0.71-3.01
Tumor stage
pT1 162 1.00 <0.001 1.00 0.171 1.00 0.002 1.00 0.227
pT2 130 2.18 1.46-3.23 1.78 0.98-3.26 2.57 1.34-4.90 1.96 0.85-4.52
pT3/4 32 2.46 1.34-4.51 1.54 0.63-3.77 4.30 1.86-9.96 2.30 0.78-6.79
Nodal stage
Negative 182 1.00 <0.001 1.00 0.01 1.00 <0.001 1.00 0.208
Positive 142 2.81 1.93-4.08 2.06 1.19-3.57 3.09 1.73-5.13 1.59 0.77-3.25
ER status
Negative 155 1.00 0.034 1.00 0.889 1.00 0.008 1.00 0.488
Positive 164 0.67 0.46-0.97 1.04 0.60-1.82 0.44 0.24-0.81 0.78 0.39-1.57
PgR status
Negative 161 1.00 0.006 1.00 0.184 1.00 0.028 1.00 0.232
Positive 150 0.59 0.40-0.86 0.68 0.38-1.20 0.54 0.31-0.93 0.65 0.31-1.38
HER2 status
Negative 249 1.00 0.002 1.00 0.934 1.00 <0.001 1.00 0.232
Positive 27 2.36 1.36-4.09 0.97 0.42-2.22 3.52 1.91-6.49 1.71 0.71-4.10
Immune phenotyope
High immune susceptibility 34 1.00 0.005 1.00 0.025 1.00 0.089 1.00 0.040
Intermediate immune susceptibility 156 2.66 1.15-6.16 2.45 0.87-6.89 5.31 0.64-31.33 5.47 0.72-41.70
Low immune susceptibility 29 4.72 1.83-12.18 4.73 1.48-15.06 11.12 1.12-55.41 10.95 1.31-91.63
Table 2 Cox univariate and multivariate analysis in the validation cohort of  breast cancer patients for recurrence free 
period and relative survival for tumor immune subtypes classified into 3 groups that are described in the Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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free period showed a statistically significant association between the 7 tumor immune 
subtypes and clinical outcome of patient (RFP p=0.001, Figure 2 A). Tumors that were 
expected to show lower immune susceptibility resulted in more patient relapses over 
time compared to tumors that were expected to show higher immune susceptibility. A 
similar though not significant trend was seen for the association between the 7 immune 
subtypes and relative survival outcome of patients (RS p=0.153, Figure 2 C). Results 
for outcome analyses were confirmed in the validation cohort (RFP p=0.017, Figure 
2B and RS p=0.219, Figure 2D). Multivariable analyses demonstrated that these 7 
tumor immune subtypes were a statistically significant independent prognostic factor in 
breast cancer patients for both RFP and RS (supplementary Table 3). Though statistical 
significance was lost in multivariable analyses in the validation cohort, a statistical trend 
remained for the association between 7 tumor immune subtypes and patient outcome 
concerning RFP (p=0.055, supplementary Table 4).






















Figure 3 Outcome analyses by tumor immune subtypes for Relapse free period (RFP) (A, B) and relative survival (RS) 
(C, D) according to the 3 tumor immune subtypes that are described in the Results section for training cohort patients 
(A, C), and for validation cohort patients (B, D). Tumor immune subtypes representative for more tumor immune 
escape resulted in an unfavorable patient outcome concerning RFP and RS compared to more immunogenic tumor 
immune subtypes. Log-rank P-values are shown in each graph. 
proefschrift.indb   78 18-12-2014   16:35:26
Tumor immune subtypes 79
Tumor immune subtypes classified into 3 groups
Distribution in patient training and validation cohort
The tumor immune subtypes, consisting of three groups as described above showed the 
following distribution in the training and validation cohort respectively: High immune 
susceptible, 16% (48/293) and 16% (34/219); Intermediate immune susceptible, 63% 
(186/293) and 71% (156/219); Low immune susceptible, 20% (59/293) and 13% (29/219). 
Associations with known clinicopathological parameters are shown in supplementary 
tables (training cohort Table 1B; validation cohort Table 2B). 
Prognostic associations with patient outcome 
The association of the tumor immune subtypes classified into 3 groups with relapse-
free period and relative survival is shown in Figure 3. Analysis of relapse-free period 
showed a significant association between tumor immune subtype and clinical outcome 
of patients (RFP p=0.004, Figure 3 A). Lower immune susceptible tumor subtypes, 
resulted in more relapses over time compared to higher immune susceptible tumor 
subtypes. Again, though not significant a similar associative trend was seen for relative 
survival outcome of patient and tumor immune subtype (RS p=0.146, Figure 3 C). 
Results of outcome analyses in the validation cohort were similar to the results found in 
the training cohort (RFP p=0.003, Figure 3 B and RS p=0.112, Figure 3D). 
Multivariable analyses demonstrated that the tumor immune subtypes were a 
statistically significant independent prognostic factor in breast cancer patients for both 
RFP (p<0.001, Table 1B) and RS (p=0.006, Table 1B) with high discriminative power; 
compared to patients with high immune susceptible tumors, patients with intermediate 
immune susceptible tumors showed an almost twice elevated risk (HR 1.95, 95%CI 
1.13-3.39) for developing relapses over time and an almost four times higher relative risk 
for survival (RR 3.84, 95% CI 1.62-9.09), while patients with low immune susceptible 
tumors showed an almost three times elevated risk on relapses over time (HR 2.98, 
95%CI 1.62-5.48) and a more than four times higher relative risk for survival (RR 4.26, 
95%CI 1.70-10.70) (Table 1B). Results of the validation cohort confirmed the associations 
found in multivariable analyses (RFP p=0.025, Table 2B and RS p=0.040, Table 2B)
DISCUSSION
The impact of the immune response and subsequent tumor immune evasion on 
tumor progression and patient outcome in breast cancer is poorly understood. Most 
studies focus on the effect of single parameters, like tumor expression of HLA class I 
or immune cell tumor infiltration, but separately these do not reflect the multifaceted 
interaction between immune cells and tumor cells. In order to get a good perspective on 
the processes involved in these interactions, we defined tumor immune subtypes. These 
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subtypes were defined based on tumor susceptibility for cellular immune responses 
using expression of key factors in these responses that reflect local presence of CTL, 
NK cells, and Treg and tumor expression of classical HLA class I and HLA-E and -G. 
Outcome analyses of the immune subtypes revealed strong associations with patient 
outcome where tumors defined as being highly susceptible to immune system attack 
showed a favorable outcome for breast cancer patients compared to patients with tumors 
defined having a low immune susceptible profile. These prognostic effects were shown 
in this study to be independent of known clinicopathological prognostic parameters and 
were additionally validated in an independent breast cancer patient cohort confirming 
the high discriminative power on patient outcome stratification. 
Prior studies by our group and others have focused on a cellular immune response and 
its effect on tumor progression and patient outcome in breast cancer 11-16. DeNardo et 
al. even provides evidence that treatment response is in part regulated by the immune 
microenvironment 20, again urging the importance of comprehensive determination of 
the tumor immune status. High tumor infiltration of CD8+ lymphocytes, representative 
for CTL infiltration, has been found to result in a favorable patient prognosis in one 
study11. However, another study reported high CTL infiltration to be associated with 
a worse patient outcome21. Yet another study could not find a statistically significant 
prognostic effect for CTL10. High Treg infiltration resulted in an unfavorable 
prognostic factor in a variety of studies10, 15, 22, while it did not show a statistically 
significant association with patient outcome in a previous study of our group16. Loss of 
expression of classical HLA class I showed to be a favorable 23 as well as an unfavorable 
16 prognostic factor in two different studies and revealed no statistically significant 
associations with patient outcome in two other studies24, 25. Concerning non-classical 
HLA-E and HLA-G, one study could not find a statistically significant relation with 
patient prognosis for HLA-G 13, 25 while a study of our group showed tumor expression 
of HLA-E and HLA-G resulted to be a statistically significant unfavorable prognostic 
parameter12. To our knowledge, the prognostic impact of NK cell infiltration has not 
been studied in breast cancer, but NK cell presence in the tumor microenvironment has 
been shown to result in a favorable patient outcome in colorectal cancer26.
Taken together, these reports show contradictory results and, therefore, do not draw a 
clear picture of the interaction between breast cancer cells and the immune system. Our 
present study shows that this may be explained by the simple fact that a successful anti-
tumor immune response depends not only on the level of expression of a single marker 
such as classical HLA class I, but on the variety of factors involved in the multifaceted 
immune response. Due to the complexity of the balance between immune surveillance 
and tumor immune escape, it is not a single marker that is able to reflect outcome of 
the interaction, but a set of key markers. In this study we analyzed a set of such crucial 
immune markers and defined tumor immune subtypes based on these markers. We 
demonstrated that a profile that represents tumors that may be more immune susceptible 
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is predictive for a more favorable clinical outcome for patients with breast cancer. In 
addition, the prognostic impact with high discriminative power that we found for these 
tumor immune subtypes, suggests that previous single marker studies are understating 
or even confounding the impact of the immune system on tumor control. The results 
found for the tumor immune subtypes are not only concordant with prior evidence on 
tumor immune biology in breast cancer4, 18, but additionally join together the conclusions 
of prior studies by linking single tumor-immune markers to functional tumor-immune 
interaction. This is the first study providing detailed insight in tumor immune biology in 
breast cancer, showing that tumor immune surveillance is of crucial importance in the 
control of tumor progression and therefore in determining patient prognosis. 
 
Many prognostic factors have been identified for breast cancer. Of these, the ASCO 
guidelines advised the use in clinical practice of urokinases plasminogen activator 
(uPA), plasminogen activator inhibitor-1 (PAI-1) and gene profiles detected with 
multiparameter gene expression assays27. The clinical value of microarray-based 
prognostic tools, like the MammaPrint, a 70-gene expression profile, and Oncotype 
DX, a 21-gene expression profile is currently being debated28, 29. One major critique is 
that these gene prints were constructed using top-down analyses and were not defined 
based on a biological rationale. Therefore, it is unclear what tumor types are represented 
by the various patient risk-groups30. Contrary to these top-down analyses, the tumor 
immune subtypes we defined are based on well-founded biological hypotheses. Future 
research will further improve this function-based approach of prognostic profiling in 
breast cancer.
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A (1) (2) (3) (4) (5) (6) (7) p-value
N % N % N % N % N % N % N % N %
Age 0.047
<40 74 19.5 11 30.6 1 8.3 21 14.1 10 27.0 8 25.0 3 17.6 4 40.0
40-50 92 24.2 7 19.4 4 33.3 44 29.5 6 16.2 3 9.4 5 29.4 1 10.0
50-60 81 21.3 6 16.7 2 16.7 29 19.5 6 16.2 13 40.6 2 11.8 4 40.0
>=60 133 35.0 12 33.3 5 41.7 55 36.9 15 40.5 8 25.0 7 41.2 1 10.0
Grade 0.033
I 53 14.1 4 11.1 4 36.4 17 11.4 1 2.7 6 18.8 4 23.5 3 30.0
II 186 49.6 16 44.4 5 45.5 78 52.3 19 51.4 17 53.1 10 58.8 1 10.0
III 136 36.3 16 44.4 2 18.2 54 36.2 17 45.9 9 28.1 3 17.6 6 60.0
Histological type 0.578
Ductal 345 91.8 31 86.1 10 90.9 141 94.6 33 89.2 29 90.6 16 94.1 10 100.0
Lobular 31 8.2 5 13.9 1 9.1 8 5.4 4 10.8 3 9.4 1 5.9 0 0.0
T-status 0.305
T1 127 34.3 6 16.7 6 50.0 52 35.4 10 27.8 13 40.6 7 43.8 2 20.0
T2 198 53.5 25 69.4 5 41.7 70 47.6 22 61.1 14 43.8 9 56.2 6 60.0
T3/4 45 12.2 5 13.9 1 8.3 25 17.0 4 11.1 5 15.6 0 0.0 2 20.0
N-status 0.321
N0 199 53.8 20 57.1 6 50.0 83 57.2 16 44.4 16 51.6 10 58.8 2 20.0
N1-3 171 46.2 15 42.9 6 50.0 62 42.8 20 55.6 15 48.4 7 41.2 8 80.0
ER-status 0.057
Negative 133 36.7 18 50.0 5 41.7 58 39.2 14 37.8 5 16.1 4 23.5 6 60.0
Positive 229 63.3 18 50.0 7 58.3 90 60.8 23 62.2 26 83.9 13 76.5 4 40.0
PgR-status 0.131
Negative 155 43.5 19 52.8 5 41.7 61 41.2 18 48.6 6 20.7 9 52.9 6 60.0
Positive 201 56.5 17 47.2 7 58.3 87 58.8 19 51.4 23 79.3 8 47.1 4 40.0
Her2-status 0.206
Overexpression - 271 89.4 26 86.7 11 100.0.0 105 85.4 28 93.3 25 96.2 16 100.0 8 100.0
Overexpression + 32 10.6 4 13.3 0 18 14.6 2 6.7 1 3.8 0 0.0 0 0.0
Local Therapy 0.714
MAST-RT 132 34.7 11 30.6 6 50.0 55 36.9 15 40.5 11 34.4 7 41.2 1 10.0
MAST+RT 80 21.1 10 27.8 1 8.3 31 20.8 5 13.5 6 18.8 2 11.8 4 40.0
BCS 168 44.2 15 41.7 5 41.7 63 42.3 17 45.9 15 46.9 8 47.1 5 50.0
Systemic therapy 0.273
CT alone 78 20.5 11 30.6 1 8.3 35 23.5 9 24.3 2 6.2 2 11.8 4 40.0
HT alone 27 7.1 3 8.3 0 0.0 11 7.4 1 2.7 3 9.4 1 5.9 0 0.0
CT&HT 4 1.1 0 0.0 0 0.0 1 0.7 1 2.7 2 6.2 0 0.0 0 0.0
None 271 71.3 22 61.1 11 91.7 102 68.5 26 70.3 25 78.1 14 82.4 6 60.0
Total 380 100 36 100 12 100 149 100 37 100 32 100 17 100 10 100
Supplementray Table 1 Correlations between tumor immune subtypes into 7 groups that are described in the Results 
section in the training cohort of  patients (A) and in the validation cohort of  patients (B) and well-established prognostic 
factors using chi-square test.
Abbreviations N number of  patients; % percentage; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET 
endocrine therapy; CT chemotherapy.
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B (1) (2) (3) (4) (5) (6) (7) p-value
N % N % N % N % N % N % N % N %
Age 0.794
<40 63 18.9 6 23.1 2 25.0 25 20.5 10 29.4 5 26.3 1 16.7 1 25.0
40-50 83 24.9 6 23.1 2 25.0 29 23.8 12 35.3 4 21.1 1 16.7 0 0.0
50-60 76 22.8 5 19.2 3 37.5 25 20.5 5 14.7 4 21.1 3 50.0 2 50.0
>=60 112 33.5 9 34.6 1 12.5 43 35.2 7 20.6 6 31.6 1 16.7 1 25.0
Grade 0.420
I 63 19.3 6 24.0 2 25.0 25 20.7 2 6.1 2 11.1 1 16.7 1 33.3
II 156 47.7 8 32.0 4 50.0 62 51.2 14 42.4 9 50.0 2 33.3 1 33.3
III 108 33.0 11 44.0 2 25.0 34 28.1 17 51.5 7 38.9 3 50.0 1 33.3
Histological type 0.109
Ductal 293 89.3 22 88.0 8 100.0.0 111 91.7 29 87.9 13 72.2 4 66.7 3 100.0
Lobular 35 10.7 3 12.0 0 10 8.3 4 12.1 5 27.8 2 33.3 0 0.0
T-status 0.541
T1 162 50.0 14 56.0 5 62.5 54 45.4 15 45.5 4 25.0 2 33.3 2 50.0
T2 130 40.1 10 40.0 2 25.0 52 43.7 5 45.5 8 50.0 2 33.3 2 50.0
T3/4 32 9.1 1 4.0 1 12.5 13 10.9 3 9.1 4 25.0 2 33.3 0 0.0
N-status 0.779
N0 182 56.2 17 68.0 5 62.5 61 51.3 18 54.5 9 50.0 3 50.0 1 33.3
N1-3 142 43.8 8 32.0 3 37.5 58 48.7 15 45.5 9 50.0 3 50.0 2 66.7
ER-status 0.411
Negative 155 48.6 13 54.2 3 37.5 46 38.0 20 58.8 8 42.1 3 50.0 2 50.0
Positive 164 51.4 11 45.8 5 62.5 75 62.0 14 41.2 11 57.9 3 50.0 2 50.0
PgR-status 0.046
Negative 161 51.8 15 62.5 2 25.0 52 42.6 24 70.6 8 44.4 4 66.7 2 50.0
Positive 150 48.2 9 37.5 6 75.0 70 57.4 10 29.4 10 55.6 2 33.3 2 50.0
Her2-status 0.316
Overexpression - 249 90.2 15 83.3 6 100.0.0 99 92.5 28 90.3 15 93.8 4 66.7 4 100.0
Overexpression + 27 9.8 3 16.7 0 8 7.5 3 9.7 1 6.2 2 33.3 0 0.0
Local Therapy
MAST-RT 153 45.8 13 50.0 4 50.0 55 45.1 14 41.2 9 47.4 3 50.0 3 75.0 0.807
MAST+RT 52 15.6 5 19.2 1 12.5 19 15.6 7 20.6 6 31.6 2 33.3 0 0.0
BCS 129 38.6 8 30.8 3 37.5 48 39.3 13 38.2 4 21.1 1 16.7 1 25.0
Systemic therapy 0.594
CT alone 49 14.7 2 7.7 1 12.5 18 14.8 6 17.6 7 36.8 1 16.7 1 25.0
HT alone 86 25.7 8 30.8 2 25.0 34 27.9 6 17.6 4 21.1 2 33.3 1 25.0
CT&HT 23 6.9 0 0.0 1 12.5 11 9.0 5 14.7 0 0.0 0 0.0 0 0.0
None 176 52.7 16 61.5 4 50.0 59 48.4 17 50.0 8 42.1 3 50.0 2 50.0
Total 334 100 26 100 8 100 122 100 34 100 19 100 6 100 4 100
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N % N % N % N %
Age 0.094
<40 74 19.5 12 25.0 31 16.7 15 25.4
40-50 92 24.2 11 22.9 50 26.9 9 15.3
50-60 81 21.3 8 16.7 35 18.8 19 32.2
>=60 133 35.0 17 35.4 70 37.6 16 27.1
Grade 0.138
I 53 14.1 8 17.0 18 9.7 13 22.0
II 186 49.6 21 44.7 97 52.2 28 47.5
III 136 36.3 18 38.3 71 38.2 18 30.5
Histological type
Ductal 345 91.8 41 87.2 174 93.5 55 93.2 0.332
Lobular 31 8.2 6 12.8 12 6.5 4 6.8
T-status 0.534
T1 127 34.3 12 25.0 62 33.9 22 37.9
T2 198 53.5 30 62.5 92 50.3 29 50.0
T3/4 45 12.2 6 12.5 29 15.8 7 12.1
N-status
N0 199 53.8 26 55.3 99 54.7 28 48.3 0.669
N1-3 171 46.2 21 44.7 82 45.3 30 51.7
ER-status 0.058
Negative 133 36.7 23 47.9 72 38.9 15 25.9
Positive 229 63.3 25 52.1 113 61.1 43 74.1
PgR-status
Negative 155 43.5 24 50.0 79 42.7 21 37.5 0.437
Positive 201 56.5 24 50.0 106 57.3 35 62.5
Her2-status
Overexpression - 271 89.4 37 90.2 133 86.9 49 98.0 0.081
Overexpression + 32 10.6 4 9.8 20 13.1 1 2.0
Local Therapy 0.928
MAST-RT 132 34.7 17 35.4 70 37.6 19 32.2
MAST+RT 80 21.1 11 22.9 36 19.4 12 20.3
BCS 168 44.2 20 41.7 80 43.0 28 47.5
Systemic therapy
CT alone 78 20.5 12 25.0 44 23.7 8 13.6 0.508
HT alone 27 7.1 3 6.2 12 6.5 4 6.8
CT&HT 4 1.1 0 0.0 2 1.1 2 3.4
None 271 71.3 33 68.8 128 68.8 45 76.3
Total 380 100 48 100 186 100 59 100
Supplementary Table 2 Correlations between clustered tumor immune subtypes into 3 groups that are described in the 
Results section in the training cohort of  patients (A) and in the validation cohort of  patients (B) and well-established 
prognostic factors using chi-square test.
Abbreviations N number of  patients; % percentage; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET 
endocrine therapy; CT chemotherapy
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N % N % N % N %
Age
<40 63 18.9 8 23.5 35 22.4 7 24.1 0.842
40-50 83 24.9 8 23.5 41 26.3 5 17.2
50-60 76 22.8 8 23.5 30 19.2 9 31.0
>=60 112 33.5 10 29.4 50 32.1 8 27.6
Grade
I 63 19.3 8 24.2 27 17.5 4 14.8 0.649
II 156 47.7 12 36.4 76 49.4 12 44.4
III 108 33.0 13 39.4 51 33.1 11 40.7
Histological type 0.035
Ductal 293 89.3 30 90.9 140 90.9 20 74.1
Lobular 35 10.7 3 9.1 14 9.1 7 25.9
T-status
T1 162 50.0 19 57.6 69 45.4 8 30.8 0.148
T2 130 40.1 12 36.4 67 44.1 12 46.2
T3/4 32 9.1 2 6.1 16 10.5 6 23.1
N-status
N0 182 56.2 22 66.7 79 52.0 13 48.1 0.253
N1-3 142 43.8 11 33.3 73 48.0 14 51.9
ER-status 0.740
Negative 155 48.6 16 50.0 66 42.6 13 44.8
Positive 164 51.4 16 50.0 89 57.4 16 55.2
PgR-status 0.901
Negative 161 51.8 17 53.1 76 48.7 14 50.0
Positive 150 48.2 15 46.9 80 51.3 14 50.0
Her2-status 0.691
Overexpression - 249 90.2 21 87.5 127 92.0 23 88.5
Overexpression + 27 9.8 3 12.5 11 8.0 3 11.5
Local Therapy
MAST-RT 153 45.8 17 50.0 69 44.2 15 51.7 0.345
MAST+RT 52 15.6 6 17.6 26 16.7 8 27.6
BCS 129 38.6 11 32.4 61 39.1 6 20.7
Systemic therapy 0.104
CT alone 49 14.7 3 8.8 24 15.4 9 31.0
HT alone 86 25.7 10 29.4 40 25.6 7 24.1
CT&HT 23 6.9 1 2.9 16 10.3 0 0.0
None 176 52.7 20 58.8 76 48.7 13 44.8
Total 334 100 34 100 156 100 29 100
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Characteristic  Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
<40 74 1.00 0.354 1.00 0.048 1.00 0.006
40-50 92 0.87 0.58-1.33 0.79 0.49-1.28 0.50 0.27-0.96
50-60 81 1.24 0.82-1.88 1.51 0.96-2.38 1.52 0.84-2.72
>60 133 0.95 0.64-1.42 1.20 0.71-2.03 1.00 0.49-2.04
Grade
I 53 1.00 0.030 1.00 0.384 1.00 0.005 1.00 0.043
II 186 1.38 0.86-2.22 1.35 0.76-2.41 1.74 0.82-3.68 0.59 0.28-1.24
III 136 1.83 1.13-2.96 1.51 0.84-2.73 2.73 1.29-5.75 1.11 0.56-2.23
Histological type
Ductal 345 1.00 0.405 1.00 0.333
Other 31 1.23 0.76-2.00 1.34 0.74-2.40
Tumor stage
pT1 127 1.00 0.001 1.00 0.153 1.00 <0.001 1.00 0.002
pT2 198 1.34 0.97-1.86 1.01 0.69-1.49 1.84 1.18-2.86 2.11 1.21-3.68
pT3/4 45 2.56 1.51-3.69 1.57 0.94-2.61 3.69 2.18-6.24 3.62 1.77-7.41
Nodal stage
Negative 199 1.00 <0.001 1.00 <0.001 1.00 <0.001 1.00 <0.001
Positive 171 3.09 2.30-4.16 2.81 1.98-3.99 2.97 2.04-4.33 2.30 1.47-3.60
ER status
Negative 133 1.00 0.890 1.00 0.157
Positive 229 1.02 0.76-1.38 0.77 0.54-1.10
PgR status
Negative 155 1.00 0.765 1.00 0.248
Positive 201 1.05 0.78-1.41 0.81 0.56-1.16
HER2 status
Negative 271 1.00 0.166 1.00 0.004 1.00 0.135
Positive 32 1.42 0.87-2.32 2.03 1.25-3.30 1.62 0.86-3.07
Immune phenotyope
(1) 36 1.00 0.002 1.00 0.010 1.00 0.098 1.00 0.002
(2) 12 0.43 0.10-1.91 0.53 0.12-2.38 0.12 0.00-62.27 0.001 0-∞
(3) 149 1.60 0.90-2.82 1.82 1.00-3.32 1.54 0.80-2.97 3.43 1.41-8.32
(4) 37 1.34 0.65-2.75 1.40 0.67-2.94 1.26 0.54-2.92 2.40 0.86-6.67
(5) 32 2.15 1.11-4.18 2.45 1.20-4.99 1.39 0.62-3.13 2.33 0.84-6.51
(6) 17 1.48 0.64-3.41 2.18 0.91-5.22 1.03 0.33-3.21 4.26 1.28-14.15
(7) 10 5.09 2.19-11.82 4.41 1.83-10.62 3.68 1.44-9.40 11.84 3.86-36.34
Supplementary Table 3 Cox univariate and multivariate analysis in the training cohort of  breast cancer patients for 
recurrence free period and relative survival for tumor immune subtypes classified into 7 groups that are described in the 
Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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Characteristic  Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
<40 74 1.00 0.354 1.00 0.048 1.00 0.006
40-50 92 0.87 0.58-1.33 0.79 0.49-1.28 0.50 0.27-0.96
50-60 81 1.24 0.82-1.88 1.51 0.96-2.38 1.52 0.84-2.72
>60 133 0.95 0.64-1.42 1.20 0.71-2.03 1.00 0.49-2.04
Grade
I 53 1.00 0.030 1.00 0.384 1.00 0.005 1.00 0.043
II 186 1.38 0.86-2.22 1.35 0.76-2.41 1.74 0.82-3.68 0.59 0.28-1.24
III 136 1.83 1.13-2.96 1.51 0.84-2.73 2.73 1.29-5.75 1.11 0.56-2.23
Histological type
Ductal 345 1.00 0.405 1.00 0.333
Other 31 1.23 0.76-2.00 1.34 0.74-2.40
Tumor stage
pT1 127 1.00 0.001 1.00 0.153 1.00 <0.001 1.00 0.002
pT2 198 1.34 0.97-1.86 1.01 0.69-1.49 1.84 1.18-2.86 2.11 1.21-3.68
pT3/4 45 2.56 1.51-3.69 1.57 0.94-2.61 3.69 2.18-6.24 3.62 1.77-7.41
Nodal stage
Negative 199 1.00 <0.001 1.00 <0.001 1.00 <0.001 1.00 <0.001
Positive 171 3.09 2.30-4.16 2.81 1.98-3.99 2.97 2.04-4.33 2.30 1.47-3.60
ER status
Negative 133 1.00 0.890 1.00 0.157
Positive 229 1.02 0.76-1.38 0.77 0.54-1.10
PgR status
Negative 155 1.00 0.765 1.00 0.248
Positive 201 1.05 0.78-1.41 0.81 0.56-1.16
HER2 status
Negative 271 1.00 0.166 1.00 0.004 1.00 0.135
Positive 32 1.42 0.87-2.32 2.03 1.25-3.30 1.62 0.86-3.07
Immune phenotyope
(1) 36 1.00 0.002 1.00 0.010 1.00 0.098 1.00 0.002
(2) 12 0.43 0.10-1.91 0.53 0.12-2.38 0.12 0.00-62.27 0.001 0-∞
(3) 149 1.60 0.90-2.82 1.82 1.00-3.32 1.54 0.80-2.97 3.43 1.41-8.32
(4) 37 1.34 0.65-2.75 1.40 0.67-2.94 1.26 0.54-2.92 2.40 0.86-6.67
(5) 32 2.15 1.11-4.18 2.45 1.20-4.99 1.39 0.62-3.13 2.33 0.84-6.51
(6) 17 1.48 0.64-3.41 2.18 0.91-5.22 1.03 0.33-3.21 4.26 1.28-14.15
(7) 10 5.09 2.19-11.82 4.41 1.83-10.62 3.68 1.44-9.40 11.84 3.86-36.34
Supplementary Table 3 Cox univariate and multivariate analysis in the training cohort of  breast cancer patients for 
recurrence free period and relative survival for tumor immune subtypes classified into 7 groups that are described in the 
Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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Characteristic  Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
<40 63 1.00 0.147 1.00 0.431
40-50 83 0.62 0.38-1.03 0.58 0.30-1.10
50-60 76 0.57 0.33-0.97 0.80 0.42-1.53
>60 112 0.68 0.42-1.10 0.77 0.35-1.69
Grade
I 63 1.00 0.001 1.00 0.61 1.00 0.026
II 156 1.45 0.82-2.59 1.55 0.62-3.89 1.83 0.64-5.28
III 108 2.54 1.43-4.52 1.62 0.61-4.30 3.27 1.16-9.21
Histological type
Ductal 293 1.00 0.298 1.00 0.300
Other 35 1.35 0.77-2.35 1.46 0.71-3.01
Tumor stage
pT1 162 1.00 <0.001 1.00 0.113 1.00 0.002
pT2 130 2.18 1.46-3.23 1.93 1.04-3.56 2.57 1.34-4.90
pT3/4 32 2.46 1.34-4.51 1.79 0.73-4.39 4.30 1.86-9.96
Nodal stage
Negative 182 1.00 <0.001 1.00 0.014 1.00 <0.001
Positive 142 2.81 1.93-4.08 2.03 1.16-3.56 3.09 1.73-5.13
ER status
Negative 155 1.00 0.034 1.00 0.728 1.00 0.008
Positive 164 0.67 0.46-0.97 1.11 0.62-1.97 0.44 0.24-0.81
PgR status
Negative 161 1.00 0.006 1.00 0.243 1.00 0.028
Positive 150 0.59 0.40-0.86 0.70 0.39-1.27 0.54 0.31-0.93
HER2 status
Negative 249 1.00 0.002 1.00 0.815 1.00 <0.001
Positive 27 2.36 1.36-4.09 1.11 0.46-2.66 3.52 1.91-6.49
Immune phenotyope
(1) 26 1.00 0.031 1.00 0.055 1.00  0.219
(2) 8 0.58 0.07-4.94 0.77 0.08-7.67 5.2E5 0-∞
(3) 122 2.10 0.83-5.31 2.04 0.61-6.89 1.5e6 0-∞
(4) 34 3.45 1.28-9.28 3.06 0.85-10.97 2.5e6 0-∞
(5) 19 4.09 1.39-12.01 3.67 0.91-1479 2.6e6 0-∞
(6) 6 3.82 0.91-16.02 4.16 0.81-21.44 3.7e6 0-∞
(7) 4 5.91 1.14-30.67 13.4 2.12-84.86 6.5e6 0-∞
Supplementary Table 4 Cox univariate and multivariate analysis in the validation cohort of  breast cancer patients for 
recurrence free period and relative survival for tumor immune subtypes classified into 7 groups that are described in the 
Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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Characteristic  Relapse Free Period Relative Survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
<40 63 1.00 0.147 1.00 0.431
40-50 83 0.62 0.38-1.03 0.58 0.30-1.10
50-60 76 0.57 0.33-0.97 0.80 0.42-1.53
>60 112 0.68 0.42-1.10 0.77 0.35-1.69
Grade
I 63 1.00 0.001 1.00 0.61 1.00 0.026
II 156 1.45 0.82-2.59 1.55 0.62-3.89 1.83 0.64-5.28
III 108 2.54 1.43-4.52 1.62 0.61-4.30 3.27 1.16-9.21
Histological type
Ductal 293 1.00 0.298 1.00 0.300
Other 35 1.35 0.77-2.35 1.46 0.71-3.01
Tumor stage
pT1 162 1.00 <0.001 1.00 0.113 1.00 0.002
pT2 130 2.18 1.46-3.23 1.93 1.04-3.56 2.57 1.34-4.90
pT3/4 32 2.46 1.34-4.51 1.79 0.73-4.39 4.30 1.86-9.96
Nodal stage
Negative 182 1.00 <0.001 1.00 0.014 1.00 <0.001
Positive 142 2.81 1.93-4.08 2.03 1.16-3.56 3.09 1.73-5.13
ER status
Negative 155 1.00 0.034 1.00 0.728 1.00 0.008
Positive 164 0.67 0.46-0.97 1.11 0.62-1.97 0.44 0.24-0.81
PgR status
Negative 161 1.00 0.006 1.00 0.243 1.00 0.028
Positive 150 0.59 0.40-0.86 0.70 0.39-1.27 0.54 0.31-0.93
HER2 status
Negative 249 1.00 0.002 1.00 0.815 1.00 <0.001
Positive 27 2.36 1.36-4.09 1.11 0.46-2.66 3.52 1.91-6.49
Immune phenotyope
(1) 26 1.00 0.031 1.00 0.055 1.00  0.219
(2) 8 0.58 0.07-4.94 0.77 0.08-7.67 5.2E5 0-∞
(3) 122 2.10 0.83-5.31 2.04 0.61-6.89 1.5e6 0-∞
(4) 34 3.45 1.28-9.28 3.06 0.85-10.97 2.5e6 0-∞
(5) 19 4.09 1.39-12.01 3.67 0.91-1479 2.6e6 0-∞
(6) 6 3.82 0.91-16.02 4.16 0.81-21.44 3.7e6 0-∞
(7) 4 5.91 1.14-30.67 13.4 2.12-84.86 6.5e6 0-∞
Supplementary Table 4 Cox univariate and multivariate analysis in the validation cohort of  breast cancer patients for 
recurrence free period and relative survival for tumor immune subtypes classified into 7 groups that are described in the 
Results section. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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PROGNOSTIC BIOMARKERS IN ELDERLY 
BREAST CANCER PATIENTS
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6C h a p t e r
Age interactions in the prognostic value of aldh1 for 
clinical outcome in breast cancer
de Kruijf EM, Mieog JSD, Bastiaannet E, Kuppen PJK, Sajet A, de Craen AJM, Smit 
VTHBM, van de Velde CJH, Liefers GJ
BMC Cancer. 2012 Jan 26;12:42. doi: 10.1186/1471-2407-12-42. 
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ABSTRACT
Purpose To compare expression and prognostic effect of the breast cancer stem cell 
marker aldehyde dehydrogenase-1 (ALDH1) in young and elderly breast cancer patients. 
Patients and Methods The study population (N = 574) consisted of all early breast 
cancer patients primarily treated with surgery in our center between 1985 and 1994. 
Median follow-up was 17.9 years (range: 0.1 to 23.5). Tissue microarray slides were 
immunohistochemically stained for ALDH1 expression and quantified by two 
independent observers who were blinded to clinical outcome. Assessment of the 
prognostic effect of ALDH1 expression was stratified according to age and systemic 
treatment.
Results Complete lack of expression of ALDH1 was found in 40% of tumors. With 
increasing age more tumors showed complete absence of ALDH1 expression (P < .001). 
In patients aged > 65 years, ALDH1 status was not associated with any clinical outcome. 
Conversely, in patients aged < 65 years, ALDH1 positivity was an independent risk 
factor of worse outcome for relapse free period (hazard ratio = 1.71 (95% CI, 1.09 to 
2.68); P = .021) and relative survival (relative excess risks of death = 2.36 (95% CI, 1.22 
to 3.68); P = .016). Ten-year relative survival risk was 57% in ALDH1-positive patients 
compared to 83% in ALDH1-negative patients.
Conclusion ALDH1 expression and its prognostic effect are age-dependent. Our 
results support the hypothesis that breast cancer biology is different in elderly patients 
compared to their younger counterparts and emphasizes the importance of taking into 
consideration age-specific interactions in breast cancer research.
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INTRODUCTION
Age at diagnosis of breast cancer is an important independent prognostic factor. Young 
age is associated with more aggressive tumors with a relatively high risk of distant 
metastasis and loco-regional recurrence,1 whereas old age is associated with more 
indolent tumors.2, 3 Although tumor characteristics differ considerably between age 
groups (including hormone receptor and human epidermal growth factor receptor 2 
(HER2) status), these tumor characteristics can only account for part of the divergence 
in survival witnessed between age groups.2 Little is known about the impact and 
significance of various prognostic and predictive factors in elderly as compared to their 
younger counterparts. As is the case with randomized trials, elderly are underrepresented 
in translational studies on molecular markers.4, 5 This caveat is especially worrisome 
since studies show that the relative survival in elderly breast cancer patient is lower, 
despite more favorable tumor characteristics, which is probably due to the fact that these 
patients receive less aggressive treatment.6 Molecular markers could aid to guide therapy 
in the fit elderly. Moreover, specific age-interactions might underlie pathophysiological 
processes in the development of primary breast cancer and subsequent local and 
distant metastases. Therefore, breast cancer researchers should account for age-specific 
differences.4
Recent evidence in tumor biology supports the cancer stem cell theory and may also 
provide a biological reason for the age-associated survival difference.7 According 
to this theory, cancer stem cells, defined as a small subset of tumor cells with stem 
cell-like features including epithelial-to-mesenchymal transition, have the capacity to 
self-renewal and differentiation, giving rise to heterogeneous tumor cell population. 
Various putative markers of breast cancer stem cells have been proposed, including 
aldehyde dehydrogenase-1 (ALDH1) activity, CD44+/CD24-, CD133, and ITGA6.7-10 
In particular, ALDH1 expression has shown promise as a clinically relevant prognostic 
marker.9, 11, 12 Moreover, various studies have shown that the subset of cancer stem cells 
is relatively resistant to chemo- and radiotherapy.13, 14 Thereby, the subpopulation of 
cancer stem cells can provide both an explanation and a therapeutic target for poor-
prognostic, treatment-resistant and recurrent breast cancer.
ALDH1 is a detoxifying enzyme responsible for the oxidation of intracellular aldehydes 
and thereby confers resistance to alkylating agents.12, 15 This detoxifying capacity might 
underlie the longevity of stem cells by protecting against oxidative stress. Moreover, 
ALDH1 may have a role in early differentiation of stem cells and stem cell proliferation 
through its role in oxidizing retinol to retinoic acid, a modulator of cell proliferation.15 
ALDH1 expression is associated with unfavorable tumor characteristics in breast cancer, 
such as high grade, absence of hormone receptor expression, positive HER2 status and 
the basal-like molecular subtype.9, 16-18  
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To study whether the expression of the breast cancer stem cell marker ALDH1 is 
associated with age and has an influence on clinical outcome, we analyzed the age-
distribution of ALDH1 expression and its prognostic role in young and elderly patients 
using long-term follow-up data of a cohort of breast cancer patients primarily treated 
with surgery in our institution. 
PATIENT AND METHODS
Study cohort
The patient population comprised all non-metastasized breast cancer patients primarily 
treated with surgery in the Leiden University Medical Center between 1985 and 1994 
with tumor material available (N = 574).19 Patients with bilateral tumors or a prior history 
of cancer (other than basal cell carcinoma or cervical carcinoma in situ) were excluded. 
The following data were known: age, tumor grade, histological type, TNM stage, local 
and systemic therapy, locoregional or distant tumor recurrence, survival, and expression 
of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth 
factor receptor 2 (HER2). All tumors were graded according to current pathological 
standards by an experienced breast cancer pathologist (V.S.). Median follow-up was 17.9 
years (range: 0.01 to 23.5). Approval was obtained from the Leiden University Medical 
Center Medical Ethics Committee. All samples were handled in a coded fashion, 
according to National ethical guidelines (“Code for Proper Secondary Use of Human 
Tissue”, Dutch Federation of Medical Scientific Societies).
Assessment of ALDH1 expression
Mouse antibody against ALDH1 (611195, BD Biosciences) was used for immuno-
histochemistry. Tissue sections of 4 μm were cut from a previously constructed tissue 
microarray of formalin-fixed paraffin-embedded tumors of 574 patients from whom 
tumor material was available.19 Immunohistochemical staining was performed according 
to previously described standard protocols.18 Human liver tissue slides served as 
positive control. Negative controls were human liver tissue slides that did undergo the 
whole immunohistochemical staining without primary antibodies. Microscopic analysis 
of ALDH1 was assessed independently by two observers in a blinded manner. Absence 
and presence of ALDH1 activity was classified as 0% and 1-100% staining of tumor 
cells, respectively (Figure 1A).9 11
Statistical analysis
Statistical analyses were performed using the statistical packages SPSS (version 16.0 
for Windows, Spps Inc, Chicago, IL, USA) and Stata (version 10.0 for Windows, 
StataCorp, College Station, TX, USA). Cohen’s kappa coefficient was used to assess 
the inter-observer agreement in quantification of ALDH1 expression. The Cohen’s 
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kappa coefficient was 0.81. The χ² test was used to evaluate associations between 
various clinicopathological parameters and ALDH1 expression. Relapse-free period 
was defined as the time from date of surgery until an event (locoregional recurrence 
and/or a distance recurrence, whichever came first). Relapse-free period is reported 
as cumulative incidence function, after accounting for death as competing risk.20 The 
Kaplan–Meier method was used for survival plotting and log-rank test for comparison 
of relapse-free period curves. Cox proportional hazard analysis was used for univariate 
and multivariable analysis for relapse-free period. Relative survival was calculated by the 
Hakulinen method as the ratio of the survival observed among the cancer patients and 
the survival that would have been expected based on the corresponding (age, sex, and 
year) general population. National life tables were used to estimate expected survival. 
Relative excess risks of death were estimated using a multivariable generalized linear 
Figure 1 ALDH1 expression and distribution over age groups. A) Representative photographs of  tissue microarray 
punches of  human breast cancer specimens immunohistochemically stained for ALDH1 with representative examples 
of  strong staining (left panel), intermediate staining (middle panel) and no staining (right panel). Bar represents 100 μm. 
B) ALDH1 status according to age (N = 496). Logistic regression P-value is shown. 
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model with a Poisson distribution, based on collapsed relative survival data, using exact 
survival times. 
Analyses were performed for all patients and stratified for age and systemic treatment. 
Age of 65 years at time of diagnosis was chosen as the cut-off point for age stratification.21 
An interaction term with age and ALDH1 status was introduced in Cox proportional 
hazard model to assess the interaction in prognostic effects of ALDH1 status for the 
age groups. Variables with a P-value of < .10 in univariate analysis were entered in 
multivariable analysis. 
Characteristic Patients < 65 years Patients > 65 years
ALDH1 negative ALDH1 positive ALDH1 negative ALDH1 positive
N % N % P N % N % P
Grade 0.02 0.79
I 19 17.3 18 8.5 11 12.9 13 16.2
II 58 52.7 103 48.6 44 51.8 38 47.5
III 33 30.0 91 42.9 30 35.3 29 36.2
Histological type 0.42 0.20
Ductal 103 92.8 191 90.1 72 84.7 73 91.2
Lobular 8 7.2 21 9.9 13 15.3 7 8.7
Tumor size 0.34 0.55
T1 45 40.2 74 36.1 27 31.0 24 31.6
T2 57 50.9 101 49.3 48 55.2 37 48.7
T3/4 10 8.9 30 14.6 12 13.8 15 19.7
Nodal status 0.02   0.71
Negative 69 62.2 101 47.9 46 56.1 46 59.0
Positive 42 37.8 110 52.1 36 43.9 32 41.0
ER status 0.61 0.01
Negative 43 41.0 91 44.0 16 19.0 30 38.0
Positive 62 59.0 116 56.0 68 81.0 49 62.0
PgR status 0.77 0.08
Negative 48 47.1 84 40.6 26 31.3 35 44.9
Positive 54 52.9 123 59.4 57 68.7 43 55.1
Her2 status 0.99 0.80
Negative 67 87.0 153 86.9 61 93.8 64 92.8
Positive 10 13.0 23 13.1 4 6.2 5 7.2
Table 1. Association of  ALDH1 status with clinicopathological charateristics, stratified by age. 
Abbreviations N=number of  patients; ALDH1=aldehyde dehydrogenase 1; ER=estrogen receptor; PgR=progesterone 
receptor; HER2=human epidermal growth factor receptor 2. 
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RESULTS
ALDH1 Expression in Patient Cohort
Immunohistochemical data of ALDH1 expression were available for 496 of the 574 
patients (86.4%). Of these patients, 326 (65.7%) were < 65 years at diagnosis and 170 
(34.3%) were > 65 years at diagnosis. The Cohen’s kappa coefficient for inter-observer 
agreement was 0.81. Complete lack of expression of ALDH1 of any tumor cell was 
found in 40.4% of the tumors. The association between ALDH1 status and age is shown 
in Figure 1B. ALDH1 expression was inversely correlated with age (P = .0015) and was 
significantly higher in patients aged < 65 years (65.3%) than in patients aged > 65 years 
(48.2%; P < .001). The association of ALDH1 expression with classic patient, tumor 
and treatment characteristics is shown in Table 1. In patients aged < 65 years, ALDH1 
expression was significantly correlated with high histological grade and positive nodal 
status. In patients aged > 65 years, ALDH1 expression was significantly correlated with 
absence of estrogen-receptor expression.
Impact of ALDH1 on Survival
The association of ALDH1 status with relapse-free period and relative survival is shown 
in Figures 2 and 3, respectively. Analysis of relapse-free period showed a trend towards 
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Figure 2. Relapse free period according to ALDH1 status for all patients (A, D), for patients aged < 65 years (B, E) 
and for patients aged > 65 years (C, F); and for patients that received any or no systemic therapy (A-C) and for patients 
that did not receive systemic therapy (D-F). Log-rank P-values are shown in each graph. 
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a significant association between ALDH1 status and clinical outcome for the whole 
population (P = .10; Figure 2A, D). In the group of patients aged younger than 65 
years, a strong association was found between ALDH1 expression and poor clinical 
outcome (P = .01; Figure 3B). In the subgroup of younger patients who did not receive 
any systemic treatment, a comparable association was found (P = .009; Figure 2E). 
In this group, 52% of patients with ALDH1-positive tumors was relapse-free at 10 
years follow-up compared to 72% of patients with ALDH1-negative tumors (absolute 
Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Age .74
<40 33 1 0
40-50 98 1.10 0.62-1.96 0
50-60 101 1.29 0.73-2.29 0
>60 44 1.29 0.66-2.52 154
Grade .03 0.21 .01 .29
I 31 1 1 24 1 1
II 131 1.45 0.76-2.75 1.06 0.40-2.78 74 1.73 0.66-4.58 1.30 0.48-3.58
III 75 2.17 1.12-4.20 1.54 0.58-4.11 44 3.66 1.39-9.61 2.01 0.70-5.75
Histological type .54 .53
Ductal 223 1 124 1
Other 15 1.24 0.63-2.45 18 0.74 0.30-1.87
Tumor stage <.001 0.05 .03 .90
pT1 137 1 1 59 1 1
pT2 109 1.66 1.16-2.37 1.60 1.01-2.55 71 2.23 1.22-4.09 1.16 0.56-2.40
pT3/4 22 2.73 1.57-4.76 2.04 1.07-3.88 18 2.11 0.82-5.45 1.23 0.42-3.63
Nodal stage <.001 <0.001 <.001 <.001
Negative 204 1 1 109 1 1
Positive 69 4.25 3.02-5.99 4.44 2.89-6.82 36 3.94 2.28-6.82 3.33 1.77-6.24
ER status .59 .22
Negative 87 1 40 1
Positive 126 0.90 0.66-1.32 95 1.53 0.78-2.98
PgR status .78 .78
Negative 84 1 55 1
Positive 123 0.95 0.64-1.40 81 1.08 0.61-1.92
HER2 status .26 .05
Negative 143 1 105 1
Positive 19 1.44 0.76-2.71 4 0.05 0.00-23.3
ALDH1 status .01 0.02 .14
Negative 77 1 1 63 1
Positive 116 1.75 1.14-2.68 1.71 1.09-2.68 61 0.64 0.35-1.16
Table 2. Univariate and multivariable analysis for relapses free period stratified by age for patients naive to systemic 
treatment. 
Abbreviations N=number of  patients; HR=hazard ratio; ER=estrogen receptor; PgR=progesterone receptor; 
HER2=human epidermal growth factor receptor 2; ALDH1=aldehyde dehydrogenase 1.
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difference = 20%). Conversely, in the elderly patients, no association was found 
between ALDH1 status and clinical outcome (P = .20; Figure 2C, F). Interaction 
analysis demonstrated a statistically significant difference in the prognostic effect of 
ALDH1 status in young and elderly patients (P = .007).
 
Analysis of relative survival showed a similar pattern as for relapse-free period: a strong 
association between ALDH1-positive tumors and poor relative survival in the younger 
patient group (Figure 3B, E) and no association between ALDH1 status and relative 
survival for elderly patients (Figure 3C, F). In the subgroup of younger patients who 
Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Age .74
<40 33 1 0
40-50 98 1.10 0.62-1.96 0
50-60 101 1.29 0.73-2.29 0
>60 44 1.29 0.66-2.52 154
Grade .03 0.21 .01 .29
I 31 1 1 24 1 1
II 131 1.45 0.76-2.75 1.06 0.40-2.78 74 1.73 0.66-4.58 1.30 0.48-3.58
III 75 2.17 1.12-4.20 1.54 0.58-4.11 44 3.66 1.39-9.61 2.01 0.70-5.75
Histological type .54 .53
Ductal 223 1 124 1
Other 15 1.24 0.63-2.45 18 0.74 0.30-1.87
Tumor stage <.001 0.05 .03 .90
pT1 137 1 1 59 1 1
pT2 109 1.66 1.16-2.37 1.60 1.01-2.55 71 2.23 1.22-4.09 1.16 0.56-2.40
pT3/4 22 2.73 1.57-4.76 2.04 1.07-3.88 18 2.11 0.82-5.45 1.23 0.42-3.63
Nodal stage <.001 <0.001 <.001 <.001
Negative 204 1 1 109 1 1
Positive 69 4.25 3.02-5.99 4.44 2.89-6.82 36 3.94 2.28-6.82 3.33 1.77-6.24
ER status .59 .22
Negative 87 1 40 1
Positive 126 0.90 0.66-1.32 95 1.53 0.78-2.98
PgR status .78 .78
Negative 84 1 55 1
Positive 123 0.95 0.64-1.40 81 1.08 0.61-1.92
HER2 status .26 .05
Negative 143 1 105 1
Positive 19 1.44 0.76-2.71 4 0.05 0.00-23.3
ALDH1 status .01 0.02 .14
Negative 77 1 1 63 1
Positive 116 1.75 1.14-2.68 1.71 1.09-2.68 61 0.64 0.35-1.16
Table 2. Univariate and multivariable analysis for relapses free period stratified by age for patients naive to systemic 
treatment. 
Abbreviations N=number of  patients; HR=hazard ratio; ER=estrogen receptor; PgR=progesterone receptor; 
HER2=human epidermal growth factor receptor 2; ALDH1=aldehyde dehydrogenase 1.
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did not receive any systemic treatment, the 10-year relative survival rate was 57% in 
patients with ALDH1-positive tumors compared to 83% in patients with ALDH1-
negative tumors (absolute difference = 26%, P = .008; Figure 3E). Interaction analysis 
demonstrated a statistically significant difference between the prognostic effect of 
ALDH1 status in young and elderly patients (P = 0.047).
Multivariable analyses were conducted for the patient groups that did not receive 
systemic treatment (276 young patients and 154 elderly patients). ALDH1 status 
remained an independent prognostic factor in the young patient group for both relapse-
Characteristic Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Age .06 .10
<40 33 1 1 0
40-50 98 1.03 0.51-2.08 0.69 0.21-2.24 0
50-60 101 1.52 0.76-3.03 1.38 0.46-5.18 0
>60 44 2.16 0.99-4.66 1.93 0.56-6.57 154
Grade .03 .95 .34
I 31 1 1 24 1
II 131 2.23 0.80-6.28 1.24 0.31-5.03 74 3.10 0.43-22.4
III 75 3.48 1.22-9.94 1.27 0.30-5.45 44 4.23 0.56-31.8
Histological type .80 .37
Ductal 223 1 124 1
Other 15 1.12 0.46-2.71 18 1.49 0.62-3.61
Tumor stage <.001 .33 .01 .09
pT1 137 1 1 59 1 1.00
pT2 109 2.67 1.41-3.64 1.42 0.73-2.76 71 5.47 0.83-35.9 4.26 0.71-25.4
pT3/4 22 4.26 2.29-7.94 1.79 0.81-3.95 18 13.2 1.90-92.1 7.90 1.18-52.9
Nodal stage <.001 <.001 .02 .43
Negative 204 1 1 109 1 1.00
Positive 69 5.03 3.32-7.62 5.82 3.16-10.7 36 2.76 1.20-6.35 1.48 0.56-3.92
ER status .11 .91
Negative 87 1 40 1
Positive 126 0.70 0.45-1.09 95 0.95 0.42-2.17
PgR status .25 .58
Negative 84 1 55 1
Positive 123 0.77 0.49-1.21 81 0.80 0.36-1.77
HER2 status .19 .89
Negative 143 1 105 1
Positive 19 1.57 0.80-3.09 4 0.85 0.09-8.40
ALDH1 status .008 .02 .35
Negative 77 1 1 63 1
Positive 116 2.12 1.22-3.68 2.36 1.17-4.73 61 0.68 0.30-1.53
Table 3. Univariate and multivariable analysis for relative survival stratified by age for patients naive to systemic treatment. 
Abbreviations N=number of patients; RER=relative excess risk; ER=estrogen receptor; PgR=progesterone receptor; 
HER2=human epidermal growth factor receptor 2; ALDH1=aldehyde dehydrogenase 1.
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free period (hazard ratio = 1.71; 95% CI, 1.09 to 2.68; P = .021; Table 2) and relative 
survival (relative excess risks of death = 2.36; 95% CI, 1.22 to 3.68; P = .016; Table 3). 
DISCUSSION
In this study, we demonstrated that the presence of ALDH1 expression is significantly 
higher in young breast cancer patients than in elderly patients. Moreover, we demonstrated 
that ALDH1 expression is an independent risk factor for decreased survival in young 
breast cancer patients, but not in elderly patients.
Characteristic Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Age .06 .10
<40 33 1 1 0
40-50 98 1.03 0.51-2.08 0.69 0.21-2.24 0
50-60 101 1.52 0.76-3.03 1.38 0.46-5.18 0
>60 44 2.16 0.99-4.66 1.93 0.56-6.57 154
Grade .03 .95 .34
I 31 1 1 24 1
II 131 2.23 0.80-6.28 1.24 0.31-5.03 74 3.10 0.43-22.4
III 75 3.48 1.22-9.94 1.27 0.30-5.45 44 4.23 0.56-31.8
Histological type .80 .37
Ductal 223 1 124 1
Other 15 1.12 0.46-2.71 18 1.49 0.62-3.61
Tumor stage <.001 .33 .01 .09
pT1 137 1 1 59 1 1.00
pT2 109 2.67 1.41-3.64 1.42 0.73-2.76 71 5.47 0.83-35.9 4.26 0.71-25.4
pT3/4 22 4.26 2.29-7.94 1.79 0.81-3.95 18 13.2 1.90-92.1 7.90 1.18-52.9
Nodal stage <.001 <.001 .02 .43
Negative 204 1 1 109 1 1.00
Positive 69 5.03 3.32-7.62 5.82 3.16-10.7 36 2.76 1.20-6.35 1.48 0.56-3.92
ER status .11 .91
Negative 87 1 40 1
Positive 126 0.70 0.45-1.09 95 0.95 0.42-2.17
PgR status .25 .58
Negative 84 1 55 1
Positive 123 0.77 0.49-1.21 81 0.80 0.36-1.77
HER2 status .19 .89
Negative 143 1 105 1
Positive 19 1.57 0.80-3.09 4 0.85 0.09-8.40
ALDH1 status .008 .02 .35
Negative 77 1 1 63 1
Positive 116 2.12 1.22-3.68 2.36 1.17-4.73 61 0.68 0.30-1.53
Table 3. Univariate and multivariable analysis for relative survival stratified by age for patients naive to systemic treatment. 
Abbreviations N=number of patients; RER=relative excess risk; ER=estrogen receptor; PgR=progesterone receptor; 
HER2=human epidermal growth factor receptor 2; ALDH1=aldehyde dehydrogenase 1.
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To the best of our knowledge, we are the first to show that expression of ALDH1 in 
tumors is age-dependent. A corresponding difference in the number of cancer stem 
cells might provide an explanation for known differences in survival between young 
and elderly breast cancer patients. A potential strength of our study is that it includes 
consecutive patients from one center, not biased by being part of a clinical trial. The age 
restriction of the majority of clinical trials prohibits inclusion of patients older than 70 
year and, indeed, less than 10% of clinical trial participants is older than 65 years.22 In 
our study, 34% of patients were 65 years or older at diagnosis of breast cancer. Therefore, 
our study was not hampered by lack of statistical power to analyse the effect of ALDH1 
in the elderly.
We showed that ALDH1 expression has a qualitative age interaction effect. In our 
study, ALDH1 is a predictor of poor prognosis in young patients, but ALDH1 did not 
influence clinical outcome in elderly patients. Recently, Zhou and colleagues pooled 
the available data on the prognostic role of ALDH1 activity in breast cancer.18 Their 
meta-analysis demonstrated that ALDH1 activity as assessed by immunohistochemistry 
was significantly associated with worse overall survival (unadjusted pooled relative risk, 
2.83; 95% CI, 2.16 to 3.67; four patient cohorts including 1,158 patients).18 However, 
the authors did not stratify for age. In other studies, no interaction was found between 
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Figure 3. Relative survival according to ALDH1 status for all patients (A, D), for patients aged < 65 years (B, E) and 
for patients aged > 65 years (C, F); and for patients that received any or no systemic therapy (A-C) and for patients that 
did not received systemic therapy (D-F). Log-rank P-values are shown in each graph
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ALDH1 expression and age.9, 13, 17 However, in these studies, an age of 40 or 50 year was 
used as a cut-off for age stratification. We used 65 years as a cut-off point as this may 
better match with the bimodal age distribution of breast cancer, which suggests that 
breast cancer may be characterized by early- and late-onset tumor types with modes near 
ages 50 and 70 years.4, 21 As argued by Anderson et al., these modal ages do not suggest 
a sharp division of distinctive tumor categories, but rather reflect central tendencies 
for the age distributions of biologically distinct cancer populations.4, 23 In line with 
this bimodal age distribution, a biological explanation of the qualitative age-interaction 
of the prognostic effect of ALDH1 expression might be that of a changing micro-
environment in elderly patients, which may result in hampered signal transduction 
between tumor stem cells and the micro-environment. Moreover, changes in metabolic 
processes might limit the role of tumor stem cells in elderly patients. Increasing evidence 
from the field of epigenetics demonstrates that hypermethylation-induced repression 
of genes required for stem cell differentiation is linearly associated with age.24 This 
suggests that, with increasing age, the role of tumor stem cells becomes more limited. 
Notwithstanding the need to clarify the underlying mechanism, this new finding on the 
age-dependent role of ALDH1 activity warrants further validation and underlines the 
need of age stratification when assessing biomarkers and new therapies for breast cancer 
patients.  
In conclusion, we demonstrated that expression of the putative breast cancer stem cell 
marker ALDH1 and its prognostic effect are age-dependent in breast cancer patients. 
We demonstrate, for the first time, the different prognostic impact of a molecular 
marker in elderly, which suggests that fundamentally different biological mechanisms 
underlie age-related breast cancer prognosis. Our results support the hypothesis that 
breast cancer biology of elderly patients and their younger counterparts is distinct and 
emphasizes the importance of analyzing and reporting age-specific effects in breast 
cancer research.
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ABSTRACT
Purpose To compare the distribution and prognostic effect of the breast cancer 
molecular subtypes in young and elderly breast cancer patients. 
Patients and Methods Our study population (n=822) consisted of all early breast 
cancer patients primarily treated with surgery in our center between 1985 and 1996. A 
total of 142/822 fresh frozen tissues were available with good quality RNA and analyzed 
by gene expression microarray. Gene expression molecular subtypes were determined 
by correlation to the expression centroids of 534 “intrinsic” genes. . Sections of a tissue 
micro array containing formalin-fixed paraffin-embedded tumor tissue of 714/822 
patients were immunohistochemically (IHC) stained for Ki67, EGFR, CK5/6. Tumor 
expression of ER, PR, HER2 was previously determined. IHC molecular subtypes 
were defined based on expression of these markers: Luminal A: ER+ and/or PR +, 
HER2- and Ki67-; Luminal B: ER+ and/or PR + and ki67+; ERBB2: ER-, PR- and 
HER2+; Basal-like: ER-, PR-, HER2- and EGFR+ and/or CK5/6+; Unclassified: ER-, 
PR-, HER2-, EGFR- and CK5/6-. IHC molecular subtypes were validated against gene 
expression defined molecular subtypes. Assessment of distribution and prognostic effect 
of molecular subtypes was stratified to age (<65 versus >=65 years).
Results Validation of molecular subtypes determined by IHC against gene expression 
revealed a substantial agreement in classification (Cohen’s kappa coefficient 0.75). A 
statistically significant association (p=0.02) was found between molecular subtypes and 
age, where Luminal tumors were more often found in elderly patients, while ERBB2, 
basal-like and unclassified subtypes were more often found in young patients. Molecular 
subtypes showed a prognostic association with outcome in young patients concerning 
relapse free period (RFP) (p=0.01) and relative survival (RS) (p<0.001). No statistically 
significant prognostic effect was found for molecular subtypes in elderly patients (RFP 
p=0.5; RS p=0.1). Additional analyses showed that no molecular subtypes showed a 
statistically significant difference in outcome for elderly compare to young patients. 
Conclusion We have shown that molecular subtypes have a different distribution and 
prognostic effect in elderly compared to young breast cancer patients, emphasizing 
the fact that biomarkers may have different distributions and prognostic effects and 
therefore different implications in elderly compared to their younger counterparts. Our 
results support the premise that breast cancer clinical behavior is significantly affected 
by patient age. We suggest that competing risks of death in elderly patients, ER-driven 
differences and micro-environmental changes in biology are underlying these age-
dependent variations in patient prognosis. 
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INTRODUCTION
Breast cancer is increasingly becoming a disease affecting older women. However, 
evidence based treatment guidelines specific for this aged breast cancer population 
are lacking1. Decisions regarding breast cancer treatment are based on prognostic and 
predictive patient and tumor characteristics discovered and analyzed in relatively young 
patient populations2-5. These characteristics have been found to differ considerably 
between elderly and young breast cancer, i.e. elderly breast cancer patients present 
more often with tumors positive for hormone receptor expression, no overexpression 
of human epidermal growth factor receptor 2 (HER2), lower proliferation rates, 
diploidy, normal p53 expression and bcl-2 overexpression6-8. This may be indicative 
for differences in underlying tumor biology and it has indeed often been suggested 
that elderly breast cancer is a biologically different tumor type of a more indolent 
character compared to young breast cancer7-9. Moreover, it suggests that biomarkers 
may show different prognostic and predictive effects in the elderly compared to young 
breast cancer patients. In addition, due to competing causes of death, life expectancy is 
significantly shorter in elderly breast cancer patient10-12. Therefore, since breast cancer 
relapses can occur after long periods of time, this further suggests that the impact and 
significance of prognostic and predictive biomarkers may vary significantly in this 
patient population. Nevertheless, as this patient population is often underrepresented 
in translational studies and randomized trials, little is known about the implications on 
outcome of prognostic and predictive biomarkers in elderly2, 3.  
Gene expression studies have identified several distinct breast cancer subtypes based 
on gene expression patterns, that showed marked differences in patient prognosis 13-15. 
This “intrinsic” classification proposes four different classes of breast tumors: Luminal 
A and B, which are mostly hormone receptor positive and show high expression of genes 
characteristic of the luminal epithelial cell layer, including expression of estrogen receptor 
(ER), GATA3 and genes regulated by these14, 15. Compared with Luminal A tumors, 
Luminal B tumor often express genes associated with high tumor proliferation14, 15. 
The “intrinsic” subtypes further include 2 main subtypes of hormone receptor negative 
tumors: Basal-like tumors, which typically are triple negative tumor (ER, progesterone 
receptor (PR), and HER2 negative) and exhibit high expression of genes characteristic 
of the basal epithelial cell layer such as cytokeratin (CK) 5, 6 and 17 13 and the ERBB2 
tumor subtype, which clusters near the basal-like tumor, are mostly hormone receptor 
negative and show high overexpression of HER2 and high HER2 gene amplification14, 
15. Concerning outcome, hormone receptor positive tumors result in the best patient 
outcome where, compared to Luminal B tumors, Luminal A tumors seem to be the 
most indolent tumors14. Hormone receptor negative “intrinsic” subtypes, ERBB2 and 
Basal-like tumors have an aggressive natural history, resulting in an unfavorable patient 
outcome14. In a large study on almost 500 breast cancer patients Perou et al. (2000) 
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found the molecular subtypes, determined with immunohistochemistry (IHC), to be 
significantly associated with tumor histological grade, lymph node status and patient 
age, where ERBB2 and Basal-like subtypes showed to correlate with unfavorable 
tumor characteristics and younger patient age16. The distribution and prognostic effect 
of molecular breast cancer subtypes specific in the elderly breast cancer population 
compared to younger breast cancer patients is still unknown. 
We used immunohistochemical (IHC) surrogates, which we validated against gene 
expression determined molecular subtypes, to identify breast tumor molecular subtypes 
in a large cohort of breast cancer patients. The aim was to investigate the distribution and 
prognostic effect of molecular subtypes of breast cancer in elderly patients compared to 
their younger counterparts. 
PATIENTS AND METHODS
Patients and tumors
The patient population comprised all non-metastasized breast cancer patients primarily 
treated with surgery in the Leiden University Medical Center between 1985 and 1996 
(n=822). Patients with bilateral tumors or a prior history of cancer (other than basal 
cell carcinoma or cervical carcinoma in situ) were excluded. The following data were 
known: age, tumor grade, histological type, TNM stage, local and systemic therapy, 
locoregional/distant tumor recurrence and survival. Expression of ER, PR and HER2 
were previously determined using standard immunohistochemistry protocols and semi-
automated quantifications17. All tumors were graded according to current pathological 
standards, by an experienced breast cancer pathologist (VS). Approval was obtained 
from the Leiden University Medical Center Medical Ethics Committee. All samples were 
handled in a coded fashion, according to National ethical guidelines (“Code for Proper 
Secondary Use of Human Tissue”, Dutch Federation of Medical Scientific Societies). 
Microarray analysis
Fresh frozen tumor material was available of 33% (268/822). Total RNA was 
isolated by phenol-chloroform extraction (Trizol reagent). The Quality control, RNA 
labeling, hybridisation and data extraction were performed at ServiceXS (Leiden, 
The Netherlands). RNA concentration was measured using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE, U.S.A). The RNA 
quality and integrity was determined using Lab-on-Chip analysis on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, U.S.A.). Biotinylated cRNA 
was prepared using the Illumina TotalPrep RNA Amplification Kit (Ambion, Inc., 
Austin, TX, U.S.A.) according to the manufacturer’s specifications starting with 200 
ng total RNA. Per sample 750 ng of cRNA was used to hybridise to the HumanHT-
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12 v4 Expression BeadChips (Illumina, Inc., San Diego, CA, U.S.A.). Each BeadChip 
contains twelve arrays. Hybridisation and washing were performed according to the 
Illumina standard assay procedure. Scanning was performed on the Illumina iScan 
(Illumina, Inc., San Diego, CA, U.S.A.). Image analysis and extraction of raw expression 
data was performed with Illumina GenomeStudio; Gene Expression software with 
default settings (no background substraction) and no normalisation. A total of 142 
(53%) breast tumor fresh frozen tissues had good quality mRNA and could be analyzed 
for gene expression. The Illumina HumanHT-12 Oligo Microarray contains 47,231 50–
mer oligonucleotide probes representing 39,809 unique genes and transcripts. Labeling 
of total RNA was performed according to manufacturer’s protocol. Hybridization was 
performed for 16-20 hours at 58 ˚C and arrays were scanned on a iScan scanner. Images 
were analyzed and data were extracted using GenomeStudio Software. Robust spline 
normalization (RSN) and variance stabilizing transformation (VST) were performed 
using R/Bioconductor Lumi Package18. 
Immunohistochemistry
Mouse antibodies against ki67 (clone MIB-1, Dako, NL), epidermal growth factor 
receptor (EGFR) (NCL-EGFR, Novocastra, UK) and CK5/6 (clone D5/16 B4, Dako, 
NL) were used for immunohistochemistry. Tissue sections of 4 μm were cut from a 
previously constructed tissue microarray (TMA) of formalin-fixed paraffin-embedded 
tumors of 714 patients from whom tumor material was available17. Immunohistochemical 
staining was performed according to previously described standard protocols19. Human 
tonsil tissue slides served as positive control. Negative controls were human tonsil 
tissue slides that did undergo the whole immunohistochemical staining without primary 
antibodies. Microscopic analysis of Ki67, EGFR and CK5/6 was assessed independently 
by two observers in a blinded manner. Cut-offs for low versus high expression of Ki67, 
EGFR and CK5/6 were based on the median expression level and were respectively 0%, 
10% and 0% positive stained cells. Immunohistochemical staining and quantification 
of ER, PR and HER2 are described elsewhere (Representative examples of all stainings 
are shown in Figure 1A)17. 
Determination molecular subtypes
Gene expression subtyping:
The gene expression subtypes were determined as follows: An “intrinsic” gene list 
consisting of 534 genes represented by 552 clones, was previously selected based on 
their low variation in expression in successive samples from the same patient’s tumor 
and at the same time, high degree of variation among tumors from different patients15. 
Hierarchical clustering of data from 122 breast tissue samples usingthese intrinsic 
genes were used to define five subtypes of breast tumors and five correspondning core 
expression centroids (i.e., average expression profile of the 534 intrinsic genes). Intrinsic 
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molecular subtypes were assigned to each sample by computing the correlation to each 
of the five centroids.. 
IHC subtyping
The IHC profiles have been previously developed by combinations of the 
following markers: ER, PR, HER2, Ki67, EGFR and CK5/616, 20. We defined the 
immunohistochemistry molecular subtypes as follows (Figure 1A): Luminal A: ER+ 
and/or PR +, HER2- and Ki67-; Luminal B: ER+ and/or PR +, HER2- and/or 
ki67+; ERBB2: HER2+; Basal-like: ER-, PR-, HER2- and EGFR+ and/or CK5/6+; 
Unclassified: ER-, PR-, HER2-, EGFR- and CK5/6-. 
Statistical analysis
Statistical analysis of gene expression data were performed with the software packages 
MATLAB (Mathworks, Natick, Ma), R/Bioconductor and Spotfire Functional Genomic 
(Spotfire, Göteborg, Sweden). Intrinsic genes were mapped to the corresponding genes 
represented on the Illumina HumanHT-12 Microarray platform. Using these mapped 
genes, we computed the Pearson’s correlation coefficient of each sample from this study 
to each of the five centroids and assigned each sample to the subtype with which it 
showed the highest correlation.  
Statistical analyses of IHC data were performed using the statistical packages SPSS 
(version 16.0 for Windows, Spps Inc, Chicago, IL, USA) and Stata (version 10.0 for 
Windows, StataCorp, College Station, TX, USA). Cohen’s kappa coefficient was used 
to assess the inter-observer agreement in quantification of Ki67, EGFR and CK5/6 
tumor expression. In addition, to assess a measurement of inter-assay agreement in 
determination of molecular subtype between gene expression and IHC (in order 
to validate the IHC subtypes with the gene expression subtypes), Cohen’s kappa 
coefficient was used. The χ² test was used to evaluate associations between various 
clinicopathological parameters and molecular subtypes. Relapse-free period (RFP) was 
defined as the time from date of surgery until an event (locoregional recurrence and/
or a distant recurrence, whichever came first). RFP is reported as cumulative incidence 
function, after accounting for death as competing risk21. The Kaplan–Meier method 
was used for survival plotting and log-rank test for comparison of relapse-free period 
curves. Cox proportional hazard analysis was used for univariate and multivariable 
analysis for relapse-free period. Relative survival (RS) was calculated by the Hakulinen 
method as the ratio of the survival observed among the cancer patients and the survival 
that would have been expected based on the corresponding (age, sex, and year) general 
population. National life tables were used to estimate expected survival. Relative excess 
risks (RER) of death were estimated using a multivariable generalized linear model with 
a Poisson distribution, based on collapsed relative survival data, using exact survival 
times. 
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Analyses were performed for all patients and stratified for age and systemic treatment. 
Age of 65 years at time of diagnosis was chosen as the cut-off point for age stratification. 
Variables with a P-value of < .10 in univariate analysis were entered in multivariable 
analysis. 
RESULTS
Patient and tumor characteristics
Figure 1 shows a diagram illustrating the various phases of exclusion or loss of patients 
in this study. Tumor material was available of 86% (714/822) of the patients. Of these 
patients, 469 (66%) were < 65 years at diagnosis and 245 (34%) were > 65 years at 
diagnosis. Median age of patients was 58 years (range 23-96 years). Median follow-up 
of patients alive was 15 years (range 12-23 years). Clinicopathological and treatment 
characteristics are shown in Table 1.
IHC expression of ER, PR, HER2, ki67, EGFR and CK5/6 in patient cohort
The Cohen’s kappa coefficient for inter-observer agreement of Ki67, EGFR and CK5/6 
quantification were 0.71, 0.91 and 0.78 respectively. Immunohistochemical data of ER, 
PR, HER2, Ki67, EGFR and CK5/6 expression was available for respectively 94% 
(669/714) and 92% (657/714), 76% (545/714), 78% (556/714), 72% (516/714) and 79% 
(561/714) of all patients (Figure 2). Missing immunohistochemical data was due to lost 
TMA cores, insufficient tumor tissue present in the core or tissue damage of tumors. 
High expression of ER, PR, HER2, Ki67, EGFR and CK5/6, were found in 58% 
(388/669), 55% (358/657), 10% (56/545), 46% (257/556), 58% (301/516), 24% (134/561). 
Validation IHC molecular subtypes with gene expression subtypes
Subtyping with IHC was possible in 99% (140/142) of these tumors (Figure 2). We were 
not able to subtype the Normal-like breast cancers using IHC, therefore this molecular 
subtype was excluded in analyses, leaving 117 tumors for which both IHC and gene 
subtyping was successful. With gene expression subtyping, 44% (51/117), 15% (18/117), 
15% (17/117), 15% (17/117) and 12% (14/117), were respectively classified as Luminal 
A, Luminal B, HER2, Basal-like and Unclassified. A total of 17% (20/117) cases were 
misclassified and 83% (97/117) of cases were classified correctly (Table 2) with IHC 
subtyping compared to gene expression subtyping. Cohen’s kappa coefficient for inter-
assay agreement in molecular subtype classification was 0.75, which can be interpreted 
as a substantial agreement. 
Moleular subtypes distribution in patient cohort 
Molecular subtypes could be determined with IHC for 77% (551/714) of all patients. 
Luminal A, Luminal B, ERBB2, Basal-like an Unclassified molecular subtypes were seen 
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in 46% (255/551), 21% (118/551), 11% (59/551), 16% (86/551), 6% (33/551) of patients 
respectively. Associations with known clinicopathological parameters are shown in 
Table 1. Statistically significant correlations were found between unfavorable tumor 
characteristics and more Luminal B, ERBBR2 and Basal-like subtypes: more ductal 
Figure 1 Molecular subtypes immunohistochemical stainings and distribution over age groups
A) Representative photographs of  tissue microarray punches of  human breast cancer specimens immunohistochemically 
stained for ER, PR, HER2, ki67, EGFR and CK5/6 and corresponding molecular subtypes. Bar represents 100 μm. B) 
Molecular subtypes according to age (<65 versus >65 years). 
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Total Molecular Subtypes
Unclassified Luminal A Luminal B ERBB2 Basal p-value
N % N % N % N % N % N %
Age
<65 361 66 25 76 154 60 63 46 78 63 73 0.02
>=65 189 34 8 24 101 40 74 37 13 22 23 27
Grade <0.001
I 116 17 7 23 59 24 9 8 4 7 7 8
II 342 49 17 55 151 61 51 44 20 34 25 29
III 224 35 7 23 40 16 57 49 35 59 53 62
Histological type 0.03
Ductal 638 91 27 87 218 87 109 93 57 97 82 97
Lobular 66 9 4 13 32 13 8 7 2 4 3 4
T-status 0.02
T1 289 42 16 50 122 49 38 33 16 28 26 31
T2 328 47 13 41 104 42 62 54 33 57 49 58
T3/4 77 11 3 9 23 9 14 12 9 16 10 12
N-status 0.008
N0 381 55 22 67 146 59 56 50 22 37 40 48
N1-3 313 45 11 33 101 41 57 50 37 63 44 52
ER-status <0.001
Negative 281 42 33 100 45 18 12 10 49 83 86 100
Positive 388 58 0 0 210 82 106 90 10 17 0 0
PgR-status <0.001
Negative 299 46 33 100 58 23 31 26 48 81 86 100
Positive 358 55 0 0 197 77 87 74 11 19 0 0
Her2-status <0.001
Overexpression - 489 90 33 100 255 100 117 100 0 0 86 100
Overexpression + 56 10 0 0 0 0 0 0 59 100 0 0
Ki67 <0.001
Negative 299 54 23 74 188 100 0 0 19 39 27 33
Positive 257 46 8 26 0 0 118 100 30 61 54 67
CK56 <0.001
Negative 427 76 33 100 156 78 91 82 41 84 38 46
Positive 134 24 0 0 42 21 20 18 8 16 45 54
EGFR <0.001
Negative 215 42 33 100 93 49 28 28 14 33 13 16
Positive 301 58 0 0 97 51 74 72 29 67 67 84
Local Therapy 0.3
MAST-RT 285 40 17 52 103 40 49 42 23 39 34 40
MAST+RT 132 19 5 15 37 15 21 18 18 31 20 23
BCS-RT 4 1 0 0 1 0 1 1 0 0 0 0
BCS+RT 293 41 11 33 114 45 47 40 18 31 32 37
Systemic therapy 0.1
CT alone 127 18 7 21 36 14 23 20 14 24 19 22
HT alone 113 16 4 12 41 16 20 17 9 15 14 16
CT&HT 27 4 1 3 6 2 3 3 7 12 7 8
None 447 63 21 64 172 68 72 61 29 49 46 54
Total 714 100 33 100 255 100 118 100 59 100 86 100
Table 1 Correlations between molecular subtypes and well-established prognostic factors using chi-square test (missing 
data not shown). Abbreviations N number of  patients; % percentage; ER estrogen receptor; PR progesterone receptor; 
HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative 
surgery; ET endocrine therapy; CT chemotherapy.
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histological tumor types, higher tumor histological grade, higher tumor stage and more 
lymph node positivity showed a positive association with more Luminal B, ERBBR2 and 
Basal-like subtypes. A statistical significant association was found between molecular 
subtypes and age, where Luminal tumor types were more often found in patients aged 
>65 years, while ERBBR2, Basal-like an Unclassified molecular subtypes were more 
often found in patients aged <65 years (p=0.02) (Figure 1B). 
Molecular subtypes and age-related prognostic associations with outcome
The association of molecular subtypes with relapse-free period and relative survival 
are shown in Figure 3 and 4. Analysis of relapse-free period and relative survival 
showed a significant association molecular subtypes and clinical outcome for the whole 
population (RFP p=0.003, Figure 3A; RS p<0.001, Figure 4A), where Unclassified 
tumor subtypes resulted in the most favorable patient outcome, followed by Luminal 
A subtypes, Luminal B subtypes, Basal-like subtypes and with the worst outcome for 
patients with ERBBR2 breast cancer subtypes. In patients who did not receive any 
systemic treatment molecular subtypes showed a similar but weaker prognostic effect 
(RFP p=0.208, Figure 3D; RS p=0.017, Figure 4D). Explanations to the loss of statistical 
significance may be due to loss in power due to less patients analyzed and to the fact 
that patients with Luminal B subtypes showed a worse outcome in patients who did not 
Figure 2 Diagram illustrating patient cohort and various stages of  loss of  cases due to unavailable tumor material, 
tumor core or tissue damage of  TMA or inadequate mRNA quality as described in the Patients and Methods and Results 
section. 
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receive systemic treatment, explainable by the fact that these tumors may benefit more 
from chemotherapy treatment than other tumor subtypes due to the high proliferative 
tumor character.  
Similarly, in the group of patients aged <65 years, a strong association was found between 
molecular subtypes and clinical outcome in all patients aged <65 (RFP p=0.014, Figure 
3B; RS p<0.001 Figure 4B) and patients aged <65 who did not receive any systemic 
treatment (RFP p= 0.057, Figure 3E; RS p=0.003, Figure 4E). In patients aged >65 
years, no significant association was found between molecular subtypes and clinical 
Immunohistochemistry Subtypes
Unclassified Luminal A Luminal B ERBB2 Basal Total
N (%) N (%) N (%) N (%) N (%) N (%)
Unclassified 7 (43.8) 5 (7.1) 0 (0) 1 (5.0) 1 (5.3) 14 (12.0)
Luminal A 1 (6.3) 48 (68.6) 2 (15.4) 0 (0) 0 (0) 51 (43.5)
Luminal B 1 (6.3) 0 (0) 11 (84.6) 3 (15.0) 3 (15.8) 18 (15.4)
ERBB2 0 (0) 0 (0) 0 (0) 16 (80) 1 (5.3) 17 (14.5)
Basal 0 (0) 3 (4.3) 0 (0) 0 (0) 14 (73.7) 17 (14.5)
Total 9 (100) 56 (100) 13 (100) 20 (100) 19 (100) 117 (100)
Table 2 Correlation between immunohistochemistry and gene expression molecular subtype classification.













Figure 3 Relapse free period according to molecular subtypes for all patients (A, D), for patients aged < 65 years (B, E) 
and for patients aged > 65 years (C, F), with no stratification for systemic treatment (A, B, C) and on selected patient 
population that did not receive any systemic treatment (D, E, F). Log-rank P-values are shown in each graph. 
proefschrift.indb   119 18-12-2014   16:35:46
120 Chapter 7
A RFP
Characteristic Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Grade
I 74 1.00 0.03 1.00 42 1.00 <0.001 1.00 0.01
II 225 1.32 0.87-2.02 1.13 0.67-1.71 0.7 117 1.84 0.89-3.80 1.48 0.67-3.26
III 164 1.72 1.12-2.66 1.27 0.73-2.22 80 3.72 1.81-7.64 2.72 1.21-6.12
Histological type
Ductal 429 1.00 0.3 209 1.00 0.5
Other 36 1.31 0.82-2.10 30 1.23 0.69-2.22
Tumor stage
pT1 203 1.00 <0.001 1.00 86 1.00 0.001 1.00 0.3
pT2 210 1.53 1.14-2.05 1.22 0.84-1.77 0.1 118 2.34 1.43-3.83 1.28 0.73-2.23
pT3/4 44 2.65 1.74-4.04 1.74 1.03-2.96 33 2.68 1.35-5.32 1.83 0.86-3.86
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 <0.001 1.00 <0.001
Positive 213 2.85 2.16-3.76 2.41 1.70-3.40 100 3.18 2.06-4.89 2.60 1.64-4.12
Mol subtypes
Unclassified 25 1.00 0.01 1.00 8 1.00 0.5
Luminal A 154 1.02 0.51-2.06 1.14 0.52-2.50 101 1.01 0.31-3.28
Luminal B 74 1.31 0.63-2.72 1.18 0.51-2.72 0.5 44 1.14 0.34-3.87
ERBB2 46 2.10 0.99-4.46 1.70 0.72-4.03 13 1.82 0.45-7.27
Basal 63 1.61 0.77-3.37 1.32 0.57-3.05 23 1.62 0.45-5.81
B RS
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Grade
I 74 1.00 0.008 1.00 42 1.00 0.02 1.00 0.1
II 225 1.65 0.94-2.90 1.15 0.60-2.21 0.8 117 4.73 0.22-100.74 8.15 0.05-1309
III 164 2.28 1.30-4.02 1.22 0.62-2.40 80 10.93 0.55-218.77 16.88 0.10-2787
Histological type
Ductal 429 1.00 0.2 209 1.00 0.8
Other 36 1.44 0.86-2.42 30 1.12 0.46-2.72
Tumor stage
pT1 203 1.00 <0.001 1.00 86 1.00    0.02 1.00 0.06
pT2 210 2.05 1.47-2.88 1.23 0.78-1.93 0.3 118 5.38 1.38-20.99 1.72 0.62-4.78
pT3/4 44 3.20 2.01-5.08 1.67 0.90-3.12 33 13.17 3.25-53.41 3.45 1.18-10.07
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 0.005 1.00 0.1
Positive 213 3.47 2.51-4.80 2.38 1.57-3.60 100 3.75 1.50-9.42 1.69 0.85-3.34
Mol subtypes
Unclassified 25 1.00 <0.001 1.00 8 1.00 0.07 1.00 0.1
Luminal A 154 0.92 0.39-2.16 1.19 0.44-3.26 0.02 101 0.63 0.12-3.17 1.98 0.18-21.25
Luminal B 74 1.49 0.62-3.59 1.60 0.56-4.51 44 0.39 0.05-3.05 1.00 0.10-10.43
ERBB2 46 3.00 1.24-7.23 2.82 0.99-8.03 13 2.16 0.39-12.12 2.85 0.25-32.41
Basal 63 1.97 0.82-4.75 2.02 0.71-5.69 23 1.40 0.26-7.66 1.69 0.16-17.79
Table 3 Cox univariate and multivariate analysis for recurrence free period (A) and relative survival (B) for molecular 
subtypes. Abbreviations N number of  patients; HR hazard ratio; RER relative excess risk; 95%CI 95% Confidence 
Interval;. * NA not applicable; too few patients in life table. 
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A RFP
Characteristic Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Grade
I 74 1.00 0.03 1.00 42 1.00 <0.001 1.00 0.01
II 225 1.32 0.87-2.02 1.13 0.67-1.71 0.7 117 1.84 0.89-3.80 1.48 0.67-3.26
III 164 1.72 1.12-2.66 1.27 0.73-2.22 80 3.72 1.81-7.64 2.72 1.21-6.12
Histological type
Ductal 429 1.00 0.3 209 1.00 0.5
Other 36 1.31 0.82-2.10 30 1.23 0.69-2.22
Tumor stage
pT1 203 1.00 <0.001 1.00 86 1.00 0.001 1.00 0.3
pT2 210 1.53 1.14-2.05 1.22 0.84-1.77 0.1 118 2.34 1.43-3.83 1.28 0.73-2.23
pT3/4 44 2.65 1.74-4.04 1.74 1.03-2.96 33 2.68 1.35-5.32 1.83 0.86-3.86
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 <0.001 1.00 <0.001
Positive 213 2.85 2.16-3.76 2.41 1.70-3.40 100 3.18 2.06-4.89 2.60 1.64-4.12
Mol subtypes
Unclassified 25 1.00 0.01 1.00 8 1.00 0.5
Luminal A 154 1.02 0.51-2.06 1.14 0.52-2.50 101 1.01 0.31-3.28
Luminal B 74 1.31 0.63-2.72 1.18 0.51-2.72 0.5 44 1.14 0.34-3.87
ERBB2 46 2.10 0.99-4.46 1.70 0.72-4.03 13 1.82 0.45-7.27
Basal 63 1.61 0.77-3.37 1.32 0.57-3.05 23 1.62 0.45-5.81
B RS
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Grade
I 74 1.00 0.008 1.00 42 1.00 0.02 1.00 0.1
II 225 1.65 0.94-2.90 1.15 0.60-2.21 0.8 117 4.73 0.22-100.74 8.15 0.05-1309
III 164 2.28 1.30-4.02 1.22 0.62-2.40 80 10.93 0.55-218.77 16.88 0.10-2787
Histological type
Ductal 429 1.00 0.2 209 1.00 0.8
Other 36 1.44 0.86-2.42 30 1.12 0.46-2.72
Tumor stage
pT1 203 1.00 <0.001 1.00 86 1.00    0.02 1.00 0.06
pT2 210 2.05 1.47-2.88 1.23 0.78-1.93 0.3 118 5.38 1.38-20.99 1.72 0.62-4.78
pT3/4 44 3.20 2.01-5.08 1.67 0.90-3.12 33 13.17 3.25-53.41 3.45 1.18-10.07
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 0.005 1.00 0.1
Positive 213 3.47 2.51-4.80 2.38 1.57-3.60 100 3.75 1.50-9.42 1.69 0.85-3.34
Mol subtypes
Unclassified 25 1.00 <0.001 1.00 8 1.00 0.07 1.00 0.1
Luminal A 154 0.92 0.39-2.16 1.19 0.44-3.26 0.02 101 0.63 0.12-3.17 1.98 0.18-21.25
Luminal B 74 1.49 0.62-3.59 1.60 0.56-4.51 44 0.39 0.05-3.05 1.00 0.10-10.43
ERBB2 46 3.00 1.24-7.23 2.82 0.99-8.03 13 2.16 0.39-12.12 2.85 0.25-32.41
Basal 63 1.97 0.82-4.75 2.02 0.71-5.69 23 1.40 0.26-7.66 1.69 0.16-17.79
Table 3 Cox univariate and multivariate analysis for recurrence free period (A) and relative survival (B) for molecular 
subtypes. Abbreviations N number of  patients; HR hazard ratio; RER relative excess risk; 95%CI 95% Confidence 
Interval;. * NA not applicable; too few patients in life table. 
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outcome in all patients aged >65 (RFP p=0.514, Figure 3C; RS p=0.126, Figure 4C) and 
neither in patients aged >65 who did not receive any systemic treatment (RFP p=0.640, 
Figure 3F; RS p=0.637, Figure 4F).
Univariate analyses were performed for molecular subtypes and known clinicopathological 
parameters: histological tumor grade, histological tumor type, tumor stage, lymph node 
status (due to their inclusion in molecular subtypes ER, PR, HER2, Ki67, EGFR and 
CK5/6 expression were not separately analyzed in univariate analysis). Multivariable 
analyses were performed including variables which had shown to be of influence 
on patient outcome (univariate p<0.1) on patients who did not receive any systemic 
treatment and were stratified for age (<65 versus >65 years). In patients aged <65 years, 
histological grade, tumor stage, lymph node status and molecular subtypes were included 
in multivariate analysis for RFP and RS. The prognostic effect of molecular subtypes 
got weaker in both analyses; it remained statistically significant for RS analysis (p=0.02 
Table 3B), but did not reach statistical significance in RFP analysis (p=0.5 Table 3A), 
probably due to their strong associations with tumor histological grade, tumor stage 
and lymph node status (Table 1). In patients aged >65 years, molecular subtypes did not 
reach the criteria to be included in multivariable analysis for RFP (Univariate p=0.9, 
Table 3A) and lost statistical significance when included in multivariable RS analysis 
(Univariate p=0.7, Table 3B). 
Figure 4 Relative survival according to molecular subtypes for all patients (A, D), for patients aged < 65 years (B, E) 
and for patients aged > 65 years (C, F), with no stratification for systemic treatment (A, B, C) and on selected patient 
population that did not receive any systemic treatment (D, E, F). Log-rank P-values are shown in each graph.
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DISCUSSION
In this study, we used IHC surrogates, which we validated against gene expression 
determined molecular subtypes, to identify breast tumor molecular subtypes in a large 
cohort of breast cancer patients. We demonstrated that the distribution of molecular 
subtypes between elderly and young patients was statistically significantly different, 
where elderly patients more frequently had less aggressive Luminal A and Luminal 
B tumor subtypes. Moreover, both RFP and RS outcome analyses showed molecular 
subtypes to be a statistically significant prognostic factor in young, but not in elderly 
breast cancer patients.
We have shown that the distribution of molecular subtypes differed between elderly 
and young breast cancer patients, where we defined elderly breast cancer patients as 
patients aged 65 years or older according to World Health Organization definition 
(www.who.int). With this cut-off point, elderly breast cancer patients showed more 
often Luminal A and Luminal B molecular subtypes less often ERBB2, basal and 
unclassified molecular subtypes.  This is in line with a previous study by Perou et al., 
who investigated the associations of molecular subtypes with patient clinical data, 
demographic data and survival16. Though they did not specifically look at elderly breast 
cancer patients, in this study on almost 500 breast cancer patients, molecular subtypes 




























Figure 5 Breast cancer specific death per age category calculated by the percentage of  observed death (O%) minus the 
expected death based on the general population according to age and time period (E%) divided by the total observed 
death (O%) per age category for the cohort breast cancer patients used in this study. Death cancer specific death 
calculation: (O%-E%/E%). 
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where Luminal A and Luminal B tumor were more often found in older aged patients16. 
In addition our data are also concordant to previous studies that showed more ER and/
or PR positivity and less overexpression of EGFR, HER2 and ki67 in tumors of elderly 
breast cancer patients22, 23. 
In addition to differing distributions in molecular subtypes, we found a different 
prognostic effect for molecular subtypes in elderly breast cancer patients compared 
to their younger counterparts. In the period analyzed adjuvant systemic treatment 
changed, where not all hormone receptor positive patients received adjuvant endocrine 
therapy and trastuzumab was not yet introduced. In addition, breast cancer patients 
received different adjuvant therapy according to their age, where elderly received less 
aggressive treatment regimens. Considering these differences in adjuvant therapy 
regimens between analyzed patients and in order to analyze a true prognostic effect, we 
stratified our analyses and selected patients who did not receive any adjuvant treatment, 
hereby filtering out any predictive adjuvant therapy effect. In the whole breast cancer 
cohort and in young breast cancer patients molecular subtypes showed to be statistically 
significant prognostic factors for RFP and RS. These prognostic effects weakened in 
multivariable analyses, however this could well be explained by correction for tumor 
histological grade, tumor stage and lymph node status and the strong associations of 
molecular subtypes with these unfavorable tumor characteristics. Importantly, molecular 
subtypes did not show any statistically significant effect on patient outcome in elderly 
breast cancer patients in this study. Further underlying differences in tumor biology 
might explain this fading prognostic effect. These underlying biological differences 
may result in the molecular subtypes to behave differently and have a different effect 
on tumor progression in elderly breast cancer patients, which may be reflected in a 
differing prognostic effect of the same molecular subtype in elderly compared to young 
patients. Indeed, as shown priory by others, elderly breast cancer tumors are of a more 
indolent and less aggressive and proliferative character (Eppenberger-Castori et al., 
2002; Nixon et al., 1994; Thomas and Leonard, 2009). However, this contradicts the fact 
that increased breast cancer specific mortality is seen with ageing, where elderly breast 
cancer patients were found to decease more often due to breast cancer regardless of a 
higher risk of mortality from other causes 24.  Joining these paradoxal findings together, 
an explanation might be sought in differences in the tumor microenvironment in elderly 
breast cancer patients compared to young breast cancer patients. With increasing age, 
there appears to be a progressive accumulation of cellular and molecular alterations 
leading to tissue dysfunction 25, 26}. This may apply to the tumor micro-environment, 
thereby facilitating tumor progression. Evidence has shown that an age-related decline 
of functional innate and adaptive immunity leads to a reduced ability to respond to 
infection and vaccinations 27. This phenomenon, known as immunosenescence, is 
characterized by a decreased output of naïve T cells, altered cytokine production and 
inoptimale functioning of T cells, B cells and NK cells  27-30. There has been increasing 
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evidence that immunosenescence might promote cancer progression in elderly breast 
cancer patients, which would explain the worse breast cancer specific outcome of 
these patients 31. If tumors become less aggressive with increasing age, but this is 
simmulataneously accompanied by an even faster deteriorating host defence, i.e. tumor 
micro-environment, this altogether can result in more tumor progression and finally 
lead to worse patient outcome. 
Another explanation for the finding that molecular subtypes are not statistically 
significant prognostic indicators in elderly breast cancer may be the competing risks 
of death in elderly patients. Elderly breast cancer patients compared to their younger 
counterparts have shown in absolute sense to develop more relapses 24,  however 
proportionally due to higher risk of dying earlier and from other causes they show 
less breast cancer relapses and breast cancer specific deaths 10-12. In fact, as shown by 
Figure 5 the approximated breast cancer specific decease declines as the patients age 
increases. Only about 60% of elderly breast cancer patients die as a consequence of 
breast cancer, compared to almost 100% of young patients. This has major implications 
on the impact and value of prognostic biomarkers in elderly breast cancer patients. 
Prognostic biomarkers, identifying patients with low versus high risk of breast cancer 
progression and breast cancer related death will show limited to no prognostic effect 
in the 40% of elderly patients which have a short-term prognosis due to breast cancer 
un-related causes, especially in those who are considered frail. These elderly patients 
are also unlikely to benefit from systemic treatment, since their cause of death will be 
other than due to breast cancer. Therefore, the clinical value of prognostic biomarkers, 
which aid at distinguishing between patients who might and might not benefit from 
systemic treatment, is also limited in this patient population. Breast cancer prognostic 
biomarkers can only have a prognostic value in elderly patients whose life expectation 
will be long enough for the cancer to progress and cause patient death, which are the 
patients reflected by the 60% of elderly breast cancer patients dying as a consequence 
of breast cancer. It is only in these fit enough patients that prognostic biomarkers may 
show differences in outcome between elderly breast cancer patients and may aid clinical 
decision making on systemic treatment. In order to improve tailored treatment in elderly 
with the aid of prognostic biomarkers, the first step would therefore be to identify these 
fit elderly patients. 
The identification of breast cancer molecular subtypes has proven breast cancer 
to be a heterogeneous group of diseases, needing different approaches to systemic 
treatment administration. This molecular taxonomy and its impact on patient clinical 
outcome have been extensively investigated in breast cancer. However, as is the case 
for most translational studies and randomized clinical trials, these studies included 
relatively young patients. To the best of our knowledge, we are the first to have shown 
that molecular subtypes have a different distribution and prognostic effect in elderly 
compared to young breast cancer patients, highlighting the fact that the prognostic effect 
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and clinical value as found for biomarkers in translational studies and randomized trials, 
cannot simply be extrapolated to elderly breast cancer patients. Our results support the 
premise that breast cancer clinical behavior is significantly affected by patient age. We 
suggest that competing risks of death in elderly patients, ER-driven differences and 
micro-environmental changes in biology are underlying these age-dependent variations 
in patient prognosis. 
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ABSTRACT
Purpose: As demonstrated recently, tumor immune subtypes, representative for various 
tumor immune control and host immune escape phases, are a strong prognostic factor 
for breast cancer outcome. With ageing, immunosenescence occurs, which might impair 
tumor immune surveillance. 
Experimental Design: All non-metastasized breast cancer patients primarily treated 
with surgery in the Leiden University Medical Center between 1985 and 1996 were 
included (n=714). Tumor immune subtypes were previously categorized in groups of 
increasing immune susceptibility using quantifications of immunohistochemically 
stained tumor infiltration of CD8+ cells, natural killer cells, T regulatory cells, and 
tumor expression of HLA class I and HLA EG. Associations between immune markers 
and age at diagnosis (<65 versus >=65 years) and outcome analyses according to age 
were performed. 
Results: A statistically significant association was found between less HLA-EG 
upregulation and patients aged >=65 years (p=0.015). In addition, though not significant, 
less low immune susceptible tumors were seen in these older patients. In patients aged 
<65 tumor, higher immune susceptibility resulted in statistically significant favorable 
patient outcome independently of known clinicopathological parameters (RFP p<0.001, 
RS p<0.001). In patients aged ≥65, immune subtypes showed no statistically significant 
association with outcome. 
Conclusions: Less immune susceptible tumors were found in elderly breast cancer 
patients, supporting the idea of immunosenescence potential role in cancer progression. 
In addition, contrary to the results found in patients aged <65 years, no statistically 
significant association was found between tumor immune subtypes and patient outcome 
in patients aged >65 years. A better understanding of processes of immunosenescence 
and tumor progression and future possibilities in immune manipulations and 
vaccinations might lead to more tailored treatment of elderly breast cancer patients. 
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INTRODUCTION
Breast cancer is the leading contributor to cancer incidence and cancer mortality in 
women worldwide, with 1.383.500 new cases in 2008 (1). Nearly one third of these 
breast cancer patients are 65 years or older (2). As breast cancer incidence increases with 
increasing age, changing demographics and continuously increasing life expectancy 
will further enlarge the number of elderly women confronted with breast cancer. A 
recent report observed that regardless of a higher risk of mortality from other causes 
and independent of known tumor and patient characteristics, mortality from breast 
cancer increased with age (3) Cancer immune surveillance and immunosenescence at 
increasing age, may contribute to an explanation of this finding. 
There has been strong evidence that the host’s immune system is able to control tumor 
progression (4). On the other hand, due to their intrinsic genetic unstable nature, tumor 
cells may acquire properties to escape from such immune recognition (5). Various 
interactions underlie this balance between tumor immune control and escape (Figure 
1A). Cytotoxic T-lymphocytes (CTL) are capable of recognising tumor associated 
antigens presented by classical human leukocyte antigen (HLA) class I (HLA-A, 
HLA-B, HLA-C) on the tumor cell surface. In order to avoid immune recognition 
from CTL, cancer cells may lose expression of classical HLA class I (6). However, this 
makes them prone to natural killer (NK) cell recognition (7). Non-classical HLA class 
I molecules (HLA-E, HLA-G) play a crucial role in immune surveillance by NK-cells. 
Expression of these molecules on the cell surface causes an inhibitory effect on NK-cell 
attack (7-9). Another known tumor escape mechanism is the attraction and induction 
of immune suppressive regulatory T cells (Treg) in the tumor microenvironment (10). 
There is evidence for a variety of these immune reactions in breast cancer, where it 
has been shown that breast cancer is highly immunogenic (11, 12), but also capable 
of evading immune recognition. (13, 13-21) This emphasizes the importance of taking 
into account the various interactions which exist between the tumor and the immune 
system. We recently defined tumor immune subtypes, based on the above mentioned 
immunological interactions, which were shown to be a highly discriminative prognostic 
biomarker with solid underlying biological rationale (22).  
With increasing age, there appears to be a progressive accumulation of cellular and 
molecular alterations leading to tissue dysfunction. This equally applies to the immune 
system, where the age-related decline of functional innate and adaptive immunity 
leads to a reduced ability to respond to infection, vaccinations or cancer (23, 24). 
Though the exact mechanisms of immunosenescence are not fully understood, various 
phenomena may be explanatory for the decline in functioning of the immune system 
with age. With increasing age thymic involution leads a decreased output of naïve T 
cells, which subsequently leads to a reduction of peripheral T cell diversity, changes in 
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phenotype, altered cytokine production, modification in immune responses (25, 26). A 
decline in production of immune cells with increasing age is seen caused by changes 
in bone marrow constitution and decline in function of haematopoietic stem cells (27, 
28). Another contributor to immunosenescence are the deficiencies in functioning of 
secondary lymphoid organs, causing less migration of immune cells to the spleen and 
therefore less antigenic stimulation (29). Both the innate and adaptive immune system 
appear to be affected by immunosenescence, where amongst many others deficiencies 
in numbers and inoptimal functioning of CD4+ T cells, CTL, B cells and NK cells are 
found (24, 30-32). 
There has been increasing evidence that age associated immunosenescence might 
contribute to cancer development and progression (33). This raised the question 
whether age at diagnosis affects the interplay between the balance in cancer immune 
surveillance and tumor immune escape and consequently its effects on tumor 
progression and patient outcome in breast cancer patients. We priory determined tumor 
immune subtypes, which reflect tumor-immune interactions and represent a strong, 
validated, independent prognostic factor in breast cancer patients (22). We evaluated the 
distribution and prognostic effect of these tumor immune subtypes in elderly patients 
versus their younger counterparts. 
MATERIALS AND METHODS
Patients and tumors
The patient population has been priory described in detail (22) and comprised all 
non-metastasized breast cancer patients primarily treated with surgery in the Leiden 
University Medical Center between 1985 and 1996. Patients with bilateral tumors or a 
prior history of cancer (other than basal cell carcinoma or cervical carcinoma in situ) were 
excluded. The following data were known: age, tumor grade, histological type, TNM 
stage, local and systemic therapy, locoregional/distant tumor recurrence, survival, and 
expression of estrogen receptor (ER), progesterone receptor (PgR), Ki67, and human 
epidermal growth factor receptor 2 (HER2) (34). All tumors were graded according to 
current pathological standards, by an experienced breast cancer pathologist. Approval 
was obtained from the Leiden University Medical Center Medical Ethics Committee. 
All samples were handled in a coded fashion, according to National ethical guidelines 
(“Code for Proper Secondary Use of Human Tissue”, Dutch Federation of Medical 
Scientific Societies). 
Immunohistochemistry and quantification of immunostaining
Immunohistochemistry and quantifications of immune markers used to construct tumor 
immune subtypes were previously performed as previously described in detail (13, 17, 
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35). Formalin-fixed paraffin-embedded tumor material was immunohistochemically 
stained according to standard protocols. Mouse antibody against CD8, PEN5 and 
Foxp3 were used for recognition of respectively CTL, NK cell and Treg infiltration (13, 
35). Stainings for classical HLA class I were performed using the mouse monoclonal 
antibodies HCA2 and HC10 (13). Non-classical HLA class I molecules using mouse 
monoclonal antibodies against HLA-E and HLA-G (17).
Expression of classical HLA class I, combined HLA-E and –G expression, CTL 
infiltration, PEN5 infiltration and Treg infiltration were categorized respectively as 
loss versus expression, no expression versus expression, high versus low infiltration and 
absent infiltration versus present infiltration (35).  
Tumor immune subtypes
Categorization of tumor immune subtypes, representing adaptive immune susceptibility 
of tumors was previously described (35). Briefly, different stages of immune surveillance 
and tumor immune escape were classified using combinations of CTL infiltration, 
NK-cell infiltration, Treg infiltration, classical HLA class I tumor expression and 
HLA-EG tumor expression. Tumors were first classified according to their immune 
susceptiblity resulting in the tumor immune subtypes which consisted of three clustered 
groups: “High immune susceptibility”, “Intermediate immune susceptibility” and “Low 
immune susceptibility”. 
Statistical analysis
Statistical analyses were performed using the statistical packages SPSS (version 20.0 for 
Windows, Spps Inc, Chicago, IL, USA) and Stata (version 10.0 for Windows, StataCorp, 
College Station, TX, USA). The χ² test was used to evaluate associations between various 
clinicopathological parameters and tumor immune subtypes. Relapse-free period 
was defined as the time from date of surgery until an event (locoregional recurrence 
and/or a distant recurrence, whichever came first). Relapse-free period is reported 
as cumulative incidence function, after accounting for death as competing risk. The 
Kaplan–Meier method was used for survival plotting and log-rank test for comparison 
of relapse-free period curves. Cox proportional hazard analysis was used for univariate 
and multivariable analysis for relapse-free period. Relative survival was calculated by the 
Hakulinen method as the ratio of the survival observed among the cancer patients and 
the survival that would have been expected based on the corresponding (age, sex, and 
year) general population. National life tables were used to estimate expected survival. 
Relative excess risks of death were estimated using a multivariable generalized linear 
model with a Poisson distribution, based on collapsed relative survival data, using exact 
survival times. Analyses were stratified by age at diagnosis (<65 years versus ≥65 years). 
Multivariable analyses were adjusted for histological grade, histological type, T stage, 
N stage, estrogen receptor expression, progesterone receptor expression, HER2 status, 
local therapy and systemic therapy.  
proefschrift.indb   133 18-12-2014   16:35:51
134 Chapter 8
RESULTS
Patient and tumor characteristics
Of the total patient population (n=714), 469 (66%) were < 65 years at diagnosis and 245 
(34%) were ≥ 65 years at diagnosis. Median age of patients was 58 years (range= 23-96 
years). Clinicopathological and treatment characteristics of patients with available data 
for analysis are shown in Table 1. More detailed patient and tumor characteristics are 
described elsewhere (35). 
Expression of immune markers by age
As priory described, immunohistochemical data of CTL infiltration, NK cell 
infiltration, Treg infiltration, classical HLA class I expression and HLA-EG expression 
were available for respectively 85% (607/714) and 91% (650/714), 95% (679/714), 83% 
(594/714) and 73% (519/714). Missing immunohistochemical data was due to tissue 
damage and unsuccessful staining of tumors. Cohen’s kappa coefficient for inter-
observer agreement of all these markers was determined previously and gave substantial 
to almost perfect agreements (13, 17, 35). The association between these markers and age 
is shown in Figure 1. Only HLA-EG expression showed a statistically significant inverse 
correlation with age (p=0.015), where expression of HLA-EG was more frequently 
found in patients aged <65 (27%) compared to patients aged ≥65 (17%). No statistically 
significant associations were found between patients aged ≥65 and patients aged <65 in 
frequency of high infiltration of CTL (31% versus 27%; p=0.253), present infiltration 
of PEN5 (51% versus 53%; p=0.599), present infiltration of Treg (45% versus 45%; 
p=0.991) or expression of classical HLA class I (77% versus 80%; p=0.282).  
Tumor immune subtypes distribution by age
Tumor immune subtypes could be determined for patients with data available for 
all immune markers; 72% (512/714) of patients. Tumor immune subtypes showed 
the following distribution: “High immune susceptibility” 16% of patients (82/512), 
“Intermediate immune susceptibility” 67% (342/512), “Low immune susceptibility” 
17% (88/512). Associations with known clinicopathological parameters are shown 
in Table 1. No statistically significant association was found between tumor immune 
subtypes and age (<65 versus ≥65; p=0.381), though low immune susceptible tumors 
were shown to occur more often in patients aged <65 (Figure 2).  
Tumor immune subtypes and prognostic associations with outcome
The age-specific association of  tumor immune subtypes with relapse-free period and 
relative survival are shown in Figure 3. In the group of patients aged <65 years, a 
strong association was found between immune subtypes and clinical outcome. Lower 
immune susceptibility, resulted in more relapses over time compared to higher immune 
susceptible tumors (RFP p<0.001, Figure 3 B; RS p< 0.001 Figure 3 E). Though a 
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similar trend was noticed in patients aged >=65 years, this was not statistically significant 
(RFP p= 0.147, Figure 3C; RS p=0.45 Figure 3F) Multivariable analyses were stratified 




High Intermediate Low p-value
N % N % N % N %
Age 341 67 222 65 64 73 0.381
<65 171 33 55 67 120 35 24 37
>=65 27 33
Grade 0.306
I 78 15 16 20 45 13 17 20
II 246 49 33 41 173 51 40 47
III 182 36 31 39 122 36 29 34
Histological type 0.255
Ductal 460 91 71 89 314 92 75 87
Lobular 46 9 9 11 26 8 11 13
T-status 0.829
T1 192 38 31 38 131 39 30 36
T2 242 48 42 52 159 48 41 49
T3/4 66 13 8 10 45 13 13 16
N-status 0.316
N0 267 54 48 60 178 54 41 48
N1-3 231 46 32 40 155 46 44 52
ER-status 0.093
Negative 205 40 39 49 138 41 28 32
Positive 302 60 41 51 202 59 59 68
PgR-status 0.460
Negative 231 46 41 51 155 46 35 42
Positive 274 54 39 49 186 55 49 58
Her2-status 0.352
Overexpression - 390 90 58 89 260 89 72 95
Overexpression + 42 10 7 11 31 11 4 5
Local Therapy 0.905
MAST-RT 207 40 34 42 139 41 34 39
MAST+RT 99 19 17 21 62 18 20 23
BCS 206 41 31 38 141 41 34 39
Systemic therapy 0.622
CT alone 100 20 15 18 68 20 17 19
ET alone 76 15 13 16 52 15 11 13
CT&ET 21 4 1 1 18 5 2 2
None 315 62 53 65 204 60 58 66
Total 512 100 82 100 342 100 88 100
Table 1 Correlations between molecular subtypes and well-established prognostic factors using chi-square test (missing 
data not shown).
Abbreviations N number of  patients; % percentage; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET 
endocrine therapy; CT chemotherapy.
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independent prognostic factor in young patients (RFP p<0.001, Table 2; RS p<0.001, 
Table 3). In patients aged ≥65 years, no statistical association was found in multivariable 
analyses between immune subtypes and clinical outcome (RFP p=0.15, Table 2; RS p= 
0.45, Table 3). 
CTL  high infiltration
Nkcell present infiltration
Treg present infiltration







Figure 1 CTL, NK cell and Treg infiltration and classical HLA class I and HLA-E and HLA-G expression Histograms 
depicting distributions of  high infiltration and high expression of  these markers amongst age groups <65 and >=65 




Figure 2 Tumor immune subtypes Bar chart depicting 
the distribution of  immune subtypes according 
to patients aged <65 years and >=65 years. No 
statistically significant differences were found.
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DISCUSSION
In this study, we evaluated the distribution and impact on tumor progression and 
patient outcome of anti-tumor immune response and tumor immune evasion in elderly 
breast cancer patients compared to their younger counterparts. We compared previously 
determined numbers of infiltrating CTL, NK cells, Tregs, expression of classical HLA 
class I and HLA-E and –G and tumor immune subtypes, representing cancer immune 
susceptibility, between these two patient populations. Our results showed no differences 
in number of infiltrating CTL, NK cells or Treg, but a trend towards less classical HLA 
class I downregulation and statistically significant less HLA-E expression or HLA-G 
upregulation of tumors. These differences were also reflected, though not statistically 
significant, in less “low immune susceptible” tumors in patients aged >=65. Moreover, 
both RFP and RS outcome analyses showed tumor immune subtypes to be a statistically 


























Figure 3 Kaplan Meier outcome analyses by tumor immune subtypes for Relapse free period (RFP) (A, B, C) and relative 
survival (RS) (D, E, F) according to the tumor immune subtypes. Tumor immune subtypes representing low immune 
susceptible resulted in a statistically significant unfavourable patient outcome concerning RFP and RS in patients aged 
<65 years. No statistically significant differences in outcome were seen in patients aged >=65 years. Log-rank P-values 
are shown in each graph.
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Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Grade
I 74 1.00 0.03 1.00 0.40 42 1.00 <0.001 1.00 0.019
II 225 1.32 0.86-2.02 1.24 0.66-2.34 117 1.84 0.89-3.80 1.93 0.63-5.97
III 164 1.72 1.12-2.66 1.50 0.79-2.86 80 3.72 1.81-7.64 4.08 1.32-12.59
Histological type
Ductal 429 1.00 0.27 1.00 0.35 209 1.00 0.49 1.00 0.19
Other 36 1.31 0.82-2.10 1.37 0.71-2.63 30 1.23 0.69-2.22 2.17 0.68-6.90
Tumor stage
pT1 203 1.00 <0.001 1.00 0.13 86 1.00 0.001 1.00 0.77
pT2 210 1.53 1.14-2.05 1.38 0.89-2.12 118 2.34 1.43-3.83 0.75 0.34-1.65
pT3/4 44 2.65 1.74-4.04 1.94 1.00-3.78 33 2.68 1.35-5.32 0.78 0.25-2.47
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 <0.001 1.00 0.004
Positive 213 2.85 2.16-3.76 3.46 2.18-5.50 100 3.18 2.06-4.89 2.76 1.39-5.49
ER status
Negative 216 1.00 0.61 1.00 0.44 72 1.00 0.43 1.00 0.005
Positive 236 0.93 0.71-1.22 0.85 0.56-1.29 157 0.83 0.53-1.31 3.08 1.41-6.74
PgR status
Negative 217 1.00 0.61 1.00 0.99 99 1.00 0.18 1.00 0.02
Positive 222 0.93 0.71-1.22 1.00 0.67-1.50 129 0.75 0.49-1.14 0.43 0.22-0.85
HER2 status
Negative 333 1.00 0.005 1.00 0.52 187 1.00 0.25 1.00 0.59
Positive 46 1.80 1.19-2.72 1.20 0.69-2.07 13 1.63 0.71-3.75 1.44 0.37-5.57
Local Therapy
MAST-RT 138 1.00 <0.001 1.00 0.56 147 1.00 <0.001 1.00 0.20
MAST+RT 91 1.97 1.38-2.81 1.08 0.62-1.89 41 2.48 1.55-3.97 1.66 0.74-3.77
BCS 24 0.78 0.56-1.07 0.84 0.54-1.29 57 0.49 0.27-0.90 0.56 0.22-1.41
Systemic Therapy
CT alone 120 1.00 0.037 1.00 0.003 7 1.00 0.17 1.00 0.13
ET alone 47 1.42 0.90-2.23 1.60 0.88-2.89 66 1.44 0.35-6.05 0.45 0.09-2.28
CT&ET 25 0.74 0.38-1.44 0.37 0.14-0.98 2 3.09 0.43-21.99 4.77 0.34-67.55
None 277 0.79 0.58-1.08 1.76 1.12-2.75 170 0.98 0.24-4.00 0.70 0.14-3.59
Immune susceptibility
High 55 1.00 <0.001 1.00 <0.001 27 1.00 0.16 1.00 0.15
Intermediate 222 1.93 1.14-3.26 2.77 1.46-5.24 120 2.24 0.96-5.23 2.62 0.98-7.01
Low 64 3.51 1.98-6.19 4.61 2.32-9.18 24 2.35 0.85-6.48 2.60 0.81-8.35
Table 2 Cox univariate and multivariable analyses for relapse free period stratified by patients aged <65 versus patients 
aged >=65 years. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS 
breast conservative surgery; ET endocrine therapy; CT chemotherapy.
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Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Grade
I 74 1.00 0.03 1.00 0.40 42 1.00 <0.001 1.00 0.019
II 225 1.32 0.86-2.02 1.24 0.66-2.34 117 1.84 0.89-3.80 1.93 0.63-5.97
III 164 1.72 1.12-2.66 1.50 0.79-2.86 80 3.72 1.81-7.64 4.08 1.32-12.59
Histological type
Ductal 429 1.00 0.27 1.00 0.35 209 1.00 0.49 1.00 0.19
Other 36 1.31 0.82-2.10 1.37 0.71-2.63 30 1.23 0.69-2.22 2.17 0.68-6.90
Tumor stage
pT1 203 1.00 <0.001 1.00 0.13 86 1.00 0.001 1.00 0.77
pT2 210 1.53 1.14-2.05 1.38 0.89-2.12 118 2.34 1.43-3.83 0.75 0.34-1.65
pT3/4 44 2.65 1.74-4.04 1.94 1.00-3.78 33 2.68 1.35-5.32 0.78 0.25-2.47
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 <0.001 1.00 0.004
Positive 213 2.85 2.16-3.76 3.46 2.18-5.50 100 3.18 2.06-4.89 2.76 1.39-5.49
ER status
Negative 216 1.00 0.61 1.00 0.44 72 1.00 0.43 1.00 0.005
Positive 236 0.93 0.71-1.22 0.85 0.56-1.29 157 0.83 0.53-1.31 3.08 1.41-6.74
PgR status
Negative 217 1.00 0.61 1.00 0.99 99 1.00 0.18 1.00 0.02
Positive 222 0.93 0.71-1.22 1.00 0.67-1.50 129 0.75 0.49-1.14 0.43 0.22-0.85
HER2 status
Negative 333 1.00 0.005 1.00 0.52 187 1.00 0.25 1.00 0.59
Positive 46 1.80 1.19-2.72 1.20 0.69-2.07 13 1.63 0.71-3.75 1.44 0.37-5.57
Local Therapy
MAST-RT 138 1.00 <0.001 1.00 0.56 147 1.00 <0.001 1.00 0.20
MAST+RT 91 1.97 1.38-2.81 1.08 0.62-1.89 41 2.48 1.55-3.97 1.66 0.74-3.77
BCS 24 0.78 0.56-1.07 0.84 0.54-1.29 57 0.49 0.27-0.90 0.56 0.22-1.41
Systemic Therapy
CT alone 120 1.00 0.037 1.00 0.003 7 1.00 0.17 1.00 0.13
ET alone 47 1.42 0.90-2.23 1.60 0.88-2.89 66 1.44 0.35-6.05 0.45 0.09-2.28
CT&ET 25 0.74 0.38-1.44 0.37 0.14-0.98 2 3.09 0.43-21.99 4.77 0.34-67.55
None 277 0.79 0.58-1.08 1.76 1.12-2.75 170 0.98 0.24-4.00 0.70 0.14-3.59
Immune susceptibility
High 55 1.00 <0.001 1.00 <0.001 27 1.00 0.16 1.00 0.15
Intermediate 222 1.93 1.14-3.26 2.77 1.46-5.24 120 2.24 0.96-5.23 2.62 0.98-7.01
Low 64 3.51 1.98-6.19 4.61 2.32-9.18 24 2.35 0.85-6.48 2.60 0.81-8.35
Table 2 Cox univariate and multivariable analyses for relapse free period stratified by patients aged <65 versus patients 
aged >=65 years. 
Abbreviations N number of  patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS 
breast conservative surgery; ET endocrine therapy; CT chemotherapy.
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Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Grade
I 74 1.00 0.007 1.00 0.33 42 1.00 0.07 1.00 0.57
II 225 1.76 0.96-3.2 1.10 0.53-2.30 117 3.82 0.46-31.80 3.09 0.16-60.7
III 164 2.46 1.34-4.50 1.53 0.72-3.26 80 6.67 0.83-53.37 4.11 0.22-76.8
Histological type
Ductal 429 1.00 0.09 1.00 0.26 209 1.00 0.42 1.00 0.86
Other 36 1.55 0.93-2.60 1.51 0.73-3.11 30 1.39 0.62-3.09 1.18 0.18-7.87
Tumor stage
pT1 203 1.00 <0.001 1.00 0.08 86 1.00 0.001 1.00 0.51
pT2 210 2.07 1.46-2.94 1.11 0.66-1.86 118 3.27 1.20-8.92 1.50 0.29-7.74
pT3/4 44 3.46 2.16-5.54 2.34 1.06-5.16 33 8.73 3.08-24.77 2.69 0.46-15.8
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 0.008 1.00 0.29
Positive 213 3.51 2.51-4.89 3.12 1.79-5.44 100 3.02 1.34-6.82 1.65 0.66-4.12
ER status
Negative 216 1.00 0.25 1.00 0.80 72 1.00 0.027 1.00 0.57
Positive 236 0.89 0.60-1.14 0.94 0.58-1.53 157 0.45 0.22-0.91 0.64 0.14-2.99
PgR status
Negative 217 1.00 0.07 1.00 0.12 99 1.00 0.13 1.00 0.71
Positive 222 0.74 0.54-1.03 0.69 0.44-1.09 129 0.53 0.23-1.21 1.40 0.24-8.08
HER2 status
Negative 333 1.00 <0.001 1.00 0.14 187 1.00 0.02 1.00 0.07
Positive 46 2.56 1.67-3.90 1.55 0.86-2.79 13 3.10 1.24-7.76 3.19 0.91-11.2
Local Therapy
MAST-RT 138 1.00 0.01 1.00 0.57 147 1.00 0.003 1.00 0.95
MAST+RT 91 1.84 1.25-2.71 1.12 0.59-2.11 41 3.45 1.61-7.38 0.90 0.25-3.28
BCS 24 2.20 0.44-7.23 0.81 0.47-1.38 57 2.53 1.01-1.95 0.80 0.18-3.59
Systemic Therapy
CT alone 120 1.00 0.05 1.00 0.005 7 1.00 0.70 1.00 0.75
ET alone 47 1.54 0.93-2.54 1.82 0.91-3.62 66 0.74 0.22-2.48 0.81 0.23-3.01
CT&ET 25 0.66 0.28-1.57 0.20 0.06-0.72 2 0.74 0.05-10.01 0.79 0.10-11.2
None 277 0.84 0.59-1.20 1.46 0.87-2.43 170 0.54 0.17-1.68 0.66 0.21-1.99
Immune susceptibility
High 55 1.00 <0.001 1.00 0.001 27 1.00 0.45 1.00 0.45
Intermediate 222 2.55 1.22-5.31 3.93 1.68-9.18 120 2.85 0.46-17.74 3.57 0.42-30.3
Low 64 4.01 1.24-8.74 5.53 2.28-13.40 24 1.99 0.22-17.92 3.85 0.46-32.3
0.16-60.7
Table 3 Cox univariate and multivariable analyses for relative survival stratified by patients aged <65 versus patients 
aged >=65 years. 
Abbreviations N number of  patients; RER hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS 
breast conservative surgery; ET endocrine therapy; CT chemotherapy.
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Characteristic  Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N RER 95% CI P RER 95% CI P N RER 95% CI P RER 95% CI P
Grade
I 74 1.00 0.007 1.00 0.33 42 1.00 0.07 1.00 0.57
II 225 1.76 0.96-3.2 1.10 0.53-2.30 117 3.82 0.46-31.80 3.09 0.16-60.7
III 164 2.46 1.34-4.50 1.53 0.72-3.26 80 6.67 0.83-53.37 4.11 0.22-76.8
Histological type
Ductal 429 1.00 0.09 1.00 0.26 209 1.00 0.42 1.00 0.86
Other 36 1.55 0.93-2.60 1.51 0.73-3.11 30 1.39 0.62-3.09 1.18 0.18-7.87
Tumor stage
pT1 203 1.00 <0.001 1.00 0.08 86 1.00 0.001 1.00 0.51
pT2 210 2.07 1.46-2.94 1.11 0.66-1.86 118 3.27 1.20-8.92 1.50 0.29-7.74
pT3/4 44 3.46 2.16-5.54 2.34 1.06-5.16 33 8.73 3.08-24.77 2.69 0.46-15.8
Nodal stage
Negative 249 1.00 <0.001 1.00 <0.001 132 1.00 0.008 1.00 0.29
Positive 213 3.51 2.51-4.89 3.12 1.79-5.44 100 3.02 1.34-6.82 1.65 0.66-4.12
ER status
Negative 216 1.00 0.25 1.00 0.80 72 1.00 0.027 1.00 0.57
Positive 236 0.89 0.60-1.14 0.94 0.58-1.53 157 0.45 0.22-0.91 0.64 0.14-2.99
PgR status
Negative 217 1.00 0.07 1.00 0.12 99 1.00 0.13 1.00 0.71
Positive 222 0.74 0.54-1.03 0.69 0.44-1.09 129 0.53 0.23-1.21 1.40 0.24-8.08
HER2 status
Negative 333 1.00 <0.001 1.00 0.14 187 1.00 0.02 1.00 0.07
Positive 46 2.56 1.67-3.90 1.55 0.86-2.79 13 3.10 1.24-7.76 3.19 0.91-11.2
Local Therapy
MAST-RT 138 1.00 0.01 1.00 0.57 147 1.00 0.003 1.00 0.95
MAST+RT 91 1.84 1.25-2.71 1.12 0.59-2.11 41 3.45 1.61-7.38 0.90 0.25-3.28
BCS 24 2.20 0.44-7.23 0.81 0.47-1.38 57 2.53 1.01-1.95 0.80 0.18-3.59
Systemic Therapy
CT alone 120 1.00 0.05 1.00 0.005 7 1.00 0.70 1.00 0.75
ET alone 47 1.54 0.93-2.54 1.82 0.91-3.62 66 0.74 0.22-2.48 0.81 0.23-3.01
CT&ET 25 0.66 0.28-1.57 0.20 0.06-0.72 2 0.74 0.05-10.01 0.79 0.10-11.2
None 277 0.84 0.59-1.20 1.46 0.87-2.43 170 0.54 0.17-1.68 0.66 0.21-1.99
Immune susceptibility
High 55 1.00 <0.001 1.00 0.001 27 1.00 0.45 1.00 0.45
Intermediate 222 2.55 1.22-5.31 3.93 1.68-9.18 120 2.85 0.46-17.74 3.57 0.42-30.3
Low 64 4.01 1.24-8.74 5.53 2.28-13.40 24 1.99 0.22-17.92 3.85 0.46-32.3
0.16-60.7
Table 3 Cox univariate and multivariable analyses for relative survival stratified by patients aged <65 versus patients 
aged >=65 years. 
Abbreviations N number of  patients; RER hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PR 
progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS 
breast conservative surgery; ET endocrine therapy; CT chemotherapy.
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The immune system plays an important role in the battle of the host against cancer 
development and progression (4). With aging, there are well-known alterations 
occurring in the immune response affecting both innate and adaptive immunity. It 
has been suggested that this process of immunosenescence might contribute to cancer 
development and progression, however this relation is nowadays still poorly understood 
(36). Previous studies have found differences in T cell and NK cell compartments 
between young and old people. T cells, especially CD8+ T cells, more often show poor 
proliferation, resistance to apoptosis and functional abnormalities, leading to a shift 
from so-called “truly naïve” T cells to “exhausted senescent” T cells. This reduced 
availability of naïve cells and T cell disfunctionalities are thought to explain the reduced 
ability of the elderly to respond to new antigens, including tumor associated antigens 
(37).  NK cells also have shown to have decreased cytotoxicity and decreased IL-2 
production in elderly patients (36). We found no statistically significant differences 
in number of infiltrating CTL or NK cells between breast cancer patients aged >=65 
years versus aged <65 years. These results however do not contradict the theory of 
immunosenescence.  As pointed out by previous studies, immunosenescence seems to 
be identified by a disfunctioning in immune recognition and cytotoxicity of CTL or 
NK cells, rather than by a non-capability of migration and infiltration in inflamed or 
carcinogeneous environments (36, 37). Like most retrospective immunohistochemical 
cohort studies, we were limited by the fact that we could not measure this direct 
functioning of tumor immune recognition and cytotoxicity.  However, since data were 
present for both immune factors and tumor response, we were able to study interaction 
between the tumor and immune system, by which we could indirectly conclude on the 
function of the immune system.
During advancing oncogenesis, tumor immune recognition and attack by the immune 
system, causes immunoselection of target cancer cells, whom on their turn evolve 
variants able to resist immune attack. This results in the appearance of new tumor 
cells variants in order to maintain a state of equilibrium between the immune system 
and the tumor. The immune system must now exert new powerful selective pressures 
on the tumor cells, which will evolve again new variants able to resist this immune 
response, which finally leads to tumor immune escape (4, 5). It therefore is likely that 
a compromised immune system, as seen with aging, may lead to a left skewed shift 
in this tumor-immune equilibrium, where less tumor immune attack correlates with 
lower stages of tumor immune escape variant phenotypes (33, 36). Our results showed a 
statistically significant difference in HLA-EG upregulation and, though not statistically 
significant, a difference in classical HLA class I expression of tumors between elderly 
and younger breast cancer patients; less HLA class I downregulation and less HLA-EG 
upregulation were found in patients aged >=65 years. These results suggest that tumors 
in elderly patients have less need to downregulate expression of classical HLA class 
I and upregulate expression of HLA-EG, because less immune selective pressure 
is given by respectively CTL and  NK cells. Our results strongly suggest a decreased 
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need for immune escape strategies in higher aged patients compared to their younger 
counterparts and are therefore in line with the left skewed tumor-immune equilibrium 
theory. Moreover, this theory is supported by the differences seen in distribution of 
tumor immune subtypes between patients aged <65 years compared to aged >=65 
years; though not significant, tumors with low immune susceptibility are seen less in 
patients aged >=65 years. 
Another method by which we indirectly measured the efficacy of tumor immune 
surveillance between elderly breast cancer patients and their younger counterparts 
were the associations of tumor immune subtypes with outcome. These subtypes were 
defined based on tumor susceptibility for cellular immune responses using expression 
of key factors in these responses: high CTL infiltration, presence of NK cells, and Tregs 
and tumor expression of classical HLA class I and HLA-E and -G. Outcome analyses 
of the immune subtypes in patients aged <65 years revealed strong associations with 
patient outcome where tumors defined as being highly susceptible to immune system 
attack showed a favourable outcome for breast cancer patients compared to patients 
with tumors defined as having a low immune susceptible profile. Though a trend 
towards similar outcomes was found in patients aged >=65 years, no such statistically 
significant association could be found. The fact that elderly breast cancer patients have 
comparable outcomes independently of the immune susceptibility of tumors is again 
highly suggestive for a less effective immune system in elderly patients and supports the 
hypothesis of immunosenescence and its contribution to cancer progression. 
The phenomenon of immunosensence in humans is still hypothetical, but has 
previously been described in animal models where less immune responses were found 
after immunotherapy in old animals compared to young animals (38). The effects of 
immunosenesence on cancer development and progression have been suggested before, 
but to the best of our knowledge, we are the first to have found such age specific 
interactions between the immune system and cancer progression in a clinical dataset. 
These results might add to an explanation on the previously observed increase in breast 
cancer specific mortality with age by our group (3). While prior studies show tumors 
in elderly breast cancer patients to be of equal or of less malignant biological character 
than tumors found in their younger counterparts (39, 40), elderly breast cancer patients 
were in our study found to decease more often due to breast cancer regardless of a 
higher risk of mortality from other causes and independent of known tumor and patient 
characteristics. These contradictive findings might be explained by processes like 
immunosenescence and changes in tumor microenvironment, where it might not so 
much be the increased malignancy of tumor as the weakening of host defense against 
cancer determining tumor progression and therefore patient outcome. Future research is 
needed to confirm our results and to further unravel the complex interactions between 
immunosenescence, tumor progression and response to therapy. A better understanding 
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of these processes and future possibilities of immune manipulations and vaccinations 
might lead to more tailored treatment of elderly breast cancer patients. 
In line with emerging evidence on immunosenescence in elderly and its hypothesized 
effects on tumor development and progression, we found less tumor immune escape 
variants and a fading prognostic effect of tumor immune subtypes in elderly breast 
cancer patients. To our knowledge we are the first to study the age-specific impact of 
the immune response and subsequent tumor immune evasion on tumor progression 
and patient outcome in a clinical set of breast cancer patients. Evidence based 
tailored treatment is highly necessitated in elderly breast cancer patients. Age-specific 
malfunctioning of the immune system in tumor control and it’s implications on patient 
prognosis and response to treatments might aid in therapeutic decisions making for 
this specific breast cancer population. In addition, these data might contribute to the 
development of immune manipulations and cancer vaccinations. 
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SUMMARY
The research in this thesis has used a well described retrospective breast cancer cohort 
including all women with non-metastasized breast cancer who were primarily operated 
in the Leiden University Medical Center between 1985 and 1996. This cohort has been 
used for all studies, which made comparisons and combinations of various markers 
possible. Elderly breast cancer patients were considered patients aged 65 years or more, 
according to the world health organization definition (www.who.int).
The main results found in this thesis were that (1) we found strong independent 
prognostic effects for biomarkers involved in immunosurveillance and tumor immune 
escape, especially when accounted for various interactions between these markers and 
(2) key prognostic biomarkers differed in their distribution and prognostic effect in 
elderly breast cancer patients compared to their younger counterparts. 
Part I: Prognostic biomarkers in the interactions between 
the host’s immune system and breast cancer
In the first part of this thesis we investigated the expression and prognostic effect of 
various crucial immunological markers and their interactions in breast cancer patients. 
In Chapter 2 frequent down regulation or loss of expression of classical HLA class 
I and high tumor infiltration of Treg were seen in tumors of breast cancer patients. 
Prior studies indicate that breast cancer is immunogenic and induces tumor associated 
antigen (TAA)-specific CTL1. Our finding of HLA class I down regulation in more 
than half of all tumors, which was concordant with results found in previous studies 
2-4, therefore implies a common phenomenon in breast cancer of selective outgrow of 
these cells which were able to escape from immune destruction5. The frequent presence 
of immunosuppressive Treg in the tumor microenvironment supports the hypothesis 
that tumors may attract these immune-suppressing cells in order to evade attack from 
effector T cells. These data are strongly suggestive for immune escape mechanisms in 
breast cancer tumors 5. Further supporting this was the specific prognostic effects found 
for HLA class I and Treg among chemotherapy-treated patients. Cyclophosphamide, 
which was included in all chemotherapy regimens of our studied population, is 
known to positively influence host immune responses against cancer through selective 
elimination of Treg 6-8. Ceasing of Treg, reduces immunosuppressive effects, resulting 
in an enhanced expansion and function of responding of CTL 6-8. This restored CTL 
functioning leads to an increased anti-tumor response and therefore might lead to a 
better patient outcome. We explain the specific prognostic effect found for HLA class 
I and Treg among chemotherapy-treated patients by this restored CTL functioning, 
which logically specifically takes place in patients with Treg presence in the tumor 
microenvironment before chemotherapy administration and in patients whose tumors 
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had not lost expression of HLA class I. This hypothesis was further supported by a 
previous study that found a decline in absolute numbers of tumor infiltrating Treg 
after preoperative chemotherapy, which was associated with a pathological complete 
response in combination with presence of CTL infiltration 9. Additional to the fact 
that our results strongly support the immunoediting hypothesis and add to the current 
knowledge of the interactions between breast cancer and the immune system, HLA 
class I and Treg are one of the few predictive factors for chemotherapy response in 
breast cancer and these markers could therefore be applied in response prediction to 
chemotherapy in breast cancer patients 10. Contrary to some previous reports however, 
no unfavorable prognostic effect was found for classical HLA class I down regulation 
or loss 3, 4, 11. An explanation to this might be the increased susceptibility to NK cell 
recognition and attack of cells with loss of HLA class I expression. The following stages 
of in tumor immune escape after classical HLA class I down regulation or loss are 
therefore focused on the escape of NK cell recognition. 
Non-classical HLA class I molecules, HLA-E and HLA-G, play an important role in 
controlling auto-immune NK cell reactions. Under normal circumstances, expression 
of the HLA-E molecule is found in most tissues that express classical HLA class I or 
HLA-G molecules and is thought to provide an important “self-signal” to the immune 
system by accommodating and presenting peptide fragments from leader sequences 
of these molecules 12, 13. HLA-G expression, on the other hand, has very restricted 
tissue expression and has been mostly found in extravillous trophoblastic cells, where it 
mediates semi-allograft immunotolerance during pregnancy 14. Expression of HLA-E 
and HLA-G on the cell surface can respectively bind with the inhibitory receptors 
CD94/NKG2A and KIR2DL4/p49 of NK cells, and thereby cause inhibition of their 
proliferation and cytotoxic effector functions 15, 16.Tumors may acquire or up regulate 
expression of HLA-E and HLA-G as protective property against immune recognition 
and elimination by NK cells 12. HLA-E is regularly expressed in various healthy tissues 
and correlates with expression of classical HLA class I molecules. This physiological 
correlation with classical HLA class I molecules has been found to be disturbed in 
tumors, suggesting that malignant cells which escape T cell immune recognition by 
down regulation of classical HLA class I expression, may further escape immune 
recognition by up regulation of HLA-E 17. In addition, expression of HLA-G protects 
against “missing self” recognition of NK. Expression of this molecule, which is rarely 
found in healthy tissues, is frequently observed in pathological conditions such as in 
tumors 18, 19. Both HLA-E and HLA-G expression showed an association with a worse 
clinical outcome in various tumor types 20-27. In Chapter 3 we showed that HLA-E 
and HLA-G expression were of independent statistically significant similar influence on 
outcome of breast cancer patients with high discriminative power, however, specifically 
in tumors devoid of classical HLA class I expression. This suggests that specifically 
in tumors devoid of classical HLA class I expression, up regulation of HLA-E and 
HLA-G expression counteracts the resulting NK cell susceptibility, leading to immune 
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escape of tumor cells. Supportive for a specific NK cell inhibition of the non-classical 
HLA class I molecules, for both HLA-E and HLA-G an inverse correlation was found 
with NK cell infiltrate in a colorectal cancer and gastric cancer study respectively 28, 29, 
while other studies demonstrated that overexpression of HLA-E and HLA-G directly 
inhibited NK-mediated cell lysis 29. 
Aside from non-classical HLA class I, the activating receptor NK cell lectin-like receptor 
gene 2D (NKG2D) ligands have great influence on NK cell recognition of pathological 
cells. NKG2D ligands bind to the NKG2D receptors on NK cells, NKT cells, γδ+ T 
cells and CD8+ T cells and provide a stimulatory activating response30. Ligands which 
bind NKG2D receptors comprise major histocompatibility complex class I chain-related 
proteins A and B (MIC-AB) and unique long 16 (UL16) binding proteins 1-6 (ULBP1-
6)31, 32. Expression of these ligands may be induced upon infection and other inducers of 
cellular stress, such as malignant transformation, and may initiate an immune response 
by binding to the NKG2D receptors on NK and T cells 33. In Chapter 4 we show that 
NKG2D ligands are frequently high expressed in breast tumors and that a statistically 
significant association exists between expression levels of these ligands and that this 
expression influences patient’s prognosis. We were able to statistically prove that high 
expression levels of MIC-AB, ULBP-2, and mostly a combination of high expression of 
both markers, resulted in a beneficial relapse free period with high discriminative power, 
comparable to results found in previous studies on colorectal cancer 34, 35. Altogether, 
these results indicate a cooperation of NKG2D ligands with each other and further add 
to the hypothesis that low expression of these ligands is a result of selective pressure by 
the immune system that results in cancer immune evasion or immunoediting. Additional 
analyses were performed in our study with two different variables that represented 
combined number of highly co-expressed ligands and amount of co-expression 
of all ligands. The results of these analyses revealed no patterns of any cooperative 
functioning between all ligands, as both variables showed no consistent and significant 
relationship with clinical outcome of disease. Supported by the results found in previous 
studies 30, 34-37  this shows that each NKG2D ligand analyzed separately does not show 
equal effects on clinical outcome, that different ligands show varying prognostic effects 
in different tumors and that a simple additive effect of all NKG2D ligands cannot be 
assumed. This indicates the complexity of NKG2D ligands functioning and emphasizes 
again the importance of interactions between various immune markers.
The above mentioned results show that loss of classical HLA class I, up regulation 
of classical HLA-E and HLA-G expression, induction of Treg in the tumor 
microenvironment and low expression of certain NKG2D ligands are frequent events 
in breast cancer, supporting the hypothesis that breast tumors are capable of evading 
immune recognition. In addition, they highlight the importance of accounting for these 
interactions within and between the immune system and breast tumors and therefore 
studying combinations of markers of immune surveillance together with markers of 
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tumor immune escape. This lead to the construction of tumor immune subtypes based 
on tumor susceptibility for cellular immune responses (Chapter 5) (Figure 1). 
Figure 1 Tumor immune subtypes showing a schematic overview of  different stages of  immune surveillance and 
tumor immune escape classified into 7 tumor immune subtypes, graded from (1) to (7) in ascending order from highly 
immunogenic and therefore high immune susceptibility (green) to high immune escape and low immune susceptibility 
(red), concerning combinations of  CTL infiltration, NK cell infiltration, Treg infiltration, classical HLA class I tumor 
expression and HLA-EG tumor expression. Tumor immune subtypes were clustered by combining from the original 
tumor immune subtypes groups as shown in by encircled groups (high immune susceptible) clustered (1) and (2)(green 
circle), (intermediate immune susceptible) clustered (3) and (4)(orange circle), (low immune susceptible) clustered (5), 
(6) and (7) (red circle). 
Outcome analyses of the immune subtypes revealed strong associations with patient 
outcome where tumors defined as being highly susceptible to immune system attack 
showed a favorable outcome for breast cancer patients compared to patients with tumors 
defined having a low immune susceptible profile. These prognostic effects were shown 
in this study to be independent of known clinicopathological prognostic parameters and 
were additionally validated in an independent breast cancer patient cohort confirming 
the high discriminative power on patient outcome stratification. The study showed that 
a successful anti-tumor immune response depends not only on the level of expression 
of a single marker such as classical HLA class I, but on the variety of factors involved 
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in the multifaceted immune response. Due to this complexity of the balance between 
immune surveillance and tumor immune escape, it is not a single marker that is able to 
reflect outcome of the interaction, but a set of key markers. While most studies focus 
on the effect of single parameters and thereby many contradictory results have been 
published on immune biomarkers, we showed that it is combinations of these markers 
which are able to reflect the multifaceted interaction between immune cells and tumor 
cells, thereby filtering out understating or confounding impacts of immunosurveillance 
and therefore predict outcome with high stratification capacity. The results found for 
the tumor immune subtypes are not only concordant with prior evidence on tumor 
immune biology in breast cancer38, 39, but additionally join together the conclusions of 
prior studies by linking single tumor-immune markers to functional tumor-immune 
interaction.
Part II: Prognostic biomarkers in elderly breast cancer 
patients 
In the second part of this thesis we studied differences in the distribution and effect on 
outcome of prognostic biomarkers in elderly breast cancer patients. 
First, in Chapter 6 we demonstrated that the presence of ALDH1, a representative 
marker for cancer stem cells, expression is significantly higher in young breast cancer 
patients than in elderly patients and demonstrated that ALDH1 expression is an 
independent risk factor for decreased survival in young breast cancer patients, but not 
in elderly patients. Cancer stem cells, defined as a small subset of tumor cells with stem 
cell-like features, including epithelial-to-mesenchymal transition, have the capacity of 
self-renewal and differentiation; giving rise to a heterogeneous tumor cell population40. 
A biological explanation of the qualitative age-interaction of the prognostic effect of 
ALDH1 expression might be that of a changing micro-environment in elderly patients, 
which may result in hampered signal transduction between tumor stem cells and the 
micro-environment. Moreover, changes in metabolic processes might limit the role of 
tumor stem cells in elderly patients. Increasing evidence from the field of epigenetics 
demonstrates that hypermethylation-induced repression of genes required for stem cell 
differentiation is linearly associated with age.41 This suggests that, with increasing age, 
the role of tumor stem cells becomes more limited. 
In Chapter 7, using gene expression validated IHC surrogates of molecular subtypes, 
we demonstrated that elderly breast cancer patient tumors show a different distribution 
of molecular subtypes where were more Luminal A and Luminal B subtypes are found 
compared to their younger counterparts.  These data are concordant to previous studies 
that showed more ER and/or PR positivity and less overexpression of EGFR, HER2 and 
ki67 in tumors of elderly breast cancer patients 42-44. Results also showed no statistically 
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significant association for molecular subtypes and patient outcome in elderly breast 
cancer patients in contrary to young breast cancer patients. We sought an explanation to 
this finding in competing risks of death in elderly breast cancer patients; elderly breast 
cancer patients compared to their younger counterparts have shown in absolute sense 
to develop more relapses 45, however proportionally due to higher risk of dying earlier 
and from other causes they show less breast cancer relapses and breast cancer specific 
deaths 46-48. Only about 60% of elderly breast cancer patients die as a consequence of 
breast cancer, compared to almost 100% of young patients. It is important to realize that 
this has major implications on the impact and value of prognostic biomarkers in elderly 
breast cancer patients. Prognostic biomarkers, identifying patients with low versus high 
risk of breast cancer progression and breast cancer related death will show limited to no 
prognostic effect in the 40% of elderly patients which have a short-term prognosis due 
to breast cancer un-related causes, especially in those who are considered frail. These 
elderly patients are also unlikely to benefit from systemic treatment, since their cause of 
death will be other than due to breast cancer. Therefore, the clinical value of prognostic 
biomarkers, which aid at distinguishing between patients who might and might not 
benefit from systemic treatment, is also limited in this patient population. 
As described in the first part of this thesis, the immune system plays an important role 
in the battle of the host against cancer development and progression. With aging, there 
are well-known alterations occurring in the immune response affecting both innate 
and adaptive immunity. It has been suggested that this process of immunosenescence 
might contribute to cancer development and progression, however this relation is 
nowadays still poorly understood 49. In Chapter 8 we evaluated the distribution and 
impact on patient outcome of anti-tumor immune response and tumor immune evasion 
in elderly breast cancer patients compared to their younger counterparts. This showed 
no differences in number of infiltrating CTL, NK cells or Treg, but a trend towards 
less classical HLA class I down regulation and statistically significant less HLA-E or 
HLA-G up regulation of tumors. These differences were also reflected, though not 
statistically significant, in less “low immune susceptible” tumors in elderly breast cancer 
patients. These results suggest that tumors in elderly patients have less need to down 
regulate expression of classical HLA class I and up regulate expression of HLA-EG, 
because of less immune selective pressure is given by respectively CTL and  NK cells. 
Our results strongly suggest a decreased need for immune escape strategies in higher 
aged patients compared to their younger counterparts suggesting a left skewed tumor-
immune equilibrium.  During advancing oncogenesis, tumor immune recognition and 
attack by the immune system, causes immunoselection of target cancer cells, whom on 
their turn evolve variants able to resist immune attack. This results in the appearance 
of new tumor cells variants in order to maintain a state of equilibrium between the 
immune system and the tumor. The immune system must now exert new powerful 
selective pressures on the tumor cells, which will evolve again new variants able to resist 
this immune response, finally leading to tumor immune escape 38, 50. It therefore is likely 
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that a comprised immune system, as seen with aging, may lead to a left skewed shift 
in this tumor-immune equilibrium, where less tumor immune attack correlates with 
lower stages of tumor immune escape variant phenotypes 49, 49. Comparable numbers of 
infiltrating CTL of NK cells between tumors of elderly and young breast cancer patients 
does not contradict the theory of immunosenescence, since  immunosenescence seems 
to be identified by a disfunctioning in immune recognition and cytotoxicity of CTL or 
NK cells, rather than by a non-capability of migration and infiltration in inflamed or 
carcinogeneous environments 49. Comparable to ALDH1 and molecular subtypes, again 
no statistically significant  association was found between tumor immune subtypes and 
outcome in elderly breast cancer patients, contrary to their younger counterparts. The 
fact that elderly breast cancer patients have comparable outcomes independently of the 
immune susceptibility of tumors is again highly suggestive for a less effective immune 
system in elderly patients and supports the hypothesis of immunosenescence and its 
contribution to cancer progression. 
Conclusions and future perspectives
Not only did our results provide further evidence supporting an immunoediting 
hypothesis; we also found various biomarkers with the ability to stratify breast cancer 
patients according to their predicted prognostic outcome with high discriminative 
power, especially when accounted for the various interactions between these markers. 
Differences in distributions and prognostic effect of these tumor immune subtypes in 
elderly breast cancer patients compared to their younger counterparts, provided further 
prove for immunoediting and immunosenescence theories. Differences in distributions 
and prognostic effects of stem cells marker ALDH-1 and molecular subtypes in these 
elderly breast cancer patients further suggest that it is underlying biological differences 
in the micro-environmental changes which might influence differences in tumor 
behavior. We also consider competing risk of death in elderly to be an important factor 
in fading prognostic effects with increasing age. We finally conclude that biomarkers 
need validation in elderly breast cancer patients, since results from young patients 
cannot be simply extrapolated to this patients group. 
Immunoediting and immunosenescence hypothesis: 
The concept that the immune system can recognize and eliminate primary developing 
tumors has existed for more than a 100 years 51. Clearer insight of interactions between 
the immune system and malignant tumors during the first years of the 21st century gave 
rise the “cancer immunoediting” hypothesis, characterized by three phases: elimination, 
equilibrium and escape 38. Tumor cells can be successfully eradicated by the immune 
system during the elimination phase. On the other hand, some tumor cells may be 
capable of escaping from these first line mechanisms of host tumor immune elimination 
and enter the next phase of cancer immunoediting; equilibrium. During this phase it 
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is suggested that there is a constant interaction between the tumor, which consists of 
rapidly mutating and genetically unstable cells, and the immune system. Many tumor 
cells, susceptible for immune recognition and attack, are eradicated by the immune 
system, but new tumor cell variants arise which have increased resistance to immune 
attack. Following these interactions, the tumor constitution is constantly shaped by the 
immune system. Following the equilibrium phase, tumors can transit to the final escape 
phase of cancer immunoediting 38. During this final phase the balance of the battle 
between the immune system and the malignant tumor becomes favorable to the latter. 
Following this balance shift, the tumor growth proceeds and tumors become clinically 
detectable. Further development of significant immune escape mechanisms by the 
tumor are suggested to result in further tumor progression and spread. Tumor immune 
escape mechanisms are various and complex, but briefly characterized by: classical HLA 
class I down regulation, HLA-E and HLA-G up regulation, down regulation of stress 
molecules NKG2D ligands and attraction of immunosuppressive regulatory T cells in 
the tumor microenvironment. Evidence supporting the cancer immunoediting theory 
has been described in various mice studies 38, 52-57. Human data is limited. Though 
our results on the distribution and prognostic effect do not prove the existence of 
the immunoediting theory in human breast cancer, it is strongly supportive for this 
hypothesis, where we show higher immune susceptible tumors to be associated with a 
beneficial patient outcome while on the other hand more tumor immune escape variants 
result in a worse patient prognosis. Importantly, our results highlight the importance 
of considering various factors in investigating the interplay between tumors and the 
immune system, accounting for the significant complexity and interactions in these 
processes. 
With increasing age, the immune system declines in functional innate and adaptive 
immunity leading to a reduced ability to respond to infection and vaccinations 58-61. There 
has been increasing evidence that age associated immunosenescence might contribute to 
cancer development and progression 49. The phenomenon of immunosenescence and its 
possible effects on cancer development and progression in humans is still hypothetical 
and especially our results on less immune escape variants and fading prognostic effect 
with increasing age in elderly breast cancer patients provides evidence for this. 
It appears that unravelling the complex interactions of the immune system in tumor 
development and progression leads to valuable new insights in the tumor biology. These 
new insights have a high potential to lead to prognostic or predictive biomarkers and 
might form the basis of new immunotherapeutical strategies. Future research providing 
new evidence for the immunoediting and immunosenescence hypotheses is needed. 
Tumor immune subtypes as prognostic biomarker in breast cancer: 
Many prognostic biomarkers have been identified for breast cancer. Of these, the 
ASCO guidelines advised the use in clinical practice of urokinases plasminogen 
activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and gene profiles detected 
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with multiparameter gene expression assays62. The clinical value of microarray-based 
prognostic tools, like the MammaPrint, a 70-gene expression profile, and Oncotype 
DX, a 21-gene expression profile is currently being debated63, 64. One major critique 
is that these gene prints were constructed using top-down analyses and were not 
defined based on a biological rationale. Therefore, it is unclear what tumor types are 
represented by the various patient risk-groups65. One can imagine that such methods 
contain a high proportion of “noise” due to the involvement of unknown chance in 
the statistical construction and the optimalisation of the factor during creation and 
that these prognostic factors almost definitely lose discriminative power due to these 
reasons. On the other hand, bottom-up analyses, where a biological factor is correlated 
to patient outcome has a high chance of not showing any prognostic association and 
therefore a high chance of failure. In addition, it generally shows lower discriminative 
power than the prior mentioned technique, since it is not optimized on prognostic 
outcome of patients. However, when a prognostic biomarker is found with this method 
it provides reliability since it is based on well-founded biological facts.  In the first part 
of this thesis we provided various prognostic biomarkers using bottom-up analyses 
based on well-founded biological hypotheses on breast cancer immunoediting. The 
final tumor immune subtypes that were constructed lead to an independent prognostic 
variable with high discriminative power, comparable to ones found in gene expression 
prognostic arrays. In addition, independent validation of this biomarker lead to similar 
results. Moreover, as shown by the predictive effect of HLA class I and Treg on 
chemotherapy response and as suggested before in literature reports, treatment response 
is in part regulated by the immune microenvironment, which gives the tumor immune 
subtypes potential for a predictive effect on existing adjuvant systemic treatment next 
to potential for development of immunotherapies 66. Such predictive effects of tumor 
immune subtypes are not yet investigated and therefore this still remains speculative. A 
drawback of tumor immune subtypes is the fact that it is still an elaborative test, where 
many stainings and quantifications need to be performed in order to get the subtype. In 
addition, it does not show prognostic significance in elderly breast cancer patients. This 
might in part be due to immunosenescence as explained above and, as explained below, 
due to competing causes of death in the elderly population. 
Biological differences in elderly versus young breast cancer: 
Patient, tumor and treatment characteristics have been found to differ considerably 
between elderly and young breast cancer, 67-69. This may be indicative for differences 
in underlying tumor biology and it has indeed often been suggested that elderly breast 
cancer is a biologically different tumor type of a more indolent character compared 
to young breast cancer 68-70. This hypothesis contradicts the fact that increased breast 
cancer specific mortality is seen with increasing age 45; elderly breast cancer patients were 
found to decease more often due to breast cancer regardless of a higher risk of mortality 
from other causes and independent of known tumor and patient characteristics. In our 
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studies we did find differences in distributions of key biomarkers, where less aggressive 
phenotypes with low numbers of ALDH-1, luminal molecular subtypes and less tumor 
immune escape were seen in elderly breast cancer patients compared to their younger 
counterparts. However, an explanation to the contradictory findings can be sought in 
the interactions between tumor and its microenvironment (Figure 2). 
Figure 2 schematically representing the balance between tumor aggressiveness and host microenvironmental defence 
against the tumor. The number of  cubusses represents the weight or strength of  the attack, or the progression and 
invasion of  the tumor (left on the balance scale) and the microenvironmental defence against this attack (right on 
the balance scale). The final equilibrium resulting from this balance results in either: (1) the tumor attack dominates 
(shown in (A) and (C)), resulting in tumor progression or (2) host microenvironmental defence dominates (shown 
in (B) and (D)), resulting in a blocked tumor progression. Situations (C) and (D) show the hypothetical situations in 
elderly patients, where the tumor host microenvironment has weakened compared to the microenivronment in younger 
patients as shown in (A) and (B). 
The outcome of the balance between the tumor and the microenvironment results 
in changes in patients’ outcome, where high tumor aggressiveness should result in 
more tumor progression and therefore a worse outcome of patients (A), whereas a low 
aggressive tumor should results in a blocked tumor progression by a well-functioning 
microenvironment and therefore a beneficial outcome of patients (B). However, usually 
not the case in young breast cancer patients, but a relevant factor which should be taken 
into account in elderly breast cancer patients, is the fact that host’s defenses against 
tumors might have deteriorated due to ageing. Herein the suggestion that elderly 
breast tumors are of a more indolent character and therefore should lead to a favorable 
outcome compared to younger breast tumors are depicted in Figure 2 by situation B, 
in case of a host defense comparable to young patients, or D, where the host defense 
has deteriorated, but the tumor aggressiveness is reduced even more. The combination 
of a less aggressive tumor with an even more lowered host defense results in tumor 
progression and therefore a worse patient outcome (C). Less aggressive tumors combined 
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with the finding of a worsened breast cancer specific outcome with increasing age can 
be explained by the fact that host defenses deteriorate faster than the aggressiveness of 
tumors. Changes in the surroundings of the tumor, i.e. the tumor microenvironment, 
with increasing age seems to be the bridge between the contradictory findings of less 
aggressive tumor types but worse patient outcomes in elderly breast cancer patients. 
In this scenario it is not so much the increased malignancy of tumors as it is the 
weakening of the host defense against cancer, in determining tumor progression and 
therefore patient outcome. As explained, a changing micro-environment might lead to 
a hampered signal transduction between tumor stem cells and the micro-environment 
in elderly breast cancer patients, causing differences in prognostic effects of ALDH1 
compared to young breast cancer patients. Moreover, the differences in distribution and 
prognostic effect for tumor immune subtypes suggest processes like immunosenescence 
to influence tumorigenesis in elderly breast cancer patients. 
Prognostic biomarkers in elderly breast cancer patients: 
None of the key biomarkers we investigated showed a statistically significant prognostic 
effect in elderly breast cancer patients. A combination of underlying differences in tumor 
biology and behavior, loss of statistical power due to differences in distribution of the 
biomarker subcategories and competing causes of death in elderly breast cancer patients 
might explain the fading prognostic significance of biomarker. The fact remains that the 
clinical value of prognostic biomarkers, which aid at distinguishing between patients 
who might and might not benefit from adjuvant systemic treatment, is limited in the 
elderly breast cancer population. Therefore we conclude that validation of biomarkers 
in elderly is required, since possible differences in the tumor microenvironment and 
in addition competing causes of death in elderly might results in a significant differing 
prognostic value and which therefore significantly interferes with patient treatment 
modalities. Importantly, considering competing causes of death in elderly breast cancer 
patients, breast cancer prognostic biomarkers can only have a prognostic value in elderly 
patients whose life expectation will be long enough for the cancer to progress and cause 
patient death. It is only in these fit enough patients that prognostic biomarkers may 
show differences in outcome between elderly breast cancer patients and may aid clinical 
decision making on systemic treatment. In order to improve tailored treatment in elderly 
with the aid of prognostic biomarkers, the first step would therefore be to identify these 
fit elderly patients. 
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Borstkanker is een van de meest gediagnostiseerde type kanker en de hoofddoodsoorzaak 
door kanker in vrouwen in de Westerse Wereld 1. De behandeling bestaat uit locoregionale 
behandeling door middel van chirurgie al dan niet gevolgd door radiotherapie en 
systemische therapie zoals chemotherapie, endocriene therapie en immunotherapie. 
Systemische therapie wordt gegeven ter voorkoming van afstandmetastasen. 
Prognostische en predictieve factoren identificeren patiënten op respectievelijk hun 
voorspelde prognose en reactie op therapie en helpen hiermee bij klinische beslissingen 
omtrent systemische behandeling van borstkankerpatiënten. 
Huidige prognostische factoren zoals leeftijd, menopausale status, tumorgrootte, 
lymfeklierstatus, histologische graad, hormoonreceptorstatus en HER2-overexpressie 
resulteren nog niet in optimale behandeling van borstkankerpatiënten 2. Om over- en 
onder-behandeling te beperken zijn er daarom nieuwe en meer accurate prognostische 
factoren vereist. 
Er is bewijs dat het adaptieve immuunsysteem tumorprogressie kan controleren 3. Echter, 
tumoren kunnen, door hun intrinsieke genetische instabiele karakter, eigenschappen 
ontwikkelen om te ontsnappen aan dergelijke immuunherkenning en eliminatie 4. 
Helaas is er weinig bekend over deze tumor-immuun-interacties in borstkanker. Daarbij 
kunnen  deze interacties invloed hebben op tumorprogressie en zijn daarmee potentiële 
prognostische biomarkers. 
Door de vergrijzing wordt borstkanker steeds meer een ziekte die oudere vrouwen aangrijpt 
5. Deze patiëntenpopulatie verschilt van de jongere borstkankerpatiëntenpopulatie in 
meerdere aspecten, waaronder co-morbiditeit en hiermee de balans van toxiciteit versus 
effectiviteit van behandeling, kortere levensverwachting en patiënt voorkeuren voor 
behandeling 6, 7. Daarbij zijn er aanwijzingen dat tumoren van oudere borstkanker 
patiënten biologisch anders zijn: meer indolent, minder agressief en minder progressief 8. 
Momenteel zijn behandelingsrichtlijnen voor borstkanker over het algemeen gebaseerd 
op onderzoek op een relatieve jongere patiëntenpopulatie en mist translationeel 
onderzoek geheel binnen deze populatie. Behandeling van oudere borstkanker patiënten 
is daarom nu niet evidence-based en translationeel onderzoek in deze patiëntenpopulatie 
is nodig. 
Doel van het proefschrift
Dit proefschrift is in twee delen opgesplitst. Deel I beschrijft biomarkers gebaseerd 
op immuun-anti-tumorbescherming en tumor-immuun-ontsnapping in borstkanker en 
hun prognostische effect. Deel II beschrijft de distributie en prognostische effecten van 
essentiële prognostische biomarkers in oudere borstkanker patiënten. 
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Het onderzoek in dit proefschrift heeft gebruik gemaakt van een groot goed omschreven 
retrospectief borstkankercohort waarin alle vrouwen werden geselecteerd met niet-
gemetastaseerde borstkanker die primair in het Leidsch Universitair Medisch Centrum 
werden geopereerd tussen 1985 en 1996. Dit cohort is voor alle studies gebruikt waardoor 
vergelijkingen en combinaties van markers mogelijk werd. Oudere borstkankerpatiënten 
werden gedefinieerd als patiënten , die de leeftijd van 65 jaar of ouder bereikt hebben, 
volgens de definities van de World Health Organisation (www.who.int). 
Resultaten beschreven in dit proefschrift
Deel I van dit proefschrift beschrijft de interacties die er plaats vinden tussen 
borstkanker en het immuun systeem en de potentiele prognostische markers hierin. Er 
is veel bewijs dat het adaptieve immuun systeem tumorprogressie kan controleren 3. 
Daarentegen is ook beschreven dat tumoren, door hun intrinsieke genetische instabiele 
karakter, eigenschappen kunnen ontwikkelen om te ontsnappen aan dergelijke 
immuunherkenning en eliminatie 4. 
Humaan-leukocyt-antigen (HLA) klasse I kan tumor-geassocieerde-antigenen 
presenteren op de celmembraan van maligne cellen aan cytotoxische-T-lymfocyten 
(CTL). Om aan deze immuunherkenning te ontsnappen kunnen maligne cellen hun 
HLA klasse I expressie verliezen 9. Daarnaast kunnen regulatoire-T-cellen (Treg) in 
de tumoromgeving een immuunsuppressief effect uitvoeren op CTL, waardoor aan 
de immuun-anti-tumorbescherming ontsnapt kan worden 10. Hoofdstuk 2 beschrijft 
dat verlies van HLA klasse I-expressie en aanwezigheid van Treg beide zeer frequent 
zijn in borstkankertumoren, wat suggereert dat immuun ontsnappingsmechanismen 
hierbij vaak voorkomen. Tevens werd een specifieke associatie gevonden voor HLA 
klasse I-expressieverlies en de aanwezigheid van Treg met een slechtere prognose in 
met chemotherapie behandelde patiënten. Dit kan verklaard worden door de gerichte 
eliminatie van Treg door cyclophosphamide-bevattende-chemotherapie danwel 
door een sneller herstel van de CTL-functie na deze behandeling. Hierdoor valt het 
immunosuppressieve effect op CTL, die voor de adjuvante therapie overheerste, weg 
waardoor deze CTL tumorcellen met HLA klasse I-expressie weer kunnen herkennen 
en elimineren. 
Als gevolg van HLA klasse I-expressieverlies kunnen maligne cellen door Natural 
Killer (NK-)cellen worden herkentd, waardoor volgende stappen in tumorimmuun 
ontsnapping gefocust zijn op ontwijking van NK-cel-aanval. 
De niet-klassieke HLA-G moleculen komen specifiek tot expressie op trofoblast cellen 
waar het betrokken is bij immunotolerantie tegen de foetus gedurende de zwangerschap 
11. HLA-E komt tot expressie in bijna alle gezonde cellen, waar het eiwit fragmenten 
van klassiek HLA klasse I of HLA-G tot expressie brengt12. Beide niet-klassieke HLA-
moleculen binden aan inhibitoire receptoren op NK-cellen, waarmee ze een belangrijk 
“zelf-signaal” geven. Maligne cellen kunnen HLA-G en HLA-E expressie verkrijgen 
of upreguleren. In hoofdstuk 3 wordt beschreven dat expressie van deze moleculen in 
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borstkankertumoren resulteert in een slechtere prognose van patiënten, maar dan wel 
specifiek binnen patiënten wiens tumoren al HLA klasse I-expressie hadden verloren. 
Dit onderbouwt de hypothese van hun rol binnen “zelf-signalen” en NK-cel-inhibitie. 
Activerende NK-cel-lectin-like-receptor-gen-2D (NKG2D) liganden hebben naast 
niet-klassieke HLA-moleculen ook invloed op NK-cel-herkenning en -eliminatie van 
pathologische cellen. Expressie van NKG2D-liganden wordt geïnduceerd in cellen 
onder stress, zoals infectie of maligne transformatie, waarop ze binden aan NKG2D-
receptoren op onder andere NK-cellen en een activerende stimulerende respons wordt 
opgewekt, waardoor deze cellen onder stress geëlimineerd kunnen worden door het 
immuun systeem 13. Hoofdstuk 4 beschrijft dat voornamelijk de combinatie van 
expressie van twee NKG2D-liganden, MIC-AB en ULBP-2, resulteerde in een beter 
prognose van borstkankerpatiënten. 
Gezien eerdere resultaten het belang hebben aangetoond van de complexiteit en 
interacties van het immuunsysteem met borstkanker (hoofdstuk 2-4), werd in hoofdstuk 
5 een biomarker gecreëerd op basis van de essentiële markers van immuun-anti-
tumorbescherming en immuun ontsnapping hieraan (Figuur 1). Deze prognostische 
Figuur 1: Deze figuur toont een schematisch overzicht van de verschillende fases van tumor-immuun ontsnapping. De 
tumorimmuun subtypes die dit weergeven zijn opgedeeld in 7 groepen, waarbij oplopend de gradaties van (1) tot (7) een 
hoge immuun vatbaarheid (groen) tot hogere immuun ontsnapping fases tonen (rood). Door middel van combinaties 
van gegevens van CTL infiltratie, NK-cell infiltratie, Treg infiltratie, klassieke HLA klasse I-expressie en HLA-EG-
expressie werden de groepen gedefinieerd. Tumorimmuun subtypes werden geclusterd door groepen te combineren van 
de 7 afzonderlijke klasses; weergegeven door de omcirkelingen in de figuur: cluster (1) en (2) (groene cirkel), cluster (3) 
en (4) (oranje cirkel) en cluster (5), (6) en (7) (rode cirkel). 
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biomarker is zeer statistisch significant, waarbij patiënten met tumoren die werden 
beschouwd als laag immuun-vatbaar een slechtere prognose hadden dan patiënten met 
tumoren die als hoog immuun-vatbaar werden beschouwd. Dit prognostische effect was 
onafhankelijk van bekende prognostische factoren en werd afzonderlijk gevalideerd in 
een onafhankelijk validatie cohort. Hierbij werd het hoog discriminatieve vermogen 
nogmaals bevestigd. Tevens werd hierdoor het belang van de interacties binnen en 
tussen het immuunsysteem en borstkanker weer benadrukt. 
Het tweede deel van het proefschrift beschrijft de verschillen in de verdeling en het 
prognostisch effect van verschillende biomarkers in oudere borstkankerpatiënten. 
Kanker-stamcellen zijn gedefinieerd als een kleine subset van de tumor met specieke 
stamcel-karaketeristieken zoals epitheliale-naar-mesenchymale transitie, de capaciteit 
tot zelfvernieuwing en -differentiatie 14. In hoofdstuk 6 hebben we aangetoond dat de 
expressie van ALDH-1, een respresentatieve marker voor stamcellen, significant hoger 
is in jongere borstkankerpatiënten vergeleken met oudere borstkankerpatiënten. Daarbij 
was ALDH-1-expressie een onafhankelijke risicofactor voor een slechtere prognose in 
jongere borstkankerpatiënten, maar niet in ouderen. Een verklaring voor de specifieke 
leeftijd-interactie van het prognostische effect van ALDH-1 kan de verandering van 
de tumor-micro-omgeving in oudere borstkankerpatiënten zijn, waarbij signalen tussen 
stamcellen en deze omgeving of metabole processen niet optimaal verlopen en de 
tumor-stamcellen gelimiteerd functioneren 15. 
Borstkanker wordt onderverdeeld in verschillende biologische/moleculaire typen op 
basis van genexpressie studies16, deze zijn: Luminal-A, Luminal-B, Basal-like, ERBB2 
en unclassified. Deze groepen hebben allen een verschillende prognose. In hoofdstuk 
7 werden de moleculaire subtypes gevalideerd in oudere borstkankerpatiënten. 
Aangetoond werd dat de subtypes Luminal-A en Luminal-B vaker werden gezien in 
oudere borstkankerpatiënten. In tegenstelling tot de jongere borstkankerpatiënten, 
werd geen associatie gezien tussen deze subtypes en prognose. Dit zou verklaard 
kunnen worden door het competitieve risico op overlijden in ouderen patiënten, waarbij 
patiënten vaker overlijden met borstkanker in plaats van aan borstkanker. Gezien 
60% van deze oudere borstkankerpatiënten overlijdt aan borstkanker is hierdoor het 
prognostische effect van alle biomarkers gelimiteerd en verzwakt. 
In het eerste deel van dit proefschrift werd het belang van het immuunsysteem in de 
ontwikkeling en progressie van een maligniteit aangetoond. Ouder worden resulteert 
in een verminderd functioneren van het adaptieve immuunsysteem en daarom is er 
de suggestie dat deze processen van “immunosenescence” mogelijk bijdragen aan het 
ontstaan en de progressie van kanker 17. Hoofdstuk 8 laat zien dat er geen verschillen 
zijn in infiltrerende CTL, NK-cellen of Tregs in de oudere populatie vergeleken met 
de jongere populatie. Er werd een trend gezien naar minder klassieke HLA klasse 
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I-afschakeling en daarbij statistisch significant minder HLA-E en HLA-G-expressie 
in deze oudere populatie. Ook werden er minder laag immuun-vatbare-tumoren 
gezien in deze patiënten. Deze resultaten suggereren een verzwakte immuun-
selectieve-druk op borstkankertumoren op hogere leeftijd, waardoor deze minder 
immuun-ontsnappingsmechanismen nodig hebben. Tevens werd geen statistisch 
significante associatie met prognose gevonden voor tumorimmuun subtypes in oudere 
borstkankerpatiënten, in tegenstelling tot de jongere populatie. De vergelijkbare 
prognoses in oudere borstkankerpatiënten van de verschillende tumorimmuun subtypes 
suggereert dat het immuunsysteem minder goed functioneert in deze patiënten en 
ondersteunt verder de immunosensescence hypothese en de rol hiervan in tumor 
ontwikkeling en progressie. 
Conclusies en toekomstperspectieven
Immunoediting en immunosenescense hypothesen:
Het concept dat het immuunsysteem tumoren kan herkennen en elimineren bestaat al 
meer dan 100 jaar 18. In het begin van de 21ste eeuw werd inzicht in de interacties van 
het immuunsysteem met maligne tumoren duidelijker toen de drie fasen van interactie: 
“eliminatie”, “equilibrium” en “escape” onder de “kanker immunoediting” hypothese 
werden beschreven 4. Tumorcellen kunnen succesvol geëlimineerd worden door het 
immuunsysteem gedurende de eliminatie-fase. Als tumorcellen weten te ontsnappen 
aan deze eerste immuunaanval, begint de volgende fase: equilibrium. Gedurende 
deze fase is er een constante interactie tussen het immuunsysteem en de tumor, die 
uit snel muterende en genetisch instabiele cellen bestaat. Tumorcellen die vatbaar 
zijn voor immuunherkenning en -aanval worden in deze fase geëlimineerd, maar 
tevens ontstaan er nieuwe tumorvarianten die eigenschappen hebben ontwikkeld om 
hieraan te ontsnappen. Deze constante interacties leiden ertoe dat de tumoropmaak 
constant gevormd wordt door het immuunsysteem. Indien tumorcellen genoeg 
immuun-ontsnappingsmechanismen hebben ontwikkeld, kunnen zij uiteindelijk de 
finale “escape”-fase bereiken. Deze laatste fase is gekarakteriseerd door de winst van 
de maligne tumor in de balans met het immuunsysteem, waar de groei van tumoren 
door kan zetten en zij klinisch detecteerbaar worden. Verdere ontwikkeling van 
significante immuun-ontsnappingsmechanismen die hierop volgen bevorderen de 
verdere progressie van de tumoren. Deze ontsnappingsmechanismen zijn complex 
en bestaan in het kort uit: klassieke HLA klasse I-afschakeling, HLA-E en HLA-G-
upregulatie, downregulatie van stressmoleculen NKG2D-liganden en aantrekking van 
immunosuppressieve Treg 4. Meerdere muisstudies hebben veel bewijs en onderbouwing 
aangeleverd voor de immunoediting-theorie, maar data van humane studies ontbreekt 19. 
Hoewel onze resultaten geen absoluut bewijs zijn voor een immunoediting-hypothese, 
suggereren onze data wel sterk dat een dergelijk fenomeen zich afspeelt in borstkanker. 
proefschrift.indb   169 18-12-2014   16:36:38
170 Chapter 10
Wij hebben aangetoond dat hoog immuun-vatbare-tumoren geassocieerd zijn met een 
goede prognose van patiënten, terwijl immuun-ontsnappingsvarianten resulteerden 
in een slechte prognose. Daarbij is het belangrijk dat onze resultaten aantonen dat 
de verschillende factoren, die betrokken zijn in het samenspel van de tumor met het 
immuunsysteem, interacties met elkaar vertonen, waarmee het belang van pathway-
analyse wordt benadrukt. 
Met toenemende leeftijd neemt de effectiviteit van het immuunsysteem af, waardoor 
minder goed gereageerd kan worden op infecties en vaccinaties 17. Er wordt 
gesuggereerd dat deze immunosenescence-mechanismen mogelijk samenhangen met 
kanker-ontwikkeling en -progressie. Een dergelijk fenomeen is puur hypothetisch, maar 
de lagere frequentie in immuunontsnappingsvarianten in ouderen en het verdwenen 
prognostische effect van immuun subtypes in deze populatie, zoals gevonden in onze 
studie, zijn in overeenstemming hiermee. 
Uit onze resultaten blijkt dat het ontrafelen van de complexe interacties van het 
immuunsysteem in tumorontwikkeling en -progressie tot waardevolle nieuwe inzichten 
in tumorbiologie brengt. Deze nieuwe inzichten hebben een hoog potentieel om te 
leiden tot prognostische en predictieve biomarkers en kunnen mogelijk de basis vormen 
van toekomstige immunotherapeutische behandelingen. Toekomstig onderzoek zal 
immunoediting en immunosenescence hypothesen in humane modellen moeten 
bewijzen. 
Tumorimmuun subtypes als prognostische biomarker in borstkanker: 
Momenteel zijn er veel prognostische biomarkers in borstkanker. De ASCO richtlijnen 
hebben het gebruik voor in de klinische praktijk geadviseerd voor urokinases plasminogen 
activator (uPA), plasminogen activator inhibitor-1 (PAI-1) en gen-expressieprofielen 
gedetecteerd met multiparameter gen-expressie-arrays 20. De klinische waarde van 
microarray-gebaseerde prognostische methoden, zoals de MammaPrint, een 70-genen 
expressieprofiel, en Oncotype DX, een 21-genen expressieprofiel wordt momenteel 
nog onderzocht in fase drie studes21, 22. Een belangrijk punt van kritiek is dat deze 
genenprints zijn geconstrueerd door top-down-analyses, waardoor het onduidelijk 
is wat voor tumortypes worden gerepresenteerd door de verschillende patiënt-risico-
groepen en het zeer lastig is genprofielen biologisch te onderbouwen23. Daarnaast bevat 
deze methode veel “ruis” door de grote kans op toeval in de statistische constructie 
en optimalisatie van dergelijke parameters. Hierdoor is er een zeer hoge kans op een 
verlies aan discrimintatief vermogen bij de validatie. Bij bottom-up-analyses wordt 
een biologische factor gecorreleerd aan patiënt prognose waaroor er een veel hogere 
kans is op het vinden van lagere discriminatieve vermogens of het niet vinden van 
prognostische associaties. Als een prognostische biomaker wordt gevonden met deze 
laatste methode geeft dit een bepaalde mate van betrouwbaarheid en controleerbaarheid 
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door de onderliggende biologische rationale. In het eerste deel van dit proefschrift 
worden verschillende prognostische biomarkers beschreven die met de bottom-up-
analyses gevonden zijn en gebaseerd zijn op biologische hypotheses en theorieën van 
borstkanker-immunoediting. De uiteindelijke tumorimmuun subtypes hebben geleid 
tot een onafhankelijke statistisch significante prognostische variabele met een hoog 
onderscheidend vermogen, vergelijkbaar met die van genexpressie-profielen. Daarbij gaf 
onafhankelijke validatie van de tumorimmuun subtypes vergelijkbare resultaten. Het 
predictieve effect van HLA klasse I en Treg op chemotherapie respons, zoals eerder 
beschreven en bewezen in ons onderzoek, geeft een indicatie van het belang en het effect 
van het immuunsysteem op therapierespons. Hiermee zijn de tumorimmuun subtypes 
potentiele predictieve biomarkers voor bestaande systemische therapie als ook natuurlijk 
potentiele immunotherapieën 24. Dergelijke effecten op therapierespons zijn nog niet 
onderzocht en blijven daarom speculatief. Een huidig nadeel aan de tumorimmuun 
subtypes, waardoor zij nog niet geïmplementeerd kunnen worden in klinische praktijk, is 
de bewerkelijkheid van de bepaling waarin meerdere immunohistochemische kleuringen 
en handmatige kwantificaties plaats moeten vinden. Daarbij zijn de tumorimmuun 
subtypes niet prognostisch in oudere borstkanker patiënten. Dit kan gedeeltelijk worden 
verklaard, zoals eerder omschreven, door immunosenescence of door de competitieve 
risico’s op overlijden in oudere borstkanker patiënten. 
Biologische verschillen in borstkanker in ouderen in vergelijk met jongeren: 
Er zijn verschillen beschreven in patiënt, tumor en behandelingskarakteristieken 
tussen oudere en jongere borstkanker patiënten 8, 25. Dit kan komen door verschillen 
in onderliggende tumorbiologie. Het is daarom vaak gesuggereerd dat borstkanker in 
ouderen patiënten een biologisch verschillend tumortype is met een meer indolent en 
minder agressief en progressief karakter vergeleken met jongere patiënten. Deze hypothese 
spreekt recente resultaten echter tegen waarin bij toenemende leeftijd een slechtere 
borstkanker specifieke overleving werd gevonden 26; oudere borstkankerpatiënten 
overleden vaker aan borstkanker ongeacht het hogere risico op mortaliteit door andere 
oorzaken en onafhankelijk van bekende tumor- en patiëntkarakteristieken. Onze 
studies toonden verschillen in distributie van essentiële biomarkers, waar minder 
agressieve fenotypes (minder ALDH-1 positiviteit, luminal moleculaire subtypes en 
minder tumorimmuun ontsnappingsvarianten) werden gevonden in oudere in vergelijk 
met jongere borstkankerpatiënten. Een verklaring in de tegenstrijdige resultaten kan 
worden gevonden in de interacties tussen tumoren en hun micro-omgeving (Figuur 2). 
De uitkomst van de balans tussen tumoren en hun micro-omgeving, zoals weergegeven 
in Figuur 2, resulteert in de prognose van patiënten: meer tumor agressiviteit resulteert 
in meer tumor progressie en daardoor in een verwachte slechtere prognose voor 
patiënten (A), lage tumor agressiviteit zou moeten resulteren in een geblokkeerde tumor 
progressie door een goed functionerende beschermende micro-omgeving waardoor een 
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betere prognose van patiënten verwacht is (B). Echter, hoewel dit vaak niet het geval 
is in jongere patiënten, speelt in oudere patiënten het minder goed functioneren van 
de verdedigingsmechanismen tegen tumoren een belangrijke rol. De situatie waarin 
gesuggereerd wordt dat tumoren in oudere borstkankerpatiënten een meer indolent 
karakter hebben en daardoor zouden moeten lijden tot een betere prognose vergeleken 
met jongere patiënten wordt weergegeven door situatie B of D in Figuur 2, waarbij 
respectievelijk de micro-omgeving en verdedigingsmechanismen even sterk worden 
geacht als in jongere patiënten (B) en waarin de verdedingsmechanismen door de leeftijd 
minder goed functionerend zijn, maar de tumor agressiviteit vanwege de leeftijdstoename 
nog meer is afgenomen (D). De combinatie van een minder agressieve tumor met een 
sterk verminderde verdediging van de micro-omgeving resulteert in tumorprogressie en 
daardoor in een verwachte slechtere patiënt-prognose (C). Deze laatste situatie, waarin 
de micro-omgeving een sterkere achteruitgang vertoont dan de tumoragressiviteit, kan 
verklaren waarom minder agressieve tumoren gecombineerd met een verslechterde 
patiënt-prognose gevonden worden in oudere borstkankerpatiënten. Veranderingen in 
de omgeving van de tumor, de tumor-micro-omgeving, lijkt de brug te vormen tussen 
de tegenstrijdige resultaten van een minder agressieve tumor met een slechtere patiënt 
prognose in oudere borstkankerpatiënten. In dit scenario is het niet zo zeer de toegenomen 
Figuur 2: Deze figuur geeft schematisch de balans tussen de agressiviteit van de aanval van de tumor ten opzichte van 
de mate van verdediging van de tumor micro-omgeving hiertegen. Het aantal kubussen in de figuur geeft de “zwaarte” 
of  sterkte weer van de aanval, en daarmee de progressie en invasie, van de tumor (links in de balans) en de verdediging 
van de micro-omgeving hiertegen (rechts in de balans). De uiteindelijke balans geeft het eindproduct hiervan weer 
waarbij: (1) de winst aan de aanval van de tumor kan vallen (weergegeven in (A) en (C)), resulterend in tumor progressie 
of  (2) de winst aan de verdediging van de micro-omgeving kan vallen (weergegeven in (B) en (D)), resulterend in een 
geblokkeerde tumor progressie.  (C) en (D) geven hypothetische situaties in oudere patiënten weer, waar de tumor 
micro-omgeving duidelijk verzwakt is ten op zichte van de micro-omgeving in jongere patiënten zoals weergegeven in 
(A) en (B).  
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maligniteit van tumoren, maar de verzwakking in verdedigingsmechanismen die de 
tumor progressie en daarmee de prognose van de patiënten bepalen. Veranderingen 
in de micro-omgeving kan leiden tot een verslechtering van signalering met tumor-
stamcellen, waardoor een verminderde functie van deze cellen gezien kan worden en 
verschillen in prognostische effecten van ALDH-1 verklaard kunnen worden in oudere 
borstkankerpatiënten vergeleken met jongeren. Daarbij zijn de verschillen in distributie 
en prognostisch effect van de tumorimmuun subtypes suggestief voor onderliggende 
verandering in de micro-omgeving door processen als immunosenesecence.
Prognostische biomarkers in oudere borstkanker patiënten: 
Geen van de biomarkers die onderzocht zijn in dit proefschrift hebben een statistisch 
significant prognostisch effect in oudere borstkankerpatiënten. Dit zou verklaard 
kunnen worden door een combinatie van onderliggende verschillen in tumorbiologie 
en -gedrag, verzwakking van statistische power door verschillen in distributie van 
biomarkers in subcategorieën en competitieve risico’s op overlijden. Geen van deze 
verklaringen kan door de resultaten van dit proefschrift worden uitgesloten danwel 
worden bevestigd. Het feit blijft dat de klinische waarde van prognostische biomarkers, 
gelimiteerd is in de oudere borstkankerpopulatie. We concluderen daarom ook dat 
validatie van biomarkers in ouderen een vereiste is, gezien de mogelijke verschillen 
in micro-omgeving en daarbij competitieve overlijdensrisico’s invloed kunnen 
hebben op prognostische effecten; wat uiteindelijk significant interfereert met patiënt 
behandelingsmodaliteiten. Het is echter belangrijk dat prognostische biomarkers alleen 
een prognostisch effect kunnen hebben in patiënten wiens levensverwachting lang 
genoeg is en wiens competitieve overlijdensrisico daarom laag is. . Het is alleen in deze 
“fitte” oudere borstkankerpatiënten dat biomarkers verschillen in prognose kunnen 
weergeven en hiermee kunnen helpen in klinische beslissingen omtrent systemische 
therapie. Het identificeren van deze patiënten zou daarom een eerste stap zijn in de 
creatie van evidence-based behandeling op maat van oudere borstkankerpatiënten. 
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zijn en altijd het geduld weten op te brengen om uitleg te geven. 
Collega’s van het Heelkunde laboratorium; veel dank voor jullie hulp bij de experimenten. 
Een speciale dank aan Gabi en Anita; naast jullie gezelligheid op het werk en daarbuiten, 
hebben jullie een groot deel van de resultaten in dit proefschrift gecreëerd met het vele 
snijd-, isoleer- en kleurwerk. 
Alle overige collega’s met wie ik lunches, vrijdag middag borrels, skivakanties en 
congresreizen heb mogen delen; deze afleidingen hebben geleidt tot onvergetelijke 
herinneringen. 
Veel dank ook aan mijn familie en naasten.
Dank aan mijn vader en Saskia, zonder wie ik dit proefschrift nooit had kunnen 
realiseren. Lieve papa, ik ben blij dat je het belang van mijn opleiding altijd zo serieus 
hebt genomen en daarin steun hebt geleverd; dank hiervoor. 
Oma, helaas hebben we deze dag niet gered. 
Cara zia Hedwig, dank voor het kunnen uitwisselen van elkaars gezeur, de goede 
gesprekken en de fijne afleidingen; ik vind het fijn jouw als tante te hebben! 
Yvette en Ellen; Lieve zussen, ik kan mij voorstellen dat het opvoeden van dat heel 
veel kleinere jongere zusje een vermoeiende taak is geweest, maar heel veel dank voor 
al jullie wijze lessen! Ik zou nooit zo ver zijn gekomen zonder wat jullie mij hebben 
bijgebracht. Maar boven alles ben ik jullie dankbaar voor alle essentiële oneindige steun 
en liefde. Grazie di cuore!
Liefste neefjes en principessa, Tim en Gwen, Justin en Kevin; geniet ervan jullie tante te 
zijn! Aan jullie, en uiteraard ook Frans en Dick: dank voor het zijn van mijn familie en 
het mogelijk maken van de fijne diners aan grote lange tafels!  
Lieve Semmie, dank voor het met mij delen van zo veel speciale momenten in het leven. 
Met alles wat wij samen hebben meegemaakt ben jij voor mij als familie geworden. Van 
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jouw ongetemde prettige gestoordheid heb ik altijd genoten en jouw grote hart heeft mij 
ontzettend veel gegeven. 
Pietro, il periodo in cui si e realizzato questo “libretto” lo abbiamo passato sia vicini sia 
lontani l’un dall’altro, comunque sempre un po’ insieme. Ti amo forte debole compagno; 
che qualche volta impara e a volte insegna. 
Grazie al mio carissimo Mostro; testa dura che non ascolta mai, ma la tua gioia, il tuo 
affetto, le tue coccole, le tue espressioni e la tua comicità mi davano il benvenuto a casa 
dal lavoro più perfetto che una persona potrebbe immaginarsi. 
Lex Veen, de kunstenaar en mens die ik bewonder. Naast jouw hulp bij posters voor 
congressen ben ik boven alles vereerd dat jouw schilderij van dit proefschrift straalt. 
Hou nooit op met je handen te volgen. 
Als laatste de grootste dank aan de twee belangrijke personen die aan mijn zijde zullen 
staan op deze bijzondere dag. 
Dr. Willemien van de Water; Allerliefste Willy, collega, vriendin, roomie, enorm veel 
dank voor je steun in moeilijke tijden, je inzichten vanuit andere perspectieven, je fijne 
besmettelijke blijdschap, je oneindige energie, je hartverwarmende attentheid, je humor, 
je bescheiden maar zekere, lieve en fijne “benigne” karakter. Zeldzaam. Ik ben trots dat 
ik jouw aan mijn zijde heb vandaag als paranymf! 
Cara Francesca; Ciccinedda, mi hai riportato l’allegria al lavoro e da lì e nata un’amicizia 
per me molto preziosa. Abbiamo condiviso in poco tempo tanti momenti importanti, 
sia felici sia un po’ difficili e tristi. Il tuo modo di vedere le cose obiettivamente, ma 
sempre con tanta dolcezza mi ha aperto gli occhi più di una volta. Grazie di essere la 
persona che sei.  
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